Library 2230 studies · 94 landmark
Every trial of a CETP inhibitor, the genetics that reframed the class, the mechanism and the HDL hypothesis it came from, grouped by primary topic and ranked by significance. Archive by year · How items are chosen and scored.
ObicetrapibAnacetrapibEvacetrapibDalcetrapibTorcetrapibOutcomes trialsThe classGeneticsLDL and apoBHDL biologyMechanismsPharmacologyCognition
Obicetrapib 53
The live agent: BROADWAY, BROOKLYN, TANDEM and the PREVAIL outcomes trial.
- BROOKLYN: obicetrapib cuts LDL-C by 36.3% and Lp(a) by 45.9% in 354 patients with heterozygous familial hypercholesterolaemia (Nat Med 2026)
- BROADWAY substudy: obicetrapib cuts p-tau217 rise by a placebo-adjusted 20% in ApoE4/E4 carriers with cardiovascular disease (J Prev Alzheimers Dis 2026)
- Pooled analysis of 2,884 patients: obicetrapib cuts coronary events by 32% (HR 0.68) beyond 6 months, ahead of the PREVAIL readout (J Am Coll Cardiol 2025)
- TANDEM: obicetrapib plus ezetimibe fixed-dose combination cuts LDL-C by 48.6% versus placebo in 407 high-risk patients (Lancet 2025)
- BROADWAY: obicetrapib lowers LDL-C by 29.9% versus 2.7% with placebo in 2,530 high-risk patients (N Engl J Med 2025)
- In BROADWAY, obicetrapib slows p-tau217 progression, most in APOE4 carriers, positioning CETP inhibition against Alzheimer's disease (Am J Prev Cardiol 2026)
- TULIP: the original TA-8995 (obicetrapib) trial cuts LDL-C by up to 45.3% and raises HDL-C by up to 179% with no serious adverse events (Lancet 2015)
- Network meta-analysis of 6,025 patients: obicetrapib outperforms bempedoic acid for LDL-C lowering on top of statins by 15 percentage points (J Clin Lipidol 2026)
- Phase 2 trial in 102 Japanese patients: obicetrapib 10mg on background statin cuts LDL-C by 45.8% and raises HDL-C by 159% (J Atheroscler Thromb 2024)
- Phase 2 trial: obicetrapib plus ezetimibe on top of high-intensity statins cuts LDL-C by 63.4%, with 87% of patients reaching under 55 mg/dL (J Clin Lipidol 2023)
- Phase 2 trial in 120 patients: obicetrapib on top of high-intensity statins cuts LDL-C by up to 51% and raises HDL-C by up to 165% (Nat Med 2022)
- Obicetrapib lowers Lp(a) by 37% in a 2,356-patient pooled analysis, with similar absolute reduction across baseline strata (Eur Heart J 2026)
41 more in Obicetrapib
- CETP inhibitors reframed: from raising HDL to lowering atherogenic lipoproteins and improving glycaemic control, with obicetrapib the current lead (Circ Res 2026)
- CETP renaissance: a review maps obicetrapib reach beyond LDL-C into dementia, glycaemic control, sepsis and kidney function (Curr Atheroscler Rep 2026)
- From torcetrapib failure to obicetrapib promise: a full review of the mechanism and trial programme through PREVAIL (J Am Heart Assoc 2026)
- Network meta-analysis of 9,248 patients ranks obicetrapib plus ezetimibe plus statin best overall, obicetrapib plus statin safest among CETP-inhibitor combinations (J Cardiovasc Pharmacol 2026)
- Post hoc BROADWAY/BROOKLYN analysis: obicetrapib attenuates kidney function decline, tracking with achieved HDL-C (Am J Prev Cardiol 2026)
- Pooled phase 3 safety data on 2,880 patients show obicetrapib matches placebo for adverse events, with no blood pressure signal (Am J Prev Cardiol 2026)
- Network meta-analysis of 2,937 patients: obicetrapib outperforms anacetrapib on LDL-C, HDL-C and overall adverse events (Daru 2026)
- Obicetrapib review: an amphipathic CETP inhibitor cutting LDL-C 30-51%, apoB 20-33% and Lp(a) 30-57% across BROOKLYN, BROADWAY and TANDEM (Cardiol Rev 2025)
- GRADE-assessed meta-analysis of 3,399 patients: obicetrapib raises the odds of reaching an LDL-C target under 55 mg/dL more than sixfold (Diabetes Obes Metab 2026)
- Updated meta-analysis of 3,381 patients: obicetrapib cuts LDL-C by 37% and, unexpectedly, new-onset diabetes by 12% (Am J Prev Cardiol 2025)
- Network meta-analysis of 33 RCTs in 120,292 adults: atorvastatin plus obicetrapib ranks best for LDL-C, rosuvastatin plus obicetrapib best for HDL-C (Clin Cardiol 2025)
- CETP inhibition as a longevity pathway: apoB lowering, not HDL raising, is the mechanism, with signals in diabetes, dementia and kidney disease (Curr Opin Lipidol 2024)
- Beyond the heart: a review finds no excess macular degeneration risk across over 70,000 CETP-inhibitor trial patients, and surveys links to dementia, diabetes and sepsis (Pharmacol Res 2023)
- From raising HDL-C to lowering LDL-C: a review argues Mendelian randomisation and anacetrapib recast the whole CETP-inhibitor class (Cardiovasc Res 2022)
- CETP inhibition reduces major cardiovascular events through apoB lowering, a review argues, with obicetrapib cutting apoB by up to 30% (Int J Mol Sci 2022)
- TA-8995 (obicetrapib) raises ABCA1-specific cholesterol efflux capacity by 28% and preBeta-1 HDL by 36%, showing functional as well as HDL-C gains (J Clin Lipidol 2016)
- Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)
- Meta-analysis of three RCTs in 3,286 patients confirms obicetrapib effects on LDL-C, apoB and HDL-C with no excess adverse events (Ann Med Surg 2026)
- Meta-analysis of 3,088 patients: obicetrapib cuts LDL-C by 32% and Lp(a) by 36% with no excess adverse events (Vasc Dis 2026)
- CETP inhibitors, state of the science: why torcetrapib, dalcetrapib, anacetrapib and evacetrapib failed and why obicetrapib is different (Curr Cardiol Rep 2026)
- Meta-analysis of 657 patients: obicetrapib combination therapy, especially with ezetimibe at 10mg, beats obicetrapib monotherapy for LDL-C lowering (Semergen 2026)
- Meta-analysis of nine RCTs in 3,516 patients confirms obicetrapib lowers LDL-C by 37% and Lp(a) by 41% with no excess adverse events (Cardiol Rev 2025)
- The two faces of CETP inhibitors: a review argues the therapeutic case has shifted from raising HDL-C to lowering apoB, with obicetrapib as proof (Curr Opin Lipidol 2025)
- REMBRANDT trial design: 300 ASCVD patients to test whether obicetrapib plus ezetimibe shrinks coronary plaque on CT angiography (Am Heart J 2025)
- Drug-drug interaction study finds no clinically meaningful effect of obicetrapib on atorvastatin or rosuvastatin exposure in healthy volunteers (Am J Cardiovasc Drugs 2025)
- Meta-analysis of nine RCTs in 3,706 patients: obicetrapib plus ezetimibe adds a further 17.8% LDL-C reduction over obicetrapib alone (J Clin Lipidol 2025)
- Unlike anacetrapib, obicetrapib clears completely from the body and does not accumulate in fat, monkey and human data show (Pharmacol Res Perspect 2024)
- Is obicetrapib a game changer? A review reframes CETP inhibition around apoB and LDL-C lowering rather than raising HDL-C (Expert Opin Pharmacother 2024)
- Obicetrapib, the rebirth of CETP inhibitors? A review of ROSE and ROSE2 phase 2 data ahead of four ongoing phase 3 trials (Curr Atheroscler Rep 2024)
- Population PK/PD model predicts obicetrapib ceiling effect: a maximum 51.1% LDL-C fall and 224% HDL-C rise (J Clin Pharmacol 2024)
- Rationale and design of BROADWAY and BROOKLYN: 2,886 participants randomised to test obicetrapib on top of maximally tolerated therapy (Am Heart J 2024)
- Reversing the tide of CETP inhibitor disappointments: a review of obicetrapib and its ROSE2 data ahead of pivotal phase 3 outcomes trials (Curr Atheroscler Rep 2024)
- HDL as a treatment target: a review says the obicetrapib outcomes trial will help decide whether to abandon the HDL hypothesis for good (Curr Atheroscler Rep 2023)
- First-in-human data: TA-8995 (obicetrapib) blocks 92-99% of CETP activity and is well tolerated across 1 to 150mg doses (Br J Clin Pharmacol 2014)
- Meta-analysis of five early RCTs in 288 patients: obicetrapib reduces LDL-C by 41% and raises HDL-C by 157% (J Clin Lipidol 2025)
- Lp(a) review names obicetrapib the only drug besides apheresis to meaningfully lower Lp(a), cutting it by 40% (Nutr Metab Cardiovasc Dis 2025)
- PK/PD trial in 48 healthy Chinese volunteers shows obicetrapib behaves like it does in White participants, supporting the global phase 3 programme (J Clin Pharmacol 2024)
- CETP pathophysiology and inhibition, an update: the drug class biology, trial status and adverse effects surveyed before obicetrapib phase 3 (Drug Discov Today 2021)
- CETP is over-expressed in non-small cell lung cancer and obicetrapib restores ferroptosis sensitivity in xenografts and organoids (Clin Transl Med 2026)
- In CETP mice, obicetrapib plus ezetimibe on top of atorvastatin regresses established atherosclerosis by 44% via LDL-receptor-driven VLDL clearance (J Lipid Res 2026)
- Machine learning and molecular dynamics show why obicetrapib binds the CETP hydrophobic tunnel more tightly than the failed torcetrapib (ChemMedChem 2025)
Anacetrapib 121
REVEAL worked, and the drug was shelved anyway.
- REVEAL extended follow-up: the coronary benefit of anacetrapib grows over time, 12% overall, with no long-term safety signal (Eur Heart J 2022)
- REVEAL: anacetrapib cuts major coronary events by 9% in 30,449 patients already on intensive statin therapy (N Engl J Med 2017)
- Landmark NEJM safety trial shows anacetrapib avoids the cardiovascular harm of torcetrapib while doubling HDL cholesterol (N Engl J Med 2010)
- REVEAL, the largest ADCY9 pharmacogenetic study yet, finds no genotype interaction with the benefit of anacetrapib, unlike the dalcetrapib hypothesis (Circulation 2019)
- REALIZE phase 3 trial: anacetrapib cuts LDL-C by 39·7% versus placebo in familial hypercholesterolaemia over one year (Lancet 2015)
- First-in-class phase I trials show anacetrapib raises HDL-C by 129% and lowers LDL-C by 38% without raising blood pressure (Lancet 2007)
- Bayesian network meta-analysis of 84,134 patients ranks evacetrapib and anacetrapib best for cardiovascular outcomes among CETP inhibitors (Medicine 2026)
- First meta-analysis of nine CETP-inhibitor RCTs finds a class-wide reduction in cardiovascular mortality and myocardial infarction (J Cardiovasc Dev Dis 2024)
- Genetic and drug-based CETP inhibition preserves HDL and improves survival in sepsis, in humans and humanized mice (Circulation 2021)
- In obese CETP-transgenic mice, anacetrapib improved HDL function but drove fatty liver and insulin resistance, a clue to trials where two-thirds of patients were obese (Diabetes 2018)
- Meta-analysis of 34,781 patients confirms the lipid benefits of anacetrapib carry no excess hepatic or muscular risk (Postgrad Med 2018)
- Anacetrapib lowers lipoprotein(a) by cutting its production rate 41%, not by speeding its clearance (ATVB 2017)
109 more in Anacetrapib
- Phase 3 trial finds anacetrapib added to statins cuts LDL-C by 37% and more than doubles HDL-C, well tolerated over 24 weeks (Am J Cardiol 2017)
- Anacetrapib impairs endothelial function in CETP-transgenic mice despite raising HDL-C fivefold, while evacetrapib does not (Atherosclerosis 2017)
- Anacetrapib raises HDL apoA-I and plasma CETP levels by slowing their clearance rather than boosting their production (ATVB 2016)
- CETP inhibitors raise blood pressure through a CETP-independent, redox- and STAT3-dependent vascular contraction pathway (J Pharmacol Exp Ther 2016)
- Anacetrapib lowers LDL-ApoB by accelerating its clearance, not by slowing its production (J Clin Invest 2015)
- CETP inhibitors trigger aldosterone-producing enzymes in adipocytes through Nox-driven reactive oxygen species and STAT3 (J Pharmacol Exp Ther 2015)
- Anacetrapib dose-dependently shrinks atherosclerotic lesions by up to 92% and adds to the benefit of atorvastatin (Eur Heart J 2015)
- Two more years of anacetrapib in the DEFINE extension sustain a 39.9% LDL-C drop and 153.3% HDL-C rise with no new safety signals (J Cardiovasc Pharmacol Ther 2014)
- Medicinal chemistry paper describes the structure-activity work that led to the discovery of anacetrapib (J Med Chem 2011)
- Only dalcetrapib preserves pre-beta HDL formation and boosts fecal sterol excretion, unlike torcetrapib and anacetrapib (J Lipid Res 2010)
- Anacetrapib binds CETP reversibly while dalcetrapib binds covalently, explaining their different inhibitory kinetics (J Lipid Res 2010)
- Anacetrapib doubles HDL cholesterol and, unlike niacin, boosts cholesterol efflux per particle at high HDL levels (ATVB 2010)
- Adrenalectomy prevents the torcetrapib blood pressure rise, proving CETP inhibition itself is not the culprit (Br J Pharmacol 2008)
- Mouse mechanism study: CETP inhibition raises HDL, which blocks IL-1beta activation via SR-B1 and cuts endotoxaemia mortality (J Lipid Res 2025)
- Anacetrapib reduces mortality from pneumococcal sepsis in mice by priming monocytes and speeding bacterial clearance (JCI Insight 2024)
- In REVEAL, new stroke, heart failure or cancer each cut quality of life and add thousands in hospital costs, but MI and coronary revascularisation alone do not (J Am Heart Assoc 2023)
- Dalcetrapib and anacetrapib generate large apoE-containing HDL particles that can bind the hepatic LDL receptor (J Lipid Res 2023)
- MK-8262 is invented as a best-in-class CETP inhibitor backup to anacetrapib after its 9% added cardiovascular risk reduction (J Med Chem 2021)
- Anacetrapib raises macrophage cholesterol efflux capacity in men, with the effect modified by haptoglobin genotype in diabetes (JAHA 2020)
- Meta-analysis of 62,431 patients across 11 RCTs finds CETP inhibitors do not reduce major adverse cardiovascular events (RR 0.97) (Cardiology 2020)
- An anacetrapib analog cuts CETP activity by 89% and reduces neointimal hyperplasia in bypassed rabbit veins by 38% (Sci Rep 2019)
- Anacetrapib parks itself in the lipid droplets of fat cells without needing active transport, explaining its long half-life and shelving (Drug Metab Dispos 2019)
- Unlike statins, anacetrapib lowers rather than raises new-onset diabetes risk on top of a coronary benefit, a review argues for a statin-plus-CETP-inhibitor combination (Atherosclerosis 2018)
- What the cetrapib trials taught us: torcetrapib, evacetrapib and anacetrapib all raised atherogenic apoproteins, muddying the HDL-raising story (Curr Opin Lipidol 2018)
- Were the benefits of REVEAL with anacetrapib really major? A critical evaluation says not significant in years one or two, and modest overall (Expert Opin Pharmacother 2018)
- The present therapeutic role of CETP inhibitors: REVEAL numbers, HDL-C +104%, LDL-C -18%, major coronary events RR 0.91, against three prior failures (Pharmacol Res 2018)
- A new piperidine-based CETP inhibitor retains potency in hypertriglyceridemic plasma where other CETP inhibitors lose efficacy (J Med Chem 2017)
- Inhibiting CETP with des-fluoro-anacetrapib cuts in-stent intimal area by 43% via a scavenger receptor-B1-dependent pathway (ATVB 2017)
- Trials and tribulations of CETP inhibitors: the REVEAL benefit traces to lower non-HDL-C, not higher HDL-C, plus a small diabetes reduction (Circ Res 2018)
- Anacetrapib, the new CETP inhibitor: raises large HDL2 and pre-beta HDL, lowers Lp(a) via ApoA production, and shows a hint of glucose benefit (Diseases 2017)
- Same drug, opposite effect: dalcetrapib raised HDL in rabbits but cut it 48% in monkeys, while anacetrapib behaved consistently across species (J Lipid Res 2017)
- Human phase 1 data confirm anacetrapib keeps accumulating in fat for a year while plasma levels plateau, explaining its long residence time (Clin Pharmacol Ther 2017)
- Anacetrapib lowers VLDL triglyceride only on a statin background, by boosting the catabolic rate of VLDL-TG (J Lipid Res 2017)
- In Japanese patients, adding anacetrapib to statins nearly doubles HDL-C and sustains lipid benefits through a 28-week extension (Atherosclerosis 2017)
- REVEAL trial design enrolled 30,449 patients to test whether anacetrapib lipid changes reduce cardiovascular events (Am Heart J 2017)
- Both 25 mg and 100 mg doses of anacetrapib substantially cut LDL-C and raise HDL-C on top of statin therapy (Am J Cardiol 2017)
- In Japanese patients with familial hypercholesterolaemia, anacetrapib cuts LDL-C by nearly 30% versus placebo in 12 weeks (Atherosclerosis 2016)
- White adipose tissue accumulates anacetrapib up to 40-fold, explaining its long elimination half-life in mice (Drug Metab Dispos 2016)
- A new non-steady-state tracer method shows anacetrapib blocks 97% of postprandial triglyceride flux into HDL (J Lipid Res 2016)
- Anacetrapib lowers VLDL/LDL cholesterol through both CETP inhibition and a separate PCSK9-lowering mechanism in mice (J Lipid Res 2015)
- Inhibiting CETP with des-fluoro-anacetrapib doubles capillary density in ischemic rabbit hindlimbs via SR-B1 and PI3K/Akt signaling (Int J Cardiol 2015)
- In vivo, anacetrapib promotes rather than blocks cholesteryl ester flux into large HDL, contradicting in vitro homotypic-transfer predictions (Eur J Pharmacol 2015)
- Modeling predicts a 550-day half-life for the tissue depot of anacetrapib, but no comparable accumulation for evacetrapib (J Clin Pharmacol 2015)
- Inhibiting CETP with des-fluoro-anacetrapib nearly doubles re-endothelialization after balloon injury in rabbit aortas (ATVB 2015)
- Atomistic simulations show anacetrapib lodges in the N-terminal tunnel of CETP to block cholesteryl ester diffusion (PLoS Comput Biol 2014)
- Anacetrapib reshapes LDL particle subfractions differently than atorvastatin, and neither drug reduces the smallest LDL particles (J Clin Lipidol 2015)
- At matched CETP inhibition, only anacetrapib boosts macrophage-to-feces cholesterol excretion in dyslipidemic hamsters (Eur J Pharmacol 2014)
- In rhesus macaques, anacetrapib reproduces the human lipid response and significantly lowers plasma PCSK9 (Eur J Pharmacol 2014)
- Even at 8 times the therapeutic dose, anacetrapib does not clinically prolong the QTcF interval (J Clin Pharmacol 2014)
- Anacetrapib lipid effects and detectable plasma drug persist for years after stopping treatment (Am J Cardiol 2014)
- In hamsters, anacetrapib raises preβ HDL and reverse cholesterol transport without affecting cholesterol absorption, unlike dalcetrapib (J Lipid Res 2013)
- Antisense CETP inhibition, unlike anacetrapib, boosts macrophage reverse cholesterol transport in CETP-transgenic mice (J Lipid Res 2013)
- Ten-arm dose-ranging trial in Japanese patients shows anacetrapib raises HDL-C up to 159% and adds to the LDL-lowering of atorvastatin (Atherosclerosis 2013)
- Anacetrapib-raised HDL retains its anti-inflammatory effect on endothelial cells (Biochim Biophys Acta 2013)
- The Friedewald formula underestimates LDL-C by 12 mg/dl after anacetrapib treatment, likely from VLDL-C overestimation (J Lipid Res 2013)
- DEFINE trial found anacetrapib safe through 76 weeks with no signal for the 25% event excess seen with a prior CETP inhibitor (Expert Rev Cardiovasc Ther 2012)
- Review focuses on anacetrapib as the CETP inhibitor without the mortality signal of torcetrapib (Vasc Health Risk Manag 2012)
- Anacetrapib shrinks medium and small LDL while paradoxically raising the smallest, densest LDL4b subfraction (J Lipid Res 2012)
- A new reverse-phase-array lipoprotein-profiling method shows dalcetrapib, unlike torcetrapib and anacetrapib, spares pre-beta HDL formation (J Lipid Res 2011)
- Eight weeks after stopping anacetrapib, HDL-C remains up to 43.4% higher, tracking residual drug levels and CETP inhibition (Am Heart J 2011)
- Anacetrapib inhibited CETP 94% and boosted macrophage-to-feces cholesterol excretion in hamsters (J Lipid Res 2011)
- Review distinguishes CETP inhibitors from the CETP modulator dalcetrapib by their opposite effects on HDL2-to-HDL3 transfer (Curr Opin Lipidol 2011)
- Population PK/PD modeling picks the 100 mg tablet dose for anacetrapib phase III without a dedicated phase IIb trial to test it (AAPS J 2011)
- DEFINE trial design paper describes screening 2,757 patients and randomizing 1,623 across 153 centers in 20 countries (Am Heart J 2009)
- A high-fat meal can raise anacetrapib exposure up to eight-fold, but age, sex, and obesity barely move it (Br J Clin Pharmacol 2009)
- Anacetrapib leaves simvastatin pharmacokinetics unchanged while adding incremental LDL-C lowering when combined (Br J Clin Pharmacol 2009)
- Phase 2 dose-ranging trial finds anacetrapib plus atorvastatin cuts LDL-C by 70% and more than doubles HDL-C (Am Heart J 2009)
- Viewpoint charts efforts to optimize anacetrapib into a best-in-class CETP inhibitor (J Med Chem 2021)
- Anacetrapib pharmacokinetics in healthy Chinese subjects closely match those seen in black and white populations (Adv Ther 2021)
- Anacetrapib accumulates to 0.6 mmol/L in mouse adipose tissue without impairing adipose function, even after weight loss (Pharmacol Res Perspect 2019)
- Review asks whether anacetrapib, the fourth CETP inhibitor tested, finally outperforms its predecessor drugs (Cardiol Rev 2019)
- The lipid-lowering effect of anacetrapib is smaller in Black subjects than White subjects despite identical pharmacokinetics (J Clin Pharmacol 2018)
- Anacetrapib reproduced the CETP-deficiency phenotype and showed a highly significant, if moderate, coronary benefit in REVEAL, a review on HDL and atherogenic inflammation notes (Atherosclerosis 2018)
- Update on novel lipid drugs: anacetrapib cut coronary events by 7% but not wider CVD outcomes, leaving CETP inhibitors without further development (Curr Opin Cardiol 2018)
- For lipid management in diabetes, CETP inhibitor trials have generally underwhelmed and are no longer being developed, a review concludes (Diabet Med 2018)
- CETP inhibitors as agents to reduce coronary heart disease risk: after earlier trial failures, REVEAL showed anacetrapib actually works (Cardiol Clin 2018)
- Nat Rev Cardiol commentary: the REVEAL coronary benefit from CETP inhibition is probably down to lowering non-HDL-C, not raising HDL-C (Nat Rev Cardiol 2017)
- A single dose of anacetrapib inhibits CETP equally well in young Japanese and white men, with a Japanese breakfast boosting exposure similarly (J Clin Pharmacol 2018)
- Review weighs whether anacetrapib can succeed as a cardioprotective CETP inhibitor where earlier drugs failed (Drug Des Devel Ther 2017)
- Review asks whether anacetrapib is the last surviving CETP inhibitor as REVEAL results loom (Expert Opin Pharmacother 2016)
- The LDL-C and HDL-C effects of anacetrapib were smaller in Black than White DEFINE trial patients (J Clin Lipidol 2015)
- Neither moderate hepatic nor severe renal impairment meaningfully alters anacetrapib pharmacokinetics (J Clin Pharmacol 2014)
- Unlike torcetrapib, anacetrapib raises HDL-C by 138% without elevating blood pressure or disturbing electrolytes (Cardiol Rev 2014)
- Chronic rifampin dosing slashes anacetrapib exposure by 65% through CYP3A induction, while a single dose barely moves it (J Clin Pharmacol 2013)
- Anacetrapib has no clinically meaningful interaction with warfarin, sparing patients a dosage adjustment (Br J Clin Pharmacol 2012)
- Review positions anacetrapib as free of the off-target toxicity of torcetrapib, with phase III trial results still awaited (Expert Opin Investig Drugs 2012)
- Anacetrapib does not meaningfully inhibit P-glycoprotein, leaving digoxin exposure essentially unchanged (Biopharm Drug Dispos 2011)
- Review by the developers of anacetrapib frames CETP inhibition as a new approach to cutting cardiovascular risk (Clin Pharmacol Ther 2012)
- Review calls anacetrapib a new weapon against dyslipidemia, pending long-term mortality data (Curr Clin Pharmacol 2011)
- Review finds anacetrapib and dalcetrapib safely raise HDL-C without the off-target effects that doomed torcetrapib (Ann Pharmacother 2011)
- Review asks whether anacetrapib offers the greatest HDL-raising, LDL-lowering promise among CETP inhibitors (Cardiovasc Ther 2011)
- Drug profile tracks the path of anacetrapib from Merck development into a 76-week international phase III trial (Am J Cardiovasc Drugs 2010)
- Anacetrapib shows moderate oral bioavailability in rats and monkeys, with most of the dose excreted unchanged in feces (Drug Metab Dispos 2010)
- Nearly 87% of an oral anacetrapib dose is eliminated unchanged in feces, with only trace CYP3A4-generated metabolites (Drug Metab Dispos 2010)
- Review finds the lipoprotein effects of anacetrapib surpass both torcetrapib and dalcetrapib, though long-term safety remains unproven (Curr Opin Investig Drugs 2009)
- Anacetrapib neither inhibits nor induces CYP3A, but ketoconazole raises its own exposure more than fourfold (J Clin Pharmacol 2009)
- Review asks whether JTT-705 (dalcetrapib) or anacetrapib can still succeed after the collapse of torcetrapib (Expert Opin Investig Drugs 2008)
- A validated mass spectrometry assay quantifies anacetrapib in fat tissue across three animal species and humans (Bioanalysis 2024)
- Review of new oral dyslipidaemia drugs names anacetrapib the only CETP antagonist that reduces cardiovascular events (Eur J Prev Cardiol 2020)
- Shrinking anacetrapib nanoparticles below 100 nm boosts bioavailability in dogs beyond what dissolution rate alone explains (J Pharm Sci 2019)
- Pharmacokinetic review details the long elimination half-life and faeces-dominant clearance of anacetrapib (Expert Opin Drug Metab Toxicol 2017)
- Dalcetrapib, but not anacetrapib, raises plasma and liver levels of the dietary antioxidants lutein and zeaxanthin (Lipids 2014)
- Review collates the bioanalytical methods developed to quantify anacetrapib, dalcetrapib, and torcetrapib in biological samples (Biomed Chromatogr 2013)
- A new palladium-catalysed C-H fluorination reaction offers a concise late-stage route to anacetrapib (Chem Commun 2021)
- LC-MS/MS method measures anacetrapib pharmacokinetics and low protein binding in rats (Biomed Chromatogr 2017)
- LC-MS/MS method quantifies anacetrapib, a stable-isotope tracer, and four metabolites in human plasma (J Chromatogr B 2016)
- Isotope-labeled anacetrapib and its metabolites are synthesized to support bioavailability and drug-metabolism studies (J Labelled Comp Radiopharm 2013)
- A hidden solvent impurity turns out to enable a scalable, chromatography-free synthesis of the anacetrapib biaryl core (J Org Chem 2011)
- AHA 2010 trials update reports DEFINE found no adverse safety signal for anacetrapib (Cardiovasc Drugs Ther 2011)
Evacetrapib 46
ACCELERATE, stopped for futility.
- Evacetrapib failed to reduce cardiovascular events despite large lipid changes in ACCELERATE (N Engl J Med 2017)
- Why raising HDL with CETP inhibitors did not help: evacetrapib and torcetrapib both boosted the harmful apoC3-containing HDL subspecies most (Arterioscler Thromb Vasc Biol 2022)
- Discovery paper introduces evacetrapib, a potent CETP inhibitor that raises HDL cholesterol without inducing aldosterone or raising blood pressure (J Lipid Res 2011)
- Reducing CETP activity with evacetrapib preserves memory in an Alzheimer's mouse model, independent of amyloid or tau markers (EMBO Mol Med 2026)
- Meta-analysis of nearly 13,000 patients confirms evacetrapib lowers LDL-C by 34 mg/dL and raises HDL-C substantially (Prostaglandins Leukot Essent Fatty Acids 2021)
- Evacetrapib raises large and medium HDL but cuts the functionally important preβ-1 HDL by 36%, a clue to why raising HDL-C didn't help (Atherosclerosis 2019)
- ACCELERATE nested case-control study finds no significant ADCY9 genotype interaction with evacetrapib, unlike the dalcetrapib signal (JAMA Cardiol 2018)
- ACCENTUATE: evacetrapib beat ezetimibe and higher-dose statin on LDL-C and Lp(a), but also raised hsCRP, a clue to why ACCELERATE later failed (Atherosclerosis 2017)
- Evacetrapib cuts small LDL particles by up to 95% and lipoprotein(a) by up to 40%, alone or added to statins (J Clin Lipidol 2016)
- Evacetrapib raises ABCA1-specific cholesterol efflux capacity and pre-beta-1 HDL, effects that statins alone do not share (JACC 2015)
- Evacetrapib raised HDL-C up to 129% and lowered LDL-C up to 36% alone or with statins in a 398-patient dose-ranging trial (JAMA 2011)
- Evacetrapib more than doubled circulating ApoA5 in the ACCELERATE and ACCENTUATE trials, explaining how CETP inhibitors lower triglycerides (J Clin Lipidol 2025)
34 more in Evacetrapib
- Evacetrapib crosses the blood-brain barrier within 30 minutes, positioning CETP inhibitors as candidates for Alzheimer's disease (Front Pharmacol 2023)
- In ACCELERATE, a rising hsCRP trajectory over follow-up predicts MACE better than a single baseline reading, even when levels stay under 2 mg/L (Am J Cardiol 2022)
- In ACCELERATE, elevated Lp(a) only predicted death, MI and stroke when hsCRP was also 2 mg/L or higher (JAMA Cardiol 2020)
- In 8,236 diabetes patients from ACCELERATE, evacetrapib raised HDL by 131% and lowered LDL by 32%, yet produced no clinical benefit (BMJ Open Diabetes Res Care 2020)
- Unlike torcetrapib, evacetrapib left plasma aldosterone unchanged in ACCELERATE, and aldosterone did not predict cardiovascular events (J Am Heart Assoc 2019)
- No benefit with evacetrapib despite raising HDL 130% and cutting LDL 37%: is this the end of the road for the cetrapibs? (Expert Opin Pharmacother 2017)
- In Japanese patients, evacetrapib added to atorvastatin cuts LDL-C by 25.70% versus placebo and more than doubles HDL-C (Circ J 2017)
- Evacetrapib monotherapy lowers LDL-C by 34.3% and raises HDL-C by 124% in Japanese patients with hypercholesterolemia (Circ J 2017)
- Rabbit developmental study finds the offspring-survival NOAEL for evacetrapib is a third of the maternal NOAEL (Birth Defects Res 2017)
- High-dose evacetrapib causes toxicity in parent rats but leaves fertility and fetal development unharmed in rats and rabbits (Birth Defects Res 2017)
- Review details how evacetrapib raised HDL-C by 128% and cut LDL-C by 35% yet produced no clinical benefit in ACCELERATE (Cardiol Rev 2017)
- Meta-analysis finds evacetrapib raises HDL-C by 86% and cuts LDL-C by 21%, with no effect on triglycerides (Curr Pharm Des 2016)
- ACCELERATE trial design targets 12,092 high-risk patients to test the effect of evacetrapib on cardiovascular outcomes (Am Heart J 2015)
- At the highest dose, evacetrapib inhibits CETP by 91% and raises HDL-C by 87% without moving 24-hour blood pressure (J Pharm Pharmacol 2014)
- Dose-ranging phase 2 trial in Japanese patients shows evacetrapib 500 mg raises HDL-C by 136% and cuts CETP activity by 95% (Am J Cardiol 2014)
- A thorough QT study finds evacetrapib safe on cardiac rhythm even at 5-fold the exposure planned for phase 3 (J Cardiovasc Pharmacol Ther 2014)
- Evacetrapib suppresses colorectal cancer cell growth by blocking Wnt/beta-catenin signaling and activating JNK (Biol Pharm Bull 2022)
- In the ACCELERATE diabetes cohort, higher baseline HbA1c independently predicted cardiovascular events despite statin therapy (J Am Heart Assoc 2020)
- Raising gastric pH with omeprazole modestly increases evacetrapib exposure, but not enough to matter clinically (Pharmacotherapy 2016)
- CETP inhibitors, challenges and perspectives: off-target failure for torcetrapib, futility for dalcetrapib and evacetrapib, early promise for anacetrapib and TA-8995 (Expert Rev Cardiovasc Ther 2016)
- Severe hepatic impairment, but not severe renal impairment, raises evacetrapib exposure and prolongs its half-life (Eur J Clin Pharmacol 2016)
- Commentary marks evacetrapib as another CETP inhibitor lost to the gap between lipid improvement and clinical benefit (Bratisl Lek Listy 2016)
- Evacetrapib inhibits every major CYP enzyme in vitro, but clinical drug-drug interactions turn out weak (Br J Clin Pharmacol 2015)
- CYP3A handles about 90% of the metabolic clearance of evacetrapib, but even strong CYP3A inhibitors barely raise its exposure (Pharmacol Res Perspect 2015)
- A high-fat breakfast raises steady-state evacetrapib exposure by 44%, with correspondingly larger lipid and CETP-activity changes (J Cardiovasc Pharmacol Ther 2015)
- Population PK/PD model finds evacetrapib exposure predicts up to a 177% HDL-C increase and 44.1% LDL-C decrease (CPT Pharmacometrics Syst Pharmacol 2014)
- Review profiles the early safety advantage of evacetrapib over torcetrapib as cardiovascular outcomes remain unknown (Curr Cardiol Rep 2012)
- Chikungunya virus is sensitive to evacetrapib in cell culture, but through an off-target effect independent of CETP itself (Viruses 2025)
- Repurposed as a cancer drug: evacetrapib blocks a CEA-KRT1 interaction that drives oxaliplatin resistance in gastric cancer (Drug Resist Updat 2025)
- In ACCELERATE, higher baseline fasting insulin independently predicted MACE and future revascularisation in diabetes patients (Diab Vasc Dis Res 2019)
- A new dissolution test detects as little as 10% crystalline drug contamination in evacetrapib spray-dried dispersion tablets (J Pharm Biomed Anal 2017)
- Stable-isotope tracer study measures evacetrapib absolute oral bioavailability at 44.8% (J Labelled Comp Radiopharm 2016)
- A chiral HPLC method resolves the methyl ester of evacetrapib from its stereoisomers and five impurities (J Chromatogr A 2015)
- A brush-type Whelk-O 1 chiral column resolves evacetrapib from its enantiomer, two diastereomers, and six impurities (J Chromatogr A 2014)
Dalcetrapib 96
Neutral in dal-OUTCOMES, revived genotype-first in dal-GenE.
- Dalcetrapib raised HDL-C by up to 40% but did not reduce cardiovascular events in dal-OUTCOMES (N Engl J Med 2012)
- dal-GenE: dalcetrapib misses its primary endpoint in ADCY9 AA-genotype patients (HR 0.88), even after a genetically pre-selected retest of dal-OUTCOMES (Eur Heart J 2022)
- Discovery study links the ADCY9 rs1967309 polymorphism to a 39% cardiovascular benefit from dalcetrapib (Circ Cardiovasc Genet 2015)
- JTT-705, a disulfide-forming CETP inhibitor, raises HDL cholesterol and slows atherosclerosis in rabbits, the original discovery paper reports (Nature 2000)
- ADCY9 and CETP show signs of having coevolved under sex-specific selection, offering a biological explanation for the pharmacogenomic signal of dalcetrapib (eLife 2021)
- Genotype-dependent dalcetrapib effects on cholesterol efflux and inflammation confirm the ADCY9 pharmacogenomic signal (Circ Cardiovasc Genet 2016)
- Dal-VESSEL trial finds dalcetrapib cut CETP activity 56% without harming endothelial function or blood pressure (Eur Heart J 2012)
- The dal-PLAQUE imaging trial finds no evidence dalcetrapib harms the arterial wall after the failure of torcetrapib (Lancet 2011)
- The first human trial of JTT-705 finds 900 mg raises HDL cholesterol by 34 percent while cutting CETP activity by 37 percent (Circulation 2002)
- Early-phase MACE signals predicted outcomes-trial results in 6 of 7 cholesterol drugs, dalcetrapib the exception (Am Heart J Plus 2026)
- dal-GenE: the MI benefit of dalcetrapib in ADCY9 AA-genotype patients survives adjustment for an 18-variable risk prediction index (Eur J Prev Cardiol 2025)
- How ADCY9 and CETP might interact inside arterial macrophages to explain the genotype-dependent effect of dalcetrapib, with dal-GenE poised to test it (Circ Genom Precis Med 2021)
84 more in Dalcetrapib
- dal-OUTCOMES secondary analysis: dalcetrapib cuts new-onset diabetes by 23% after acute coronary syndrome, NNT of 40 (Diabetes Care 2020)
- Pharmacogenomics review details how ADCY9 genotype determines the cardiovascular effect of dalcetrapib in dal-OUTCOMES (ATVB 2017)
- The dal-ACUTE trial finds dalcetrapib raises HDL cholesterol by a third after acute coronary syndrome but boosts cholesterol efflux by only a tenth (Eur Heart J 2014)
- Cysteine 13 of CETP is the key residue that lets dalcetrapib decouple cholesteryl ester transfer from HDL remodeling (Biochim Biophys Acta 2013)
- L-type calcium channels explain how torcetrapib raises aldosterone and blood pressure, an effect dalcetrapib does not share (J Hypertens 2010)
- Structure-activity studies identify JTT-705 as the optimum CETP inhibitor among a series of disulfide and thioester compounds (J Med Chem 2000)
- Dalcetrapib reduces red blood cell sickling in sickle cell disease and boosts the effect of voxelotor when combined (Clin Hemorheol Microcirc 2026)
- Adcy9 gene inactivation shrinks infarct size and preserves cardiac function after MI, but mainly when CETP is absent (Can J Cardiol 2023)
- Beyond failed HDL trials: a review argues the dal-GenE genomic-test approach to dalcetrapib and ADCY9 is the key to actionable HDL therapy (J Cardiovasc Pharmacol 2021)
- dal-GenE trial design: only patients with the ADCY9 AA genotype will be enrolled, testing whether the benefit of dalcetrapib is genetically confined (Am Heart J 2020)
- Even NMR-measured HDL particle concentration, not just HDL-C, failed to predict cardiovascular risk in dal-Outcomes (Am Heart J 2020)
- ADCY9 inactivation cuts atherosclerosis by 65 percent in mice, but only when CETP is absent (Circulation 2018)
- Pharmacogenetics of HDL-targeting and statin therapies: dal-OUTCOMES and dal-PLAQUE-2 gave concordant results for dalcetrapib in the favourable genotype (Curr Atheroscler Rep 2017)
- Dalcetrapib raises plasma campesterol only in patients with intact ABCA1 and ApoA1, a crossover trial finds (Lipids 2014)
- A distinct HDL-like particle seen in complete genetic CETP deficiency is absent in dalcetrapib-treated volunteers (Curr Vasc Pharmacol 2012)
- Update captures dal-OUTCOMES futility and the decision by Roche to end the dalcetrapib program in May 2012 (Future Cardiol 2012)
- Adding dalcetrapib to pravastatin reshapes HDL composition and boosts two cholesterol efflux pathways in a phase IIb dose-ranging study (Am Heart J 2012)
- Review recounts the termination of dalcetrapib and the broader questions it raises for CETP inhibition and the HDL hypothesis (Drug Des Devel Ther 2012)
- Unlike torcetrapib, dalcetrapib shifts cholesterol homeostasis toward absorption markers rather than synthesis markers (Atherosclerosis 2011)
- Doses of dalcetrapib up to 4500 mg, far above the therapeutic dose, are well tolerated in a phase I ascending-dose study (Clin Drug Investig 2011)
- Review of phase II dalcetrapib data flags its unique CETP-binding mechanism ahead of dal-OUTCOMES (Expert Opin Investig Drugs 2010)
- A 48-week trial finds dalcetrapib raises HDL cholesterol by a third with no measurable effect on lymph node size (Eur Heart J 2010)
- Torcetrapib raises blood pressure and RAAS gene expression in rats, but dalcetrapib does neither (Br J Pharmacol 2009)
- Dal-OUTCOMES trial design targets 15,600 recent-ACS patients to test whether dalcetrapib reduces cardiovascular events (Am Heart J 2009)
- Pooled phase II data show dalcetrapib raises HDL cholesterol up to 36 percent without the blood pressure or aldosterone effects seen with torcetrapib (Am J Cardiol 2009)
- A mathematical model shows torcetrapib and JTT-705 inhibit CETP more potently than classic competitive inhibition would predict (J Lipid Res 2009)
- A critical appraisal argues high CETP may actually lower cardiovascular risk when triglycerides are low, complicating the case for CETP inhibition (Eur J Clin Invest 2007)
- Torcetrapib raises large alpha-1 HDL particles by more than 50 percent in humans, mainly by slowing ApoA-I breakdown (Curr Opin Lipidol 2006)
- CETP is shown to directly drive formation of cholesterol-rich remnant lipoprotein particles, and JTT-705 blocks the effect (Clin Chim Acta 2007)
- Adding JTT-705 to pravastatin raises HDL cholesterol by 28 percent after just 4 weeks in a placebo-controlled trial (Am J Cardiol 2005)
- JTT-705 blocks vascular smooth muscle cell proliferation and angiogenesis through a mechanism independent of CETP inhibition (Atherosclerosis 2005)
- JTT-705 (dalcetrapib) inhibits CETP and raises HDL-C across five animal species, mimicking CETP-deficient humans in marmosets (Eur J Pharmacol 2003)
- JTT-705 raises HDL cholesterol but fails to reduce aortic atherosclerosis in rabbits with severe hypercholesterolaemia (Clin Sci 2002)
- The same cysteine-binding chemistry that makes dalcetrapib a CETP inhibitor also lets it block the SARS-CoV-2 3CL protease (ACS Omega 2021)
- Dalcetrapib (JTT-705) blocks SARS-CoV-2 cell fusion by disrupting spike protein disulfide bonds (FASEB J 2021)
- Repeated dosing shows dalcetrapib does not accumulate in rats despite forming covalent disulfide bonds with tissue thiols (Xenobiotica 2021)
- A PBPK model correctly predicts higher exposure to the active thiol form of dalcetrapib in chronic kidney disease (Xenobiotica 2021)
- A review of dalcetrapib pharmacokinetics finds no clinically significant drug interactions across over 13,000 patients and volunteers (Clin Pharmacokinet 2018)
- In dal-Outcomes, Lp(a) after acute coronary syndrome did not predict recurrent ischaemic events on background statin therapy (JAMA Cardiol 2018)
- Metabolite profiling identifies more than 80 breakdown products of dalcetrapib in human plasma, none of them major (J Pharm Biomed Anal 2018)
- A review proposes that HDL regulates the beta2-adrenergic receptor pathway through the same ADCY9 signaling axis linked to dalcetrapib response (Arch Med Res 2015)
- Simvastatin blunts the boost that dalcetrapib gives to cholesterol efflux from macrophages in vitro (Cardiovasc Drugs Ther 2015)
- Dalcetrapib is rapidly hydrolyzed to its active thiol and excreted largely unchanged in rats and monkeys (Xenobiotica 2014)
- Hepatic and renal impairment increase dalcetrapib active-thiol exposure by up to 81% (Clin Pharmacokinet 2013)
- The weight-loss drug orlistat cuts exposure to active dalcetrapib by more than half by blocking its ester hydrolysis (J Cardiovasc Pharmacol 2012)
- Review details the mode of action and clinical profile of dalcetrapib as dal-OUTCOMES interim results end its development (Expert Opin Investig Drugs 2012)
- Liver tumors seen in a 2-year mouse study of dalcetrapib trace to a rodent-specific pathway not relevant to humans (Toxicol Appl Pharmacol 2012)
- Dalcetrapib cut CETP activity up to 58% and raised HDL-C up to 34% regardless of diabetes or metabolic syndrome status (Diabetes Obes Metab 2012)
- A high-fat meal raises exposure to dalcetrapib by up to 44 percent across three phase I crossover studies (Clin Ther 2011)
- Intestinal and hepatic first-pass metabolism strips more than 90 percent of active dalcetrapib-thiol in monkeys (Xenobiotica 2011)
- Ezetimibe does not blunt the HDL-raising effect of dalcetrapib, and each drug leaves the other pharmacokinetics largely unchanged (Br J Clin Pharmacol 2010)
- Atorvastatin reduces exposure to dalcetrapib without diminishing its cardiovascular benefit, two crossover studies find (Expert Opin Investig Drugs 2010)
- Even at more than 6 times the therapeutic dose, dalcetrapib does not prolong the QT interval in healthy subjects (Eur J Clin Pharmacol 2010)
- Rosuvastatin raises its own peak concentration by 26 percent when combined with dalcetrapib, but the LDL benefit of the combination still exceeds statin alone (J Clin Pharmacol 2010)
- The rodent-specific scavenger receptor MARCO drives the off-target lipid uptake seen with dalcetrapib in mouse macrophages (Toxicol In Vitro 2010)
- JTT-705, the dalcetrapib precursor compound, blocks LPS-triggered TNF-alpha production in mice by targeting a cysteine on MD-2 (J Biol Chem 2009)
- Dalcetrapib inhibits CYP enzymes in vitro but has no clinically relevant drug interaction with a five-probe drug cocktail (Curr Med Res Opin 2009)
- Ketoconazole unexpectedly lowers exposure to dalcetrapib rather than raising it, contrary to typical CYP3A4-inhibitor interactions (Clin Ther 2009)
- A review links the B1B1 CETP genotype to higher CETP activity, lower HDL cholesterol, and more pronounced postprandial lipemia (Curr Med Chem 2009)
- JTT-705 (dalcetrapib) raised HDL-C 26% and improved endothelial function only in low-baseline-HDL patients (Thromb Res 2009)
- A review concludes the mineralocorticoid-driven hypertension seen with torcetrapib is not a CETP-inhibitor class effect, since JTT-705 and MK-825 do not raise blood pressure (Nat Clin Pract Cardiovasc Med 2008)
- A review of CETP inhibition in dyslipidemia finds that the benefit of raising HDL depends heavily on triglyceride-rich lipoprotein levels (Curr Atheroscler Rep 2007)
- Torcetrapib can double HDL cholesterol while lowering LDL cholesterol by up to 42 percent, a review of CETP inhibitors reports (Curr Opin Pharmacol 2006)
- A review traces the CETP-inhibitor rationale from CETP-deficient Japanese populations with high HDL to early human trials of torcetrapib and JTT-705 (J Am Coll Cardiol 2006)
- A review finds genetic and plasma CETP-level studies give no clear answer on whether CETP inhibition will reduce atherosclerosis risk (Curr Drug Targets Cardiovasc Haematol Disord 2005)
- Prospective cohort data link elevated CETP concentration to higher cardiovascular risk only when triglycerides are also high (Curr Opin Lipidol 2004)
- JTT-705 reshapes HDL toward larger, apolipoprotein E-rich particles with more antioxidant enzyme activity in rabbits (Arterioscler Thromb Vasc Biol 2004)
- JTT-705 raises HDL cholesterol in rabbits by speeding up apolipoprotein A-I synthesis, not by slowing its breakdown (Atherosclerosis 2004)
- HDL from rabbits treated with JTT-705 removes cholesterol from macrophages just as efficiently as normal HDL, despite higher CETP-inhibited levels (Atherosclerosis 2002)
- Systematic review of 49 cardiovascular calcification trials finds dalcetrapib among the singleton agents showing no benefit (J Am Heart Assoc 2023)
- Review highlights ADCY9 pharmacogenomics as a model for rescuing dalcetrapib and future lipid trials (Curr Opin Lipidol 2016)
- dal-PLAQUE substudy finds dalcetrapib did not affect progression of vascular calcification (J Am Coll Cardiol 2016)
- High-pressure crystallization confirms a predicted, more stable polymorph of dalcetrapib before late-stage development (Nat Commun 2015)
- Probenecid raises exposure to the active thiol form of dalcetrapib by up to 21 percent (Int J Clin Pharmacol Ther 2013)
- Dalcetrapib is hydrolyzed within 20 seconds in human intestinal fluid, but is stable in gastric fluid at low pH (Int J Pharm 2012)
- Dalcetrapib does not affect the pharmacokinetics of a combined oral contraceptive in a crossover trial (Int J Clin Pharmacol Ther 2012)
- Torcetrapib can raise HDL cholesterol by up to 106 percent alone or combined with atorvastatin, a review of emerging HDL-raising therapies notes (Curr Drug Targets 2007)
- A review makes the case for CETP inhibition as a novel strategy to reduce residual atherosclerotic risk beyond statin therapy (Eur Heart J 2007)
- A review of HDL-raising therapy notes that both JTT-705 and torcetrapib attenuate aortic atherosclerosis in cholesterol-fed rabbits (Pharmacol Ther 2006)
- A review outlines early evidence that CETP inhibitors JTT-705 and torcetrapib raise HDL and lower LDL cholesterol in mildly dyslipidaemic patients (Expert Opin Investig Drugs 2006)
- Torcetrapib 120 mg per day raises HDL cholesterol by 46 percent and lowers LDL cholesterol by 8 percent in subjects with low HDL, a review reports (Expert Opin Investig Drugs 2004)
- LC-MS/MS method quantifies dalcetrapib-thiol and its S-methyl and S-glucuronide metabolites down to 5 ng/mL (J Pharm Biomed Anal 2012)
- The dal-PLAQUE study is designed to track dalcetrapib effects on carotid plaque burden and inflammation with MRI and PET/CT (Am Heart J 2011)
- The dal-VESSEL study is designed as the largest trial of brachial flow-mediated dilatation to test dalcetrapib effects on endothelial function (Curr Med Res Opin 2011)
Torcetrapib 117
ILLUMINATE: the off-target pressor effect that defined the class.
- A 34-year genetic study finds CETP-lowering variants cut ischemic heart disease risk by 24 percent with no adverse effects seen with torcetrapib (J Am Coll Cardiol 2012)
- Mendelian randomization shows the hypertensive effect of torcetrapib is not caused by CETP inhibition (Circulation 2010)
- The ILLUMINATE trial halts torcetrapib development after finding a 58 percent rise in death from any cause despite a 72 percent HDL cholesterol increase (N Engl J Med 2007)
- The ILLUSTRATE trial finds coronary atheroma regression on torcetrapib only in patients reaching the highest quartile of HDL-C rise (Circulation 2008)
- Pooled RADIANCE trial data link the carotid-thickening harm of torcetrapib to a mineralocorticoid effect, not to its HDL-raising action (Circulation 2008)
- The RADIANCE 2 trial finds torcetrapib raises blood pressure and HDL but does not slow carotid thickening in mixed dyslipidaemia (Lancet 2007)
- The ILLUSTRATE trial finds no significant slowing of coronary atheroma progression from torcetrapib despite reaching an LDL-to-HDL ratio below 1.0 (N Engl J Med 2007)
- The RADIANCE 1 trial finds torcetrapib worsens common carotid thickening in familial hypercholesterolemia despite raising HDL to 81.5 mg per dL (N Engl J Med 2007)
- Twice-daily torcetrapib doubles HDL cholesterol in the first published proof-of-concept trial of a CETP inhibitor (N Engl J Med 2004)
- The first human trial of torcetrapib raises HDL cholesterol by up to 91 percent while producing a lipid profile resembling partial CETP deficiency (Arterioscler Thromb Vasc Biol 2004)
- A proteomic risk score could have flagged harm from torcetrapib within 3 months of ILLUMINATE, revealing unexpected immune and inflammatory effects (Circulation 2018)
- The excess mortality and cardiovascular harm of torcetrapib were confined to the low-dose atorvastatin subgroup in ILLUMINATE (J Lipid Res 2012)
105 more in Torcetrapib
- Torcetrapib improved glycemic control in 6,661 diabetic ILLUMINATE participants despite the overall harm of the trial (Circulation 2011)
- People with genetically reduced CETP levels have lower, not higher, blood pressure, arguing against a CETP class effect behind the hypertension seen with torcetrapib (Mayo Clin Proc 2010)
- Torcetrapib impairs blood vessel dilation through a mechanism unrelated to CETP inhibition or HDL elevation, unlike a structurally different CETP inhibitor (J Cardiovasc Pharmacol 2010)
- Torcetrapib induces adrenal aldosterone and cortisol via intracellular calcium signaling, unrelated to CETP inhibition (Endocrinology 2009)
- CETP gene variants that raise HDL cholesterol actually lower diastolic blood pressure, arguing the hypertension seen with torcetrapib is compound specific (Pharmacogenet Genomics 2008)
- Torcetrapib binds CETP roughly 5-fold tighter to HDL, locking it into a nonproductive complex that blocks all major lipid transfer (J Lipid Res 2006)
- Proteomics plus Mendelian randomisation could have flagged the blood-pressure toxicity of torcetrapib before ILLUMINATE, a proof-of-concept analysis argues (medRxiv preprint 2025)
- Torcetrapib raised HDL ApoC-III and LpA-I subclasses without altering ApoB particles in ILLUMINATE (Am J Cardiol 2017)
- Torcetrapib cuts insulin levels by 49 percent and improves glucose uptake across tissues in insulin-resistant hamsters (Atherosclerosis 2014)
- Network pharmacology points to PDGFR, HGFR, and IL-2 receptor as possible off-target drivers of the cardiovascular harm from torcetrapib (BMC Syst Biol 2012)
- CETP inhibition alone fails to boost reverse cholesterol transport in hamsters unless paired with the LDL-lowering drug berberine (Arterioscler Thromb Vasc Biol 2013)
- Crystal structures show torcetrapib and a second inhibitor block the lipid-transfer tunnel of CETP at its narrow neck (J Biol Chem 2012)
- Torcetrapib cuts apoB-48 production by nearly half, but the effect vanishes in patients already on atorvastatin (J Lipid Res 2012)
- Review argues the off-target harm of torcetrapib is not a class effect shared by dalcetrapib, anacetrapib, and evacetrapib (Drugs 2012)
- CETP inhibition boosts the cholesterol-removing power of large HDL2b particles after a meal, but not their delivery to the liver (Atherosclerosis 2012)
- Torcetrapib boosts reverse cholesterol transport by 118 percent in obese, insulin-resistant transgenic mice (Clin Transl Sci 2011)
- Torcetrapib impairs endothelial function and raises vascular oxidative stress in hypertensive rats, reversed by endothelin blockade (Eur Heart J 2012)
- CETP actually boosts the ability of HDL to block LDL oxidation, a finding that may help explain why torcetrapib failed to slow vascular disease (IUBMB Life 2011)
- Torcetrapib raises blood pressure in dogs through systemic and pulmonary vasoconstriction that also strains the heart (J Cardiovasc Pharmacol 2009)
- HDL from patients on high-dose torcetrapib removes more cholesterol from macrophages, correlating with the atheroma regression seen on the drug (Am J Cardiol 2009)
- Barter reflects on ILLUMINATE: the harm caused by torcetrapib likely reflects off-target effects, not CETP inhibition itself (Am J Cardiol 2009)
- Torcetrapib and CP-532,623 raise blood pressure via a chemotype-specific mechanism dissociated from CETP inhibition timing (J Cardiovasc Pharmacol 2009)
- Genome-wide protein-ligand network analysis maps the off-target pathways behind the hypertensive side effect of torcetrapib (PLoS Comput Biol 2009)
- Torcetrapib raises apolipoprotein A-II levels by slowing its clearance and shifting it into a different HDL subpopulation (J Lipid Res 2009)
- Torcetrapib partly restores healthy HDL2 and HDL3 function in type IIB hyperlipidemia, boosting cholesterol efflux by up to 38 percent (Arterioscler Thromb Vasc Biol 2009)
- A review notes a meta-analysis linking CETP-lowering alleles to reduced coronary heart disease, distinct from the off-target failure of torcetrapib (J Lipid Res 2009)
- Natural variation in plasma CETP levels does not affect RAAS responsiveness or blood pressure reactivity in healthy men (Expert Opin Ther Targets 2008)
- Torcetrapib produces smaller but more inflamed, less stable plaques than atorvastatin in humanized transgenic mice (Circulation 2008)
- A Nature Reviews Drug Discovery analysis asks whether the torcetrapib failure means functional quality of HDL matters more than its circulating quantity (Nat Rev Drug Discov 2008)
- Both raising and lowering CETP activity can enhance reverse cholesterol transport, depending on the species and pathway studied (Cardiovasc Res 2008)
- A review proposes that the now-known crystal structure of CETP could guide the design of inhibitors that avoid the nonproductive HDL complex formed by torcetrapib (Am J Cardiol 2007)
- Torcetrapib reduces VLDL apolipoprotein E levels alone, but on background atorvastatin instead boosts its content and speeds VLDL clearance (J Lipid Res 2008)
- Torcetrapib cuts postprandial VLDL-1 by 40 percent and reduces its atherogenic cholesteryl-ester content in type IIB hyperlipidemia (Arterioscler Thromb Vasc Biol 2008)
- A review says the CETP crystal structure could enable inhibitors that avoid the nonproductive HDL-binding complex formed by torcetrapib (Curr Opin Cardiol 2007)
- Torcetrapib cuts aortic atherosclerosis by 60 percent in rabbits fed an atherogenic diet, tracking the ratio of total cholesterol to HDL (J Lipid Res 2007)
- Doubling the dose of torcetrapib from 60 to 120 mg turns a modest boost in macrophage cholesterol efflux into a dramatic one (Arterioscler Thromb Vasc Biol 2007)
- Torcetrapib alone raises HDL cholesterol by up to 54.5 percent, with less LDL benefit in patients with high triglycerides (J Am Coll Cardiol 2006)
- Adding torcetrapib to atorvastatin raises HDL cholesterol by up to 40 percent with no dose-related rise in adverse events (J Am Coll Cardiol 2006)
- Torcetrapib alone clears apoB100 faster, but added to atorvastatin it instead cuts LDL and IDL production (Arterioscler Thromb Vasc Biol 2006)
- Two novel CETP gene variants are found in humans, and torcetrapib inhibits both variant and normal CETP equally (Biochim Biophys Acta 2005)
- CETP directly delivers HDL cholesteryl ester to the liver through a receptor-independent pathway that torcetrapib only partly blocks (Arterioscler Thromb Vasc Biol 2005)
- Torcetrapib raises apolipoprotein A-I in alpha1-migrating HDL by up to 382 percent at twice-daily dosing, without changing fecal sterol excretion (Arterioscler Thromb Vasc Biol 2005)
- Torcetrapib inhibits every common CETP genetic variant equally, even the two that are naturally more stable in the body (J Biol Chem 2005)
- A turmeric compound, calebin A, binds CETP nearly as tightly as torcetrapib in a computational drug-discovery screen (Res Pharm Sci 2026)
- How CETP moves cholesterol between lipoproteins: a structural review of the mechanism behind torcetrapib, anacetrapib and obicetrapib (Curr Atheroscler Rep 2023)
- Adding torcetrapib to atorvastatin lowers lipoprotein(a) by 11 percent while modestly raising PCSK9, an ILLUMINATE biomarker substudy finds (J Clin Lipidol 2018)
- BMS-795311 matches torcetrapib for raising HDL in hamsters without raising blood pressure or aldosterone synthase (J Med Chem 2015)
- Lipid-based drug delivery greatly improves oral exposure to two CETP inhibitors, torcetrapib and CP-532,623, in beagle dogs (Eur J Pharm Biopharm 2014)
- Novel non-THQ torcetrapib analog PF-04445597 avoids the aldosterone-inducing effect linked to torcetrapib toxicity (Xenobiotica 2014)
- Torcetrapib raises blood pressure across four independent cardiovascular models, validating them as predictive lead-optimization tools (J Cardiovasc Pharmacol 2012)
- A review of biomarker and imaging trials shows the favorable lipid effects of torcetrapib failed to predict a 58 percent rise in mortality (Can J Cardiol 2012)
- A structural-and-metabolic-network computational model predicts off-target causes of the hypertensive side effect of torcetrapib in kidney tissue (PLoS Comput Biol 2010)
- Review traces the ILLUMINATE mortality signal of torcetrapib to adrenal aldosterone secretion, not receptor blockade (Hypertens Res 2010)
- Noninvasive high-definition oscillometry matches implanted telemetry for tracking torcetrapib-induced blood pressure rises in dogs (J Am Assoc Lab Anim Sci 2010)
- A review of CETP molecular mechanisms notes the negative phase III torcetrapib trials challenged the future of the drug class (Cell Mol Life Sci 2010)
- A humanized transgenic mouse model shows torcetrapib raises HDL cholesterol by 53 percent, less than a potent PPAR-alpha agonist (J Cardiovasc Pharmacol Ther 2010)
- A review argues that after the torcetrapib failure, HDL functionality biomarkers are needed since HDL cholesterol alone is not a functional measure (Expert Rev Cardiovasc Ther 2010)
- A review argues that the harms of torcetrapib trace to its own tight CETP binding and an aldosterone-like effect, not to CETP inhibition itself (Rom J Intern Med 2010)
- A review argues the mortality signal from torcetrapib traces to off-target toxicity, not to CETP inhibition itself (Am J Cardiol 2009)
- Torcetrapib does not block CETP or LPS-binding-protein interactions, ruling out a direct sepsis-mortality mechanism (J Lipid Res 2010)
- A conformationally constrained CETP inhibitor matches the HDL-raising efficacy of torcetrapib across hamsters, transgenic mice, and monkeys (J Med Chem 2009)
- A translational-medicine commentary argues the failure of 4 large torcetrapib trials calls for biomarker-driven drug development, not abandonment of CETP as a target (Biochem Pharmacol 2009)
- A review draws lessons from ILLUMINATE on the hypertension risk of CETP inhibitors despite raising HDL cholesterol by up to 100 percent (Curr Hypertens Rep 2009)
- A review weighs four possible explanations for why torcetrapib raised cardiovascular risk despite raising HDL cholesterol (Ann Med 2009)
- A review argues the off-target effects of torcetrapib, not the CETP-inhibition mechanism itself, likely overrode any cardiovascular benefit (Cardiol Clin 2008)
- Biosensor mapping places the torcetrapib binding site at Cys-13 in the CETP lipid-binding pocket (Bioconjug Chem 2008)
- A review argues ABCA1 and ABCG1 transporters, not raw HDL cholesterol level, drive HDL's atheroprotective effect after the torcetrapib failure (Cell Metab 2008)
- A review argues four disappointing torcetrapib trials require refining the HDL hypothesis, since HDL may be more carrier protein than cholesterol transporter (Ann Med 2008)
- A review questions whether CETP inhibitors can ultimately reduce cardiovascular events after torcetrapib raised blood pressure without slowing coronary atherosclerosis (Am J Cardiol 2007)
- A meta-analysis of 23 trials finds HDL-raising tracks with reduced atherosclerosis progression for every drug class except the torcetrapib-atorvastatin combination (J Clin Lipidol 2007)
- Review asks whether torcetrapib will become the next big advance in coronary heart disease prevention (Curr Atheroscler Rep 2007)
- A review previews a large-scale CETP-inhibitor imaging and outcomes program as the next frontier after statin-driven atherosclerosis regression (Can J Cardiol 2006)
- Doubling torcetrapib to its maximum tolerated dose more than doubles HDL cholesterol when combined with atorvastatin (Drugs Today 2006)
- A review of torcetrapib/atorvastatin combination therapy covers the chemistry, mechanism, and pharmacokinetics behind their complementary lipid effects (Expert Rev Cardiovasc Ther 2005)
- An acoustic-fusion formulation of torcetrapib boosts drug exposure roughly 8-fold over a crystalline suspension in rats (Int J Pharm 2021)
- Torcetrapib increases large HDL particles more than a novel FXR antagonist in a hamster model of dyslipidemia (Pharmacol Res Perspect 2018)
- A review appraises whether newer CETP inhibitors can avoid the off-target effects that undid torcetrapib (Curr Cardiol Rep 2016)
- Torcetrapib raises HDL cholesterol in primates without touching non-HDL cholesterol, distinguishing it from an FXR antagonist tested alongside it (Life Sci 2014)
- A review argues the torcetrapib setback shifted focus from HDL cholesterol quantity to HDL particle functionality (Am J Ther 2014)
- A review questions whether CETP inhibition can reduce cardiovascular events given the complex link between CETP loss-of-function and coronary risk (Curr Cardiol Rep 2011)
- A review finds niacin remains the most potent HDL-raising therapy while CETP inhibitors stand closest to clinic despite the mortality signal seen with torcetrapib (Curr Treat Options Cardiovasc Med 2010)
- A workaround measures two acyl-glucuronide metabolites of torcetrapib in monkey urine without ever having reference standards for them (Biomed Chromatogr 2010)
- A review of nonstatin add-on therapies finds torcetrapib raised mortality in coronary patients despite a marked rise in HDL cholesterol (Curr Atheroscler Rep 2009)
- Adding a bile correction factor sharpens allometric prediction of human pharmacokinetic parameters for orally dosed torcetrapib (Eur J Drug Metab Pharmacokinet 2009)
- A perspective argues the torcetrapib failure should redirect HDL drug development away from raw cholesterol concentration and toward specific antiatherosclerotic components (Ann Clin Biochem 2009)
- A review argues the torcetrapib failure highlights HDL functionality, not raw HDL cholesterol level, as the real therapeutic target (Curr Opin Investig Drugs 2008)
- Torcetrapib is extensively metabolized in humans with terminal half-lives of 211 to 373 hours (Drug Metab Dispos 2008)
- A review proposes injecting synthetic HDL directly as an alternative after torcetrapib, the furthest-developed HDL-raising pill, was halted for excess mortality (Nutr Metab Cardiovasc Dis 2008)
- A review attributes the excess deaths seen with torcetrapib to an off-target effect, not to CETP inhibition, while low HDL remains an important risk marker (Curr Opin Endocrinol Diabetes Obes 2008)
- A review argues the torcetrapib failure shifted laboratory focus from HDL cholesterol concentration to HDL particle heterogeneity and function (Clin Chem 2008)
- A new LC-MS/MS assay quantifies torcetrapib in hamster and dog plasma down to 1 nanogram per mL (Biomed Chromatogr 2008)
- A post hoc review of the safety monitoring board for the torcetrapib trial warns against over-relying on formal statistical stopping rules (Eur J Clin Pharmacol 2008)
- A regulatory perspective argues the termination of torcetrapib means future HDL therapies will need preapproval proof of effects on actual disease progression (Am J Cardiol 2007)
- A chiral HPLC method separates the two torcetrapib enantiomers in hamster plasma down to 0.1 microgram per mL (J Chromatogr B 2007)
- A review argues the torcetrapib failure highlighted the gap between HDL cholesterol levels and HDL anti-inflammatory function (J Clin Lipidol 2007)
- Hypothesis paper proposes that the ILLUMINATE deaths from torcetrapib trace to eNOS inhibition via HDL-SR-BI signaling loss (Med Hypotheses 2007)
- Torcetrapib shifts almost entirely into triglyceride-rich lipoproteins in hyperlipidemic human plasma (Pharm Res 2006)
- A review argues raising HDL with torcetrapib is a promising new approach to atherosclerosis, pending trials with hard clinical endpoints (Recent Pat Cardiovasc Drug Discov 2006)
- A review of four lipid transfer proteins highlights the early human results of torcetrapib as opening a new era in coronary heart disease prevention (Atherosclerosis 2005)
- A review catalogs the chiral and achiral bioanalytical methods developed to measure torcetrapib across six species (Bioanalysis 2009)
- Torcetrapib forms more than 28 species-dependent metabolites in rats, monkeys, and mice (Drug Metab Dispos 2008)
- A diabetes-dyslipidemia review predicts the disappointing torcetrapib results will renew interest in niacin therapy (Curr Opin Endocrinol Diabetes Obes 2008)
- Chiral LC-MS/MS assay separates torcetrapib enantiomers in hamster plasma down to 5 ng/mL (J Chromatogr B 2007)
- Self-emulsifying formulation cuts the food effect of torcetrapib from 5-fold to 3-fold in dogs (Int J Pharm 2008)
- RADIANCE 1 and 2 are designed to compare torcetrapib plus atorvastatin against atorvastatin alone in over 1,650 patients using carotid ultrasound (Curr Med Res Opin 2007)
Outcomes trials 36
The hard-endpoint record of the whole class.
- Drug-target Mendelian randomization confirms CETP as an effective target for coronary heart disease with an on-target macular degeneration risk (Nat Commun 2021)
- A genome-wide association study identifies protective CETP gene variants underlying cardiovascular resilience in older adults (J Am Heart Assoc 2023)
- A meta-analysis of 62,565 patients confirms CETP inhibitors raise HDL cholesterol by 130 percent yet still fail to reduce cardiovascular events (J Cardiovasc Pharmacol 2026)
- Two CETP gene variants independently predict worse outcomes after ischemic stroke, alongside HMGCR and PCSK9 variants (J Am Heart Assoc 2024)
- Mendelian randomisation across ancestries: CETP inhibition should protect against cardiovascular disease equally in East Asian and European populations (Nat Commun 2024)
- Drug-target Mendelian randomization finds CETP and other lipid drug targets have distinct metabolomic signatures despite similar CAD benefit (PLoS Biol 2022)
- JACC review: four CETP inhibitors reached phase 3, one died, two were stopped for futility, and the survivor was shelved over fat accumulation (J Am Coll Cardiol 2019)
- CETP inhibitor trials reframe the HDL hypothesis around apoB lowering rather than HDL-C raising (Drugs 2026)
- Review surveys why raising HDL with CETP inhibitors and apoA1 infusion has failed to cut cardiovascular events (Clin Med Res 2025)
- CETP inhibitors in precision medicine: a review ties three phase 3 failures, the shelving of anacetrapib over fat accumulation, and the ADCY9 pharmacogenomic clue together (Clin Chim Acta 2020)
- Meta-analysis of 332,912 patients: lowering apoB only cuts cardiovascular risk when it works through the LDL receptor, not via CETP inhibitors or fibrates (Eur J Prev Cardiol 2020)
- Do CETP inhibitors have a role in treating cardiovascular disease? A review weighs harm, futility and modest benefit against emerging genomic clues (Am J Cardiovasc Drugs 2019)
24 more in Outcomes trials
- CETP and its inhibitors, a foundational review: structure, mechanism, non-lipid functions and the full outcomes-trial record for four small-molecule inhibitors (J Lipid Res 2018)
- CETP genetic variants do not predict recurrent heart attacks in secondary prevention patients, but may raise mortality after bypass surgery (Am J Cardiol 2013)
- Review tallies the HDL-C and LDL-C effects of each CETP inhibitor ahead of anacetrapib and evacetrapib outcomes in 2017 (Curr Pharm Des 2013)
- Review tallies CETP inhibitor trial results from the 2006 failure of torcetrapib to the early promise of evacetrapib (Curr Opin Lipidol 2012)
- Barter and Rye review the CETP inhibition hypothesis after the harm caused by torcetrapib and the futility of dalcetrapib (J Lipid Res 2012)
- Schwartz reviews conflicting CETP genetic and animal evidence ahead of the anacetrapib and dalcetrapib outcomes trials (Curr Atheroscler Rep 2012)
- Review compiles dal-VESSEL, dal-PLAQUE, and DEFINE lipid results ahead of dal-OUTCOMES and REVEAL in 2013 and 2017 (Vasc Health Risk Manag 2012)
- Barter and Rye ask where CETP inhibition stands after the off-target failure of torcetrapib (Trends Pharmacol Sci 2011)
- Review traces CETP inhibition from a Japanese deficiency discovery to the ILLUMINATE termination of torcetrapib and early anacetrapib data (Cardiol Rev 2008)
- Plasma CETP, alongside EPCR, is an independent MACE risk factor in older men with chronic coronary syndrome and improves on the Framingham score (Front Cardiovasc Med 2022)
- Meta-analysis of 154,601 patients: HDL-raising drugs including CETP inhibitors do not cut cardiovascular or all-cause mortality, and any MI benefit traces to fibrates (Eur J Prev Cardiol 2019)
- CV risk, CV benefit, or both? A review takes stock of CETP inhibitors after preclinical promise met mostly disappointing outcome trials (Clin Pharmacol Ther 2018)
- Patent review tracks CETP inhibitor development from 2009 to 2017 despite four phase 3 drugs falling short on cardiovascular outcomes (Expert Opin Ther Pat 2018)
- Review surveys CETP inhibitor outcome trials from the harm of torcetrapib to the futility of later agents (Curr Opin Lipidol 2016)
- Review compares torcetrapib, evacetrapib, dalcetrapib and anacetrapib trial outcomes and the future of CETP inhibition (J Cardiovasc Pharmacol Ther 2017)
- CETP inhibition is not yet dead, argues a pro perspective ahead of the REVEAL trial (Arterioscler Thromb Vasc Biol 2016)
- Review previews two pending phase 3 trials that will decide the future of CETP inhibition (Curr Opin Lipidol 2015)
- Systematic review tracks CETP inhibitors from the toxicity of torcetrapib to the greater potency and safety of anacetrapib and evacetrapib (Am J Ther 2015)
- Perspective reviews the discovery and development of CETP inhibitors for reducing residual cardiovascular risk (J Med Chem 2014)
- Review narrates the CETP inhibitor class from the mortality excess of torcetrapib to the still-pending REVEAL and ACCELERATE trials (Curr Opin Cardiol 2013)
- Higher preoperative plasma CETP is one of four protein signals linked to atrial fibrillation after bypass surgery (J Thorac Cardiovasc Surg 2021)
- A hospital pharmacy bulletin sums up CETP inhibitors for practising pharmacists: three failures, then a REVEAL success for anacetrapib (Hosp Pharm 2017)
- Review recounts how ILLUMINATE, RADIANCE, and ERASE ended the promise of torcetrapib for isolated low HDL syndrome (Am J Ther 2008)
- Brief review previews CETP inhibitor trial results as REVEAL data for anacetrapib approaches (Eur Cardiol 2015)
The class 298
CETP inhibition as a strategy: rationale, comparisons, where it stands.
- Genetically lower CETP activity reduces dementia risk in a 1,091,775-person Mendelian randomization meta-analysis (Alzheimers Dement 2025)
- Landmark genetic study explains why CETP inhibitors lower LDL cholesterol without reducing cardiovascular events (JAMA 2017)
- Meta-regression of 312 175 patients shows CETP inhibitors deliver less cardiovascular benefit than their LDL-lowering predicts (JAMA 2016)
- Structural study proposes a tunnel-bridging mechanism for how CETP transfers cholesteryl ester between HDL and LDL (Nat Chem Biol 2012)
- First crystal structure of CETP reveals a 60-angstrom tunnel holding four lipid molecules (Nat Struct Mol Biol 2007)
- Cys-13, positioned near CETP's neutral-lipid-binding site, is identified as essential for irreversible inhibitor binding via mutagenesis and mass spectrometry (J Lipid Res 2000)
- A CETP-targeting vaccine cuts plasma CETP activity, raises HDL by 42%, and shrinks aortic lesions 39.6% in rabbits (Arterioscler Thromb Vasc Biol 2000)
- Drug-target Mendelian randomization finds lower CETP concentration cuts Lewy body and Parkinson's dementia risk, especially in APOE-e4 carriers (Alzheimers Res Ther 2024)
- A 425,354-person UK Biobank Mendelian randomization study finds genetically lower CETP cuts coronary artery disease risk with additive benefit alongside PCSK9 (JAMA Cardiol 2022)
- CETP inhibition is identified as the optimal target for managing dyslipidemia in systemic lupus erythematosus (Int Immunopharmacol 2025)
- Drug-target Mendelian randomization finds genetically proxied CETP inhibition protects against subarachnoid hemorrhage with no safety signal (Eur Stroke J 2025)
- Mendelian randomization finds CETP inhibition uniquely associated with increased breast cancer risk among lipid-lowering drug targets (Cancer Causes Control 2024)
286 more in The class
- Landmark hypothesis proposes CETP as an immunological gatekeeper that could be repurposed to treat sepsis (Trends Endocrinol Metab 2020)
- Protein-truncating CETP variants lower coronary heart disease risk by 30 percent in a 58 469-participant sequencing study (Circ Res 2017)
- A chimeric anti-CETP vaccine shrinks aortic plaques by over 40 percent in cholesterol-fed rabbits (Life Sci 2005)
- Liver-targeted antisense oligonucleotides against CETP suppress atherosclerosis in cholesterol-fed rabbits (J Biol Chem 1998)
- First demonstration that liver-targeted antisense oligonucleotides against CETP lower LDL and raise HDL in cholesterol-fed rabbits (J Biol Chem 1996)
- Cis-Mendelian randomization finds CETP modification reduces both coronary disease and type 2 diabetes risk (Cardiovasc Diabetol 2026)
- CETP rs3764261 genotype modifies the HDL-C lowering effect of a vegetarian diet in 9,263 adults (Taiwan Biobank) (Front Nutr 2026)
- Mendelian randomization finds genetically proxied CETP inhibition sharply raises the risk of primary Sjögren's syndrome (Curr Pharm Biotechnol 2026)
- CETP inhibitors reduce disease severity in experimental colitis by reprogramming macrophages and boosting gut barrier function (J Lipid Res 2025)
- Mendelian randomization finds genetically proxied CETP inhibition reduces sepsis-related critical care admission and death (World J Emerg Med 2025)
- CETP-derived peptide Seq-1 directly suppresses pro-fibrotic gene expression in liver cells beyond its role in the anti-CETP vaccine (Arch Med Res 2024)
- Combining CETP and SGLT2 inhibition genetically improves glycaemic control beyond either alone (Front Endocrinol (Lausanne) 2024)
- Drug-target Mendelian randomization links genetically lower CETP to longer human lifespan (Aging 2023)
- Genetic evidence suggests the HDL cholesterol-sepsis association is not causally mediated through CETP (Clin Transl Sci 2023)
- Mendelian randomization finds genetically proxied CETP inhibition, mediated through HDL cholesterol, reduces Crohn's disease risk (Front Immunol 2023)
- Meta-analysis finds CETP inhibitor therapy cuts diabetes incidence by 12 percent (Diabetes Metab 2018)
- CETP redistributes the vasoprotective lipid sphingosine-1-phosphate from HDL to apoB lipoproteins, changing which signals it triggers (Arterioscler Thromb Vasc Biol 2017)
- Yamashita argues CETP inhibition may backfire by generating small dense LDL and downregulating hepatic SR-BI (Curr Opin Lipidol 2016)
- Mendelian randomization meta-analysis of 40,000 subjects finds lower circulating CETP causally reduces coronary heart disease risk (Circ Cardiovasc Genet 2015)
- BMJ meta-analysis of 117,411 patients finds niacin, fibrates, and CETP inhibitors do not reduce mortality on top of statins (BMJ 2014)
- Provocative 2014 opinion piece argues the evidence had turned against CETP inhibition and calls for an urgent trial review (F1000Res 2014)
- Meta-analysis of 12 trials finds CETP inhibitors raise HDL-c by 20.5 mg/dL and lower LDL-c by 17.1 mg/dL, with a blood-pressure signal from torcetrapib (PLoS One 2013)
- Higher on-statin CETP mass predicts fewer recurrent coronary events in the PROVE IT-TIMI 22 trial (Am J Cardiol 2010)
- Low plasma CETP predicts higher mortality in nondiabetic coronary disease patients in the KAROLA cohort (Eur J Clin Invest 2010)
- LURIC study of 3,256 angiography patients finds low, not high, CETP levels predict mortality (Circulation 2010)
- Higher circulating CETP activity predicts fewer cardiovascular events over 15 years in the Framingham Heart Study (Circulation 2009)
- Genetically low CETP predicts higher 10-year mortality in statin-treated men with coronary artery disease (Eur Heart J 2008)
- Hepatic lipase and CETP gene variants interact to raise HDL-C, but the combined genotype does not lower cardiovascular risk (J Clin Endocrinol Metab 2007)
- CETP haplotype linked to higher HDL-C across three populations shows no association with coronary heart disease risk (Hum Genet 2007)
- CETP inhibition in rabbits blocks one HDL cholesteryl ester removal pathway but does not compromise overall clearance from plasma (Arterioscler Thromb Vasc Biol 2005)
- An apoE-peptide carrier delivers antisense DNA into cell nuclei, cutting CETP mRNA over 50% and CETP activity to 53.8% of control in CHO cells (Arterioscler Thromb Vasc Biol 1999)
- CETP activity enhances plasma cholesteryl ester formation, confirmed in transgenic mice, hamsters, and humans with genetic CETP deficiency (Arterioscler Thromb Vasc Biol 1997)
- CGS 25159, a synthetic isoflavan CETP inhibitor, cuts VLDL+LDL cholesterol 28% and raises HDL cholesterol 29% in hamsters (Atherosclerosis 1997)
- Two novel compounds inhibit CETP by distinct mechanisms: U-95,594 competitively blocks all lipid transfer, U-617 selectively and irreversibly blocks CE transfer (Biochemistry 1995)
- A monoclonal antibody against CETP raises hamster HDL cholesterol 33% and cuts HDL triglyceride 42% in vivo (Atherosclerosis 1994)
- Natural flanking sequences enable dietary cholesterol to boost human CETP gene transcription up to fivefold in transgenic mice (J Clin Invest 1992)
- A neutralizing monoclonal antibody doubles HDL cholesteryl ester in rabbits by blocking CETP in vivo (J Clin Invest 1989)
- Mendelian randomisation suggests genetically proxied CETP inhibition may lower intracranial aneurysm risk (Neurosurg Rev 2026)
- A review traces how CETP-inhibitor design evolved from first-generation scaffolds plagued by off-target toxicity to optimized late-generation clinical candidates (Eur J Med Chem 2026)
- CETP inhibitors cut lipoprotein(a) by 46 percent, the largest reduction among all lipid-lowering drug classes in a 147-trial meta-analysis (Atherosclerosis 2025)
- Mendelian randomization links CETP inhibition to lower lacunar stroke risk via cerebral small vessel disease genetics (Brain 2025)
- Genetic CETP deficiency review: heterozygotes have lower ASCVD risk, homozygotes show no excess risk, and very high HDL-C raises AMD questions (J Atheroscler Thromb 2025)
- Mendelian randomization links CETP inhibition and elevated LDL cholesterol to Lewy body dementia risk (Prog Neuropsychopharmacol Biol Psychiatry 2025)
- Genetic proxies for CETP inhibition are linked to lower preeclampsia risk in a Mendelian randomization study (Int J Womens Health 2025)
- Meta-analysis of seven studies: adding a CETP inhibitor to high-intensity statins significantly raises HDL-C and lowers LDL-C with no added adverse events (Front Endocrinol 2025)
- Mendelian randomization finds genetically raised HDL via CETP predicted to lower small vessel stroke risk (J Am Heart Assoc 2024)
- Mendelian randomization links the LDL-lowering effect of CETP to reduced obstructive sleep apnea risk (Toxicol Appl Pharmacol 2024)
- A multiancestry Mendelian randomization study suggests CETP inhibition may protect against preeclampsia via HDL cholesterol (Hypertension 2023)
- Mendelian randomization identifies CETP inhibition as a potential heart failure prevention strategy, acting mainly through apoB (Eur J Prev Cardiol 2023)
- Review asks whether CETP inhibitors are still worth pursuing after two decades of disappointing trials (Curr Atheroscler Rep 2022)
- A review asks whether genomic analyses and post hoc trial insights can revive CETP inhibitors for cardiovascular prevention after past disappointments (Curr Opin Lipidol 2022)
- Updated meta-analysis confirms CETP inhibitors cut new-onset diabetes risk by 16 percent (Eur Heart J Cardiovasc Pharmacother 2022)
- LDL particle size governs how the natural CETP inhibitor ApoF binds and activates in hyperlipidaemic plasma (J Lipid Res 2022)
- A review argues the failure of CETP inhibitors and niacin to reduce cardiovascular events undermines the HDL cardioprotection hypothesis (Drugs 2020)
- Liposomal CETP vaccine protects rabbits against atherosclerosis where the failed clinical peptide vaccine did not (Pharm Dev Technol 2019)
- Review contrasts disappointing CETP antagonists with the anti-inflammatory promise of the CETP agonist probucol (Atherosclerosis 2018)
- Modeling shows adding a CETP inhibitor would push LDL-target attainment above 95 percent in familial hypercholesterolemia, versus just 54 percent with ezetimibe alone (J Clin Lipidol 2018)
- Electron microscopy shows torcetrapib and anacetrapib block CETP by favoring binary complexes over ternary lipoprotein bridging (Biochim Biophys Acta 2017)
- Molecular dynamics simulations show torcetrapib, anacetrapib, and evacetrapib all destabilize the hydrophobic tunnel of CETP (J Biomol Struct Dyn 2018)
- Only 42% of 96,944 CETP-inhibitor trial subjects ever appeared in a published report, a case study in biomarker-driven drug development finds (Circ Cardiovasc Qual Outcomes 2017)
- Mendelian randomization finds HDL-raising CETP variants also raise the risk of age-related macular degeneration (Ophthalmology 2017)
- A Mediterranean diet enriched with olive oil lowers CETP activity and improves multiple HDL functions in the year-long PREDIMED trial (Circulation 2017)
- CETP rs708272 B2 allele is linked to a more antiatherogenic LDL subfraction profile in statin-treated coronary heart disease patients (Biochem Genet 2016)
- Plasma CETP causes pancreatic beta cell dysfunction via islet cholesterol accumulation in mice (Nutr Metab 2016)
- Phase 1 single ascending dose study of the CETP inhibitor CKD-519 shows potent target inhibition (Drug Des Devel Ther 2016)
- A review argues the failure of niacin to reduce cardiovascular events, alongside CETP inhibitor trial results, exposes the flaws of the HDL cholesterol hypothesis (Curr Atheroscler Rep 2015)
- A review argues cholesterol efflux capacity, not HDL cholesterol, is the more meaningful marker after CETP inhibitor and niacin trials failed to reduce cardiovascular outcomes (Prog Cardiovasc Dis 2015)
- Review from the discoverer of CETP deficiency in Japan surveys anacetrapib and evacetrapib as candidate cures for atherogenic dyslipidemia (Mol Cells 2014)
- Less lipophilic hexahydrofuroquinoline CETP inhibitor clears fat tissue quickly and avoids off-target hypertension signals (J Med Chem 2014)
- Meta-analysis of 69,515 patients finds niacin and CETP inhibitors do not reduce cardiovascular mortality (Nutr Metab Cardiovasc Dis 2015)
- Review asks whether anacetrapib and evacetrapib can succeed where torcetrapib and dalcetrapib failed to reduce cardiovascular risk (Annu Rev Med 2014)
- 10-Dehydrogingerdione raises HDL cholesterol by suppressing CETP and curbs oxidative and inflammatory markers in rabbits (Atherosclerosis 2013)
- Perspective argues HDL functionality, not HDL-C concentration, should guide the future evaluation of CETP inhibitors (Clin Pharmacokinet 2013)
- Schaefer argues CETP inhibitors fail to cut coronary risk because they disrupt normal HDL metabolism (Curr Opin Lipidol 2013)
- CETP inhibition boosts postprandial insulin secretion via enhanced cholesterol efflux from beta cells (Circ Res 2013)
- Endogenous CETP activity above 34% marks high cardiovascular risk in a cohort of 1,403 patients (Atherosclerosis 2013)
- Unlike torcetrapib, dalcetrapib, evacetrapib, and anacetrapib do not raise blood pressure or aldosterone (Curr Opin Lipidol 2012)
- Review weighs whether CETP inhibition can rescue the HDL-raising hypothesis after AIM-HIGH, HERS, ILLUMINATE, and dal-OUTCOMES (Curr Treat Options Cardiovasc Med 2012)
- Review distills lessons from the torcetrapib failure for the CETP inhibitors that followed it into clinical development (Curr Clin Pharmacol 2012)
- First-in-human single dose study of the CETP inhibitor BAY 60-5521 shows dose-dependent CETP inhibition and HDL rise (Br J Clin Pharmacol 2012)
- A Nature Reviews Endocrinology paper argues HDL actively regulates glucose metabolism, positioning CETP inhibitors for rapid clinical translation to diabetes (Nat Rev Endocrinol 2012)
- Hop-derived xanthohumol prevents atherosclerosis in CETP-transgenic mice by inhibiting CETP and enriching HDL with apoE (PLoS One 2012)
- Sirtori weighs the cancer and sepsis signals of torcetrapib against the dramatic 139% HDL rise seen with anacetrapib (Expert Opin Investig Drugs 2011)
- Oxazolidinone-substituted benzoxazole CETP inhibitors raise HDL cholesterol up to 33 mg/dl in mice while avoiding hERG channel binding (Bioorg Med Chem Lett 2011)
- The original benzoxazole scaffold-redesign paper discovers CETP inhibitor 11v, raising HDL cholesterol by 24 mg/dl in mice (Bioorg Med Chem Lett 2011)
- Review argues CETP may be atheroprotective and aid host defense, complicating the case for inhibiting it (Cardiovasc Ther 2011)
- A review argues CETP inhibitor trial failures show HDL-C elevation alone is insufficient, motivating apoA-I-targeted therapies instead (Drugs 2010)
- Davidson explains how triglycerides turn CETP into a generator of small, dense, atherogenic LDL and HDL particles (J Clin Lipidol 2010)
- Chapman and colleagues place CETP at the center of how statins, fibrates, niacin, and CETP inhibitors modulate HDL (Eur Heart J 2010)
- Multiple-dose study of the CETP inhibitor CP-800,569 shows dose-dependent HDL rise and LDL fall (Clin Pharmacol Ther 2009)
- Hegele argues the pressor effect of torcetrapib, not CETP inhibition itself, doomed the drug and asks if the class deserves another chance (Curr Opin Cardiol 2009)
- Apolipoprotein CI regulates CETP activity in human plasma but not in rabbit plasma, a species-specific mechanism (J Lipid Res 2009)
- Serum cholesterol efflux capacity is preserved or enhanced in genetically CETP-deficient patients (Clin Chim Acta 2008)
- Review questions whether CETP inhibitors remain a viable therapeutic approach after a major trial failure (Cardiovasc Ther 2008)
- CETP overexpression in transgenic mice does not impair macrophage reverse cholesterol transport or HDL's LDL-antioxidant activity (Atherosclerosis 2007)
- Rare CETP variants, not the common TaqIB marker, best explain the link of the gene to coronary artery disease in 4,811 patients (J Am Coll Cardiol 2007)
- Low serum albumin is the main driver of elevated CETP in children with active nephrotic syndrome (Clin Biochem 2007)
- Chimeric fusions of CETP with the bacterial-binding protein BPI retain function from both parent proteins up to a threshold (Biochemistry 2006)
- A review describes proof-of-principle preclinical and clinical results for a semi-annual CETP vaccine to raise HDL and address unmet cardiovascular need (Vascul Pharmacol 2006)
- Partial, not complete, CETP inhibition preferentially blocks lipid transfer to LDL while sparing HDL flux (Atherosclerosis 2006)
- Plasma cholesteryl ester transfer, driven by CETP and triglycerides, predicts carotid intima-media thickness in type 2 diabetes (Diabetes 2005)
- Human apoA-I overexpression strips apoC-I from HDL and removes most of HDL's natural CETP-inhibitory capacity in transgenic rats (J Lipid Res 2005)
- Review highlights two small-molecule CETP inhibitors substantially raising HDL cholesterol in clinical trials (Curr Opin Cardiol 2005)
- Type 2 diabetes eliminates the CETP elevation normally seen in obesity by suppressing hepatic CETP expression (J Clin Endocrinol Metab 2005)
- Elevated CETP mass helps explain smaller, denser LDL particles in familial hypercholesterolemia (J Lipid Res 2004)
- Insulin down-regulates CETP gene expression, reversing the elevation seen with insulin deficiency in transgenic mice (J Lipid Res 2003)
- Phase 1 trial finds a CETP vaccine induces anti-CETP antibodies and is well tolerated in healthy adults (Atherosclerosis 2003)
- Chiral optimization yields the most potent acyclic CETP inhibitor reported, with an IC50 of 0.77 nanomolar in buffer (J Med Chem 2003)
- Antisense knockdown of CETP in HepG2 cells raises cholesterol efflux to apoA-I but impairs SR-BI-mediated HDL cholesteryl ester uptake by the liver (Am J Physiol Endocrinol Metab 2003)
- Chiral resolution of a trifluoro-3-amino-2-propanol lead reveals a 40-fold potency boost, reaching IC50 0.02 micromolar against CETP (J Med Chem 2002)
- Clamp-induced suppression of CETP activity is unrelated to whole-body insulin sensitivity, exercise-training study finds (Metabolism 2001)
- A fructose-enriched diet raises plasma and adipose CETP in hamsters despite lowering, not raising, insulin levels (Life Sci 2001)
- Serum CETP is higher in women and higher still in Chinese myocardial infarction and stroke patients than in healthy controls (Clin Chim Acta 2001)
- One week of a high-cholesterol diet paradoxically shrinks myocardial infarct size in CETP-transgenic mice (Coron Artery Dis 2001)
- Insulin fails to activate the CETP gene promoter in transfected rat fibroblasts, despite a role for C/EBPalpha (Mol Cell Biochem 2000)
- Blocking CETP-mediated cholesteryl ester transfer with an antibody makes LDL more resistant to oxidative modification (J Lipid Res 2000)
- CETP is expressed early in human preadipocyte-to-adipocyte differentiation, ahead of known adipogenic transcription factors (Atherosclerosis 1999)
- Ovariectomy reduces CETP activity in liver and adipose tissue of transgenic mice, and hormone replacement fails to restore it (Metabolism 1998)
- A 28-residue peptide from hog plasma, related to apoC-III, inhibits CETP and clears 75 percent of plasma activity within an hour in vivo (Biochim Biophys Acta 1998)
- Simvastatin and cholestyramine both lower serum CETP activity in rabbits while leaving LCAT activity essentially unchanged (Cardiovasc Drugs Ther 1998)
- CETP contains an essential free cysteine in a hydrophobic pocket, inactivated by thiol-modifying reagents at nanomolar concentrations (Biochem Biophys Res Commun 1996)
- CETP mRNA abundance in human adipose tissue tracks membrane cholesterol content, not stored lipid droplet cholesterol (J Lipid Res 1995)
- Acute hyperinsulinemia lowers plasma CETP activity in diabetic patients but not in healthy subjects (Metabolism 1994)
- Antibody-mediated CETP inhibition raises HDL 30 to 40 percent and produces large apoE-rich HDL particles in hamsters, peaking at day 4 (J Lipid Res 1994)
- A natural CETP inhibitor in selectively bred high-HDL baboons is identified as an N-terminal apoC-I fragment that binds apoA-I (J Lipid Res 1993)
- CETP activity tracks its own mRNA closely in cholesterol-fed rabbits, while hepatic lipase regulation appears mostly post-transcriptional (Biochim Biophys Acta 1991)
- A neutralizing antibody's epitope maps to CETP's C-terminal lipid-binding region, revealing its inhibition mechanism (J Biol Chem 1989)
- Inhibiting CETP amplifies apoA-IV and apoE redistribution among lipoproteins during ex vivo plasma incubation (J Lipid Res 1989)
- Review highlights CETP inhibition improving survival in a mouse model of sepsis (Curr Opin Lipidol 2026)
- Molecular dynamics show mixed cholesteryl-ester and triglyceride cargo twists CETP into strained, asymmetric conformations (Phys Chem Chem Phys 2026)
- Review surveys how current and emerging lipid therapies, including CETP inhibitors, affect lipoprotein(a) levels (Eur Cardiol 2026)
- Beyond small-molecule inhibitors: a review surveys CETP-targeted immunotherapy and vaccines as an emerging route to raising HDL (Hum Vaccin Immunother 2025)
- Chlorinated diaryl sulfonamides identified as potent new CETP inhibitors reaching 100 percent inhibition (Curr Comput Aided Drug Des 2025)
- Unlike statins and ezetimibe, CETP inhibitors show only a slight, non-significant rise in CRP across a 53-trial meta-analysis (Cardiovasc Res 2024)
- Review questions whether elevated HDL cholesterol truly protects against cardiovascular disease (J Clin Endocrinol Metab 2024)
- Novel trifluoromethyl benzamides identified as potent CETP inhibitors with sub-micromolar activity (Curr Comput Aided Drug Des 2024)
- Review names CETP among four validated targets for novel lipid-lowering therapies to prevent cardiovascular disease (Nat Rev Cardiol 2023)
- Mendelian randomization finds HDL cholesterol protective against diabetic retinopathy, but genetically proxied CETP inhibition shows no effect (Atherosclerosis 2023)
- A review of HDL biology in atherosclerotic cardiovascular disease highlights the shift from HDL quantity to HDL quality, with attention to CETP inhibitor trial outcomes (Clin Investig Arterioscler 2023)
- Bis(trifluoromethyl) benzylamino benzamides identified as potent new CETP inhibitor lead compounds (Med Chem 2022)
- Molecular dynamics simulations reveal how sugar chains on CETP shape its lipid-transfer tunnel (J Chem Inf Model 2021)
- Trivalent implant vaccine targets PCSK9, ApoB, and CETP as "cholesterol checkpoint" proteins (Adv Ther (Weinh) 2021)
- Cyclic and bicyclic urea and sulfamide cores yield new CETP inhibitors effective in vivo (Bioorg Med Chem Lett 2020)
- Apolipoprotein F emerges as a natural, LDL-selective inhibitor of CETP (Curr Opin Lipidol 2020)
- Population pharmacokinetic-pharmacodynamic model recommends a 200 to 400 mg dose of the CETP inhibitor CKD-519 (Pharmaceutics 2020)
- Book chapter reviews CETP research from its discovery to the disappointing clinical-trial era (Adv Exp Med Biol 2020)
- LXR and PPAR-alpha agonists suppress ApoF, the natural CETP regulator, via a shared hormone response element (Biochim Biophys Acta Mol Cell Biol Lipids 2019)
- A reformulated version of the CETP inhibitor DRL-17822 reduces its food-driven exposure spike (Clin Pharmacol Drug Dev 2019)
- Lead triphenylethanamine CETP inhibitor shows clean blood pressure profile and robust efficacy (ACS Med Chem Lett 2019)
- Combining policosanol with 10-dehydrogingerdione strengthens CETP inhibition and lowers platelet activation in dyslipidaemic rabbits (Appl Biochem Biotechnol 2018)
- N,N-substituted amine derivatives yield a sub-micromolar CETP inhibitor lead compound (Molecules 2017)
- A review traces the evolution of HDL-raising therapeutics from niacin and fibrates to CETP inhibitors, reconstituted HDL, and apoA-I mimetics (Curr Pharm Des 2017)
- Fluorinated benzamide CETP inhibitors reach sub-micromolar potency, with fluorine position dictating activity (Med Chem 2017)
- MF59-adjuvanted CETP vaccine protects rabbits from atherosclerosis without a strong antibody or CETP-activity effect (Iran J Basic Med Sci 2016)
- Review distinguishes humanized-mouse from rabbit models to find where CETP inhibition truly protects against atherosclerosis (Eur J Clin Invest 2016)
- Review weighs past CETP inhibitor trial failures against hopes for newer, more favourable agents (Clin Med Insights Cardiol 2016)
- Optimised benzylaminopropanamide derivative HL16 emerges as a sub-micromolar CETP inhibitor active in hamsters (Bioorg Med Chem 2015)
- Policosanol-loaded reconstituted HDL inhibits CETP activity by up to 47 percent and promotes tissue regeneration (Rejuvenation Res 2015)
- Review argues CETP inhibitors remain the most potent HDL-raising agents but their cardiovascular benefit is still unproven (Clin Ther 2015)
- Review argues patient stratification, and caution in sepsis, are needed before CETP can succeed as a drug target (Expert Opin Ther Targets 2015)
- Meta-analysis finds adding a CETP inhibitor to statin therapy does not reduce cardiovascular events (Int J Cardiol 2015)
- Modeling shows the short half-life of the CETP inhibitor RG7232 drives oscillating on/off effects on lipoprotein metabolism (CPT Pharmacometrics Syst Pharmacol 2015)
- Meta-regression of 167 311 patients finds raising HDL cholesterol with CETP inhibitors does not predict clinical benefit (Heart 2015)
- Review argues HDL-raising therapy remains an unmet cardiovascular need after torcetrapib and dalcetrapib failures (Transl Med UniSa 2015)
- A review names failed CETP-inhibitor and niacin trials as key evidence complicating the HDL-cholesterol paradigm for cardiovascular prevention (Clin Pharmacol Ther 2014)
- Amino-acid-modified fungal pigment derivatives yield micromolar, non-competitive CETP inhibitors (Nat Prod Res 2014)
- Review names CETP inhibition among the most promising pharmacological approaches to raising HDL despite recent trial failures (Curr Opin Lipidol 2013)
- A review names CETP inhibition among three specific pharmacological strategies to boost reverse cholesterol transport (Indian J Exp Biol 2013)
- Review surveys torcetrapib, dalcetrapib, anacetrapib, and evacetrapib as HDL-raising targets after the mortality signal in ILLUMINATE (Curr Vasc Pharmacol 2012)
- Baseline plasma CETP activity is elevated in dyslipidaemic patients and correlates with triglycerides (Int J Clin Pharmacol Ther 2012)
- Optimised DPPE-derivative CETP inhibitor shows robust efficacy without raising blood pressure in telemetered rats (J Med Chem 2012)
- Tetrahydronaphthyridine CETP inhibitors reach nanomolar potency and raise HDL-C in transgenic mice (Bioorg Med Chem Lett 2012)
- Modeling predicts an effective human dose for the CETP inhibitor BAY 60-5521, later confirmed in a first-in-man study (Br J Clin Pharmacol 2012)
- Review surveys the controversial CETP-atherosclerosis relationship and emerging roles in Alzheimer's disease, inflammation and obesity (IUBMB Life 2011)
- A review classifies novel HDL-raising drugs into four strategies, including CETP inhibition, to address residual cardiovascular risk (Nat Rev Cardiol 2011)
- Review argues lipid therapy must look beyond LDL, citing CETP inhibition as promising but still unproven in outcome trials (Curr Pharm Des 2011)
- Two CETP inhibitors reach systemic circulation mainly via lymphatic transport, 22 to 28% of dose (Pharm Res 2010)
- Patent landscape review tracks CETP inhibitor development from 2000 through the termination of torcetrapib (Expert Opin Ther Pat 2009)
- Review highlights a paradox, CETP protects against bacterial infection but promotes atherosclerosis (Atherosclerosis 2009)
- Neither high CETP activity nor low HDL cholesterol predicts cardiovascular events in stage V chronic kidney disease (Nephrol Dial Transplant 2008)
- Review reconsiders the protective reputation of HDL after the abrupt ILLUMINATE failure of torcetrapib (Biochem Pharmacol 2008)
- A review classifies CETP among the HDL-elevating drug targets, distinct from ApoA1-mimetic fast-acting approaches, for treating atherosclerosis (Cardiovasc Hematol Agents Med Chem 2007)
- Review of thirteen clinical CETP-inhibition studies finds pharmacological inhibitors raise HDL-C more consistently than vaccines (Curr Med Res Opin 2006)
- Review dissects biochemical pathways beyond HDL-C by which CETP inhibition might protect against atherosclerosis (Arterioscler Thromb Vasc Biol 2006)
- Displaying CETP B cell epitopes on asparaginase induces high-titer anti-CETP antibodies lasting over eighteen weeks in mice (Protein Pept Lett 2006)
- ABCG1's discovery as a large-HDL cholesterol exporter suggests CETP inhibition may enhance, not reduce, cholesterol efflux (Curr Opin Lipidol 2005)
- Clinician update reviews how CETP inhibition raises HDL by 50 to 100 percent in humans but flags mixed results across metabolic contexts (Circulation 2005)
- Review names CETP inhibition as one of the two most important new targets for raising HDL cholesterol (Neth Heart J 2004)
- Review surveys CETP as a pivotal HDL-raising drug target as human CETP inhibitor data become available (J Lipid Res 2004)
- Adjuvant-free Hsp65-CETP fusion vaccine induces antibodies lasting over 12 weeks and partially normalizes CETP activity in mice (Vaccine 2004)
- Review confirms CETP promoter variant -629 C to A, not TaqIB, drives CETP activity, and finds no TaqIB-pravastatin pharmacogenetic interaction (Curr Opin Lipidol 2004)
- Review positions CETP as a new therapeutic target, noting statins and fibrates already attenuate its activity indirectly (Pharmacol Ther 2004)
- Review proposes CETP-driven cholesteryl ester transfer as the metabolic link between high triglycerides and low HDL cholesterol in insulin resistance (Eur J Clin Invest 2003)
- Early phase I and II data show CETP inhibitors raise HDL-C by up to 70 percent, though effects on triglycerides remain unclear (Curr Opin Investig Drugs 2003)
- Review argues the time is right to test CETP inhibition in randomized human atherosclerosis trials (Arterioscler Thromb Vasc Biol 2003)
- Early review surveys progress toward antisense and small-molecule CETP inhibitors as HDL-raising therapies (Curr Opin Drug Discov Devel 2001)
- Replacing a tetrafluoroethoxy group with 2-furyl heteroaryl moieties yields submicromolar CETP inhibitors in a new trifluoro-propanol series (Bioorg Med Chem Lett 2001)
- Different dietary fatty acids produce distinct postprandial CETP activity responses in healthy young men (Am J Clin Nutr 2001)
- A chiral CETP inhibitor binds the protein 5,000-fold more efficiently than its natural lipid substrate (Biochemistry 2000)
- Ferroverdin B, isolated from a soil Streptomyces, is among the most potent microbial CETP inhibitors known, with an IC50 of 0.62 micromolar (J Antibiot (Tokyo) 1999)
- Fungal azaphilones inhibit CETP by forming a covalent bond with a lysine amine, with potency tracking ketone placement on the isochromane ring (J Antibiot (Tokyo) 1999)
- An (i, i+4) residue array between His466 and Asp470 stabilizes an amphipathic alpha-helix in CETP's C-terminus (Biochim Biophys Acta 1998)
- Phage-display screening yields a pentapeptide, WRMWY, that competitively inhibits CETP (J Pept Res 1998)
- Negatively charged surface lipids slow CETP-mediated cholesteryl ester transfer between microemulsion particles, positively charged lipids speed it up (Biochem J 1997)
- Hepatic CETP secretion rises with dietary cholesterol in a dose-dependent, strain-independent manner in rabbits (Comp Biochem Physiol B Biochem Mol Biol 1996)
- Antibody-mediated CETP inhibition in hamsters produces apoE-rich, apoA-I-poor HDL particles that revert toward baseline within two weeks (Lipids 1995)
- Palmitic and lauric acid diets do not differ in CETP activity from each other, but lauric acid raises CETP activity above baseline (J Nutr 1995)
- PD 140195, a triazole-thiol CETP inhibitor that mimics cholesteryl ester structurally, works noncompetitively and selectively blocks cholesteryl ester over triglyceride transfer (Lipids 1994)
- Sodium butyrate induces a 3- to 4-fold rise in CETP mRNA in HepG2 liver cells, a model for CETP hepatic regulation (Eur J Biochem 1993)
- Review forecasts CETP activity as a promising future pharmaceutical target beyond conventional lipid-lowering (Circulation 1993)
- CETP variants rs2033254 and rs12708980 associate with lower intestinal cholesterol absorption markers in a European GWAS (Nutrients 2026)
- Preclinical safety battery clears the anti-CETP intranasal vaccine HB-ATV-8 for cardiac, mutagenic and metabolic risk (Arch Med Res 2026)
- Review surveys the evolving landscape of lipid-lowering drug targets, from statins to CETP and Lp(a) inhibition (Eur Heart J 2025)
- A review positions CETP alongside PCSK9 and CYP7A1 as the three central druggable regulators of cholesterol homeostasis (Life Sci 2024)
- Review links HDL dysfunction in type 2 diabetes to impaired glycaemic control and highlights CETP inhibitors as a candidate therapy (Curr Med Chem 2024)
- Review proposes CETP inhibition among potential HDL-directed treatments for sepsis (Int J Mol Sci 2022)
- QSAR models predict CETP inhibitory potency of 108 oxazolidinone derivatives (SAR QSAR Environ Res 2020)
- Ursolic acid ester derivatives designed as novel plant-based CETP inhibitors (Bioorg Med Chem Lett 2019)
- Preclinical pharmacokinetic modeling predicts a human dose of the CETP inhibitor CKD519 before phase 1 data revealed a gap (Pharmaceutics 2019)
- Review questions whether HDL cholesterol is a modifiable treatment target after disappointing CETP inhibitor trials (JRSM Cardiovasc Dis 2019)
- Early formulation work solves the poor solubility of the CETP inhibitor CKD-519 ahead of phase 1 testing (Int J Pharm 2018)
- Review ranks CETP and ANGPTL3 inhibition among the most promising novel LDL-lowering strategies (Curr Opin Lipidol 2018)
- CETP inhibitors do not appear to raise new-onset diabetes risk unlike LDL-receptor-acting drugs (J Cardiovasc Pharmacol Ther 2018)
- Lipid-based formulations boost oral exposure of a poorly soluble CETP inhibitor up to 10-fold in preclinical species (J Pharm Sci 2018)
- Review maps CETP-mediated transfer as the indirect route of reverse cholesterol transport to the liver (Anatol J Cardiol 2017)
- CETP inhibitors lower lipoprotein(a) by around 50 percent, review notes, in comparison with apheresis and other new drugs (Atheroscler Suppl 2017)
- A new cycloalkene-scaffold CETP inhibitor raises HDL cholesterol in hamsters (Eur J Med Chem 2016)
- Novel benzylaminopropionanilide CETP inhibitors raise HDL and lower LDL in hamsters (Bioorg Med Chem 2016)
- A structure-guided approach discovers a novel indoline series of CETP inhibitors (ACS Med Chem Lett 2016)
- Handbook chapter surveys emerging HDL-targeted drugs, from CETP inhibitors to PPAR and LXR agonists (Handb Exp Pharmacol 2015)
- Review updates the pipeline of emerging hyperlipidaemia drugs, focused mainly on anacetrapib and evacetrapib (Expert Opin Emerg Drugs 2014)
- New synthesis route scales a polycyclic CETP inhibitor to multikilogram quantities (Org Lett 2014)
- Review of hypertriglyceridemia drugs places CETP and ANGPTL3/4 inhibitors among agents enhancing triglyceride-rich lipoprotein clearance (Prog Lipid Res 2014)
- Review previews upcoming dyslipidaemia drugs, from CETP inhibitors to PCSK9 inhibitors and MTP inhibitors (J Cardiovasc Pharmacol Ther 2015)
- Review questions where CETP inhibitors will fit clinically outside patients with very low HDL cholesterol (Expert Opin Investig Drugs 2014)
- Diphenylpyridylethanamine-based aminoheterocycles optimised as CETP inhibitors with better metabolic stability (Bioorg Med Chem Lett 2014)
- Review surveys HDL-targeted therapies as CETP inhibitor trials split between discontinuation and ongoing phase III testing (Circ Res 2014)
- Review argues CETP inhibitor failures show over-reliance on HDL cholesterol as an efficacy marker (Clin Lipidol 2013)
- Review asks why targeting HDL for cardiovascular protection has not delivered clinical benefit (J Cardiovasc Pharmacol 2013)
- Validated comparative QSAR modelling of 104 CETP inhibitors identifies key structural drivers of potency (Comput Biol Med 2013)
- A stroke-prevention review flags CETP inhibitor trial success as a potential turning point for dyslipidemia treatment (Maturitas 2013)
- Review notes CETP inhibitors raise HDL-C by 31-138 percent, but whether this lowers coronary risk remains unresolved (Circ J 2013)
- Broad review on residual cardiovascular risk after statins notes anacetrapib and evacetrapib survive where two other CETP compounds failed (Vasc Health Risk Manag 2013)
- Fluorinated diphenylpyridylethanamine derivatives balance metabolic stability and CETP potency (Bioorg Med Chem Lett 2012)
- Quinoline-3-carboxamide derivatives reach 80.1 percent CETP inhibitory activity in newly designed series (Molecules 2012)
- Review synthesises structural and biophysical evidence for how CETP moves lipids between HDL and LDL (Biochem Soc Trans 2011)
- Natural compound isolated from ginger rhizome inhibits CETP with an IC50 of 35 micromolar (Arch Pharm Res 2011)
- New biphenyl oxazolidinone CETP inhibitor scaffold reaches sub-100 nanomolar potency (ACS Med Chem Lett 2011)
- Chromanol derivatives emerge as a novel class of orally active CETP inhibitors suitable for clinical development (Bioorg Med Chem Lett 2011)
- 2-Arylbenzoxazole CETP inhibitors raise HDL cholesterol in cynoCETP transgenic mice (Bioorg Med Chem Lett 2011)
- Lead biphenyl CETP inhibitor 12d significantly raises HDL in a transgenic mouse model (Bioorg Med Chem Lett 2010)
- Lead benzylamino-methanone compound achieves 30 percent CETP inhibition at 10 micromolar (Molecules 2010)
- Novel tetrahydrochinoline derivatives yield a potent CETP inhibitor with favourable pharmacokinetics for clinical development (Bioorg Med Chem Lett 2010)
- Pharmacophore and QSAR modelling identifies new CETP inhibitor leads including NSC 40331 at 6.5 micromolar (Eur J Med Chem 2010)
- A new benzoxazine class of CETP inhibitors raises HDL cholesterol in transgenic mice and hamsters (Bioorg Med Chem Lett 2010)
- Lead 2-arylbenzoxazole compound inhibits CETP with an IC50 of 28 nanomolar (Bioorg Med Chem Lett 2009)
- Improved asymmetric synthesis route delivers a potent tetrahydroquinoline CETP inhibitor without a hazardous aryltin reagent (Org Lett 2009)
- Review surveys CETP's role in lipid metabolism and the state of small-molecule inhibitor development for raising HDL-C (Curr Top Med Chem 2009)
- Clinician's overview names CETP inhibitors the most potent HDL-raising drugs, but torcetrapib fell to excess cardiovascular harm (Angiology 2009)
- 3D-QSAR modelling of 61 dibenzodioxepinone and dibenzodioxocinone compounds maps the structural features driving CETP inhibitory potency (Molecules 2008)
- Review weighs conflicting evidence for CETP as a pro- versus antiatherogenic therapeutic target (Expert Opin Ther Targets 2008)
- Serum CETP is lowest at birth and rises sharply to peak levels in infancy, reference data from healthy Chinese children (Clin Biochem 2008)
- Array synthesis optimizes a high-throughput screening hit into a novel 2-arylbenzoxazole CETP inhibitor series (Bioorg Med Chem Lett 2008)
- 2D and hologram QSAR models of 85 trifluoro-aminopropanol CETP inhibitors identify key structural drivers of potency (Bioorg Med Chem 2007)
- Tetrazole and ester substituted tetrahydroquinoxalines emerge as a potent new class of CETP inhibitors (Bioorg Med Chem Lett 2007)
- Review surveys recent findings on plasma lipid transfer proteins including CETP's role in HDL delivery and coronary risk (Curr Opin Lipidol 2006)
- Review traces how statins raise HDL cholesterol partly via a secondary reduction in CETP activity (Curr Atheroscler Rep 2006)
- Optimized dibenzodioxocinone derivatives yield low-nanomolar CETP inhibitors stable in rat plasma (Bioorg Med Chem Lett 2005)
- Review makes the case for pharmacological CETP inhibition as a therapeutic strategy pending clinical trial confirmation (Curr Top Med Chem 2005)
- Review weighs CETP inhibition's physiology and animal-to-human evidence as a candidate route to raising HDL cholesterol (Curr Atheroscler Rep 2004)
- CETP localizes to germinal centre B cells and their neoplastic lymphoma counterparts (Histopathology 2004)
- Electron-withdrawing substituents boost potency in a new propanethioate class of CETP inhibitors, reaching 50 percent inhibition at 2 micromolar (Bioorg Med Chem Lett 2004)
- Chemically induced P-407 mouse model of hyperlipidemia indirectly raises CETP activity while directly inhibiting lipoprotein and hepatic lipase (J Cardiovasc Pharmacol 2004)
- Review argues the role of CETP and reverse cholesterol transport defects in diabetic atherosclerosis remains unproven, despite altered HDL composition (Diabetes Metab Res Rev 2000)
- A domino Mukaiyama-Michael/Michael/Aldol cyclization efficiently builds pentasubstituted arene cores for potent CETP inhibitors (Angew Chem Int Ed Engl 1999)
- Erabulenols A and B, new fungal metabolites from a soil Penicillium isolate, inhibit human CETP with IC50 values of 47.7 and 58.2 micromolar (J Antibiot (Tokyo) 1998)
- A fungal depsipeptide, SCH 58149, shows weak CETP inhibitory activity with an IC50 of 50 micromolar (Bioorg Med Chem Lett 1998)
- Polyacetylene compounds isolated from Korean ginseng roots inhibit human CETP (Chem Pharm Bull (Tokyo) 1996)
- A multi-step synthesis from diosgenin yields two novel cholest-15-one steroids tested for CETP-inhibiting activity (Bioorg Med Chem 1995)
- Review weighs the shuttle versus ternary-complex models for how CETP transfers lipids and flags evidence for a pro-atherogenic role (Clin Exp Pharmacol Physiol 1994)
- Fragment-based design yields a novel pentacyclic triterpenoid CETP inhibitor with sub-micromolar potency (Eur J Med Chem 2017)
- New tetrazolyl tetrahydroquinoline CETP inhibitors raise HDL cholesterol in a transgenic mouse model (Bioorg Med Chem Lett 2012)
- Modifying the alpha-alkoxyamide moiety of arylbenzoxazole CETP inhibitors yields an orally bioavailable lead (Bioorg Med Chem Lett 2010)
- CETi-1, AVANT Immunotherapeutics CETP-targeting vaccine, entered Phase II trials for hypercholesterolemia and atherosclerosis by 2001 (Curr Opin Investig Drugs 2004)
- Ferroverdins B and C, natural CETP inhibitors from Streptomyces, are elucidated as iron complexes of nitroso-hydroxybenzoate ligands (J Antibiot (Tokyo) 1999)
- Erabulenols A and B, fungal CETP inhibitors, share a phenalenone-tetrahydrofuran core, with a hydroxy-methylketonyl benzyl group distinguishing erabulenol B (J Antibiot (Tokyo) 1998)
Genetics 651
CETP variants, deficiency and the Mendelian randomisation that reframed the class.
- Landmark study links large HDL and LDL particle size and the CETP 405 valine allele to exceptional human longevity (JAMA 2003)
- The human CETP gene is cloned and sequenced for the first time (Nature 1987)
- Genetic CETP deficiency, mimicking a lifetime of CETP inhibition, trades a lower cardiovascular death and MI risk for a matching rise in AMD (JAMA Cardiol 2022)
- Landmark JAMA meta-analysis of over 190,000 people finds CETP genotypes that inhibit CETP activity only weakly reduce coronary risk (JAMA 2008)
- The CETP 405-valine allele is identified as the first genotype linked to inherited exceptional human longevity (Mech Ageing Dev 2005)
- Duff Memorial Lecture synthesizes how CETP and PLTP knockouts revealed the liver pathways governing HDL catabolism (Arterioscler Thromb Vasc Biol 2000)
- Landmark REGRESS trial finds the CETP B1B1 genotype predicts who benefits from pravastatin against coronary atherosclerosis progression (N Engl J Med 1998)
- Annual Review synthesizes CETP structure, the reverse cholesterol transport hypothesis, and the SREBP-driven regulation of the CETP gene (Annu Rev Nutr 1998)
- Landmark Omagari study first shows CETP-deficiency-driven high HDL cholesterol is not a longevity syndrome (Arterioscler Thromb Vasc Biol 1997)
- Landmark Honolulu Heart Program study first shows CETP gene mutations raise coronary heart disease risk despite raising HDL cholesterol (J Clin Invest 1996)
- Landmark ECTIM study is the first to show alcohol intake determines whether the CETP B2 allele protects against heart attack (J Clin Invest 1995)
- CETP deficiency from two prevalent mutations is identified as the first common genetic cause of high HDL cholesterol in the general population (J Clin Invest 1994)
639 more in Genetics
- The original discovery of CETP mutation D442G reveals a dominant-negative multimeric mechanism causing threefold HDL elevation in heterozygotes (J Clin Invest 1993)
- Landmark Nature paper shows CETP-expressing transgenic mice develop far worse atherosclerosis than non-expressing controls (Nature 1993)
- A common CETP gene splicing mutation causes markedly elevated HDL in Japan without excess atherosclerosis (N Engl J Med 1990)
- The original discovery of the intron 14 splice-site mutation identifies the molecular cause of CETP deficiency in four Japanese families (Biochem Biophys Res Commun 1990)
- Two Japanese siblings with markedly increased HDL are found homozygous for a CETP intron-14 splice-site mutation eliminating the protein (Nature 1989)
- The human CETP gene is first mapped to chromosome 16q12-21 using somatic cell hybrids and in situ hybridization (Genomics 1987)
- Large Copenhagen study shows CETP-mutation-driven HDL elevation actually raises heart disease risk in women, not lowers it (Circulation 2000)
- A novel transposon-based method sequences 5kb of CETP's 5' regulatory region, revealing a 5.7kb fragment drives far stronger transcription than the minimal promoter (Gene 1997)
- 13,677-subject meta-analysis confirms CETP TaqIB drives HDL and CAD risk but does not affect pravastatin response (Circulation 2005)
- CETP protein-truncating variants cut coronary artery disease risk even in Japanese patients with severe familial hypercholesterolemia (Atherosclerosis 2025)
- Large Chinese biobank study finds genetically lower CETP activity raises HDL cholesterol but not vascular protection (JAMA Cardiol 2018)
- CETP variants that raise HDL cholesterol also increase risk of intracerebral haemorrhage (Ann Neurol 2016)
- CETP binds factor Xa and boosts prothrombinase activity, and the VTE-linked Gln451 variant shows five-fold higher thrombin generation than wild-type (J Atheroscler Thromb 2016)
- Two CETP splice-affecting variants raise mortality and heart attack risk specifically in men, mechanism traced to liver mRNA splicing (PLoS One 2012)
- Genome-wide analysis of 18,245 women finds CETP is the only HDL-raising locus that also lowers heart attack risk, supporting a causal role (Circ Cardiovasc Genet 2009)
- CETP coding variants R451Q and A373P predict coronary calcium independent of HDL cholesterol in a multi-ethnic cohort (Atherosclerosis 2008)
- Genome-wide meta-analysis of 20,000-plus people confirms CETP among eleven established lipid loci and finds new ones (Nat Genet 2008)
- A CETP variant that raises HDL cholesterol paradoxically raises coronary risk once HDL-cholesterol is accounted for, large PREVEND study finds (J Clin Endocrinol Metab 2006)
- CETP Taq1B B2B2 genotype predicts higher cardiovascular risk despite equal statin response in familial hypercholesterolemia (Eur J Hum Genet 2005)
- CETP TaqIB genotype fails to predict cardiovascular events or pravastatin benefit in the CARE trial cohort (J Am Coll Cardiol 2004)
- Human CETP expression completely prevents diet-induced atherosclerotic lesions in diabetic obese db/db mice (Arterioscler Thromb Vasc Biol 2003)
- CETP -629A allele cuts cardiovascular mortality risk in half in coronary artery disease patients, independent of HDL cholesterol or CETP activity (J Am Coll Cardiol 2003)
- Combined CETP gene polymorphisms explain up to 10 percent of the variation in carotid intima-media thickness (Eur J Clin Invest 2001)
- CETP mutations that lower HDL cholesterol paradoxically cut ischemic heart disease risk 36% in women, Copenhagen City Heart Study finds (Circulation 2000)
- CETP TaqIB B2 allele lowers CHD risk in men in the Framingham Offspring Study (Arterioscler Thromb Vasc Biol 2000)
- ApoE or LDL receptor knockout raises hepatic CETP transgene expression eightfold, revealing a cholesterol-sensing mechanism independent of both (J Clin Invest 1996)
- CETP-deficient humans clear LDL apoB faster, explaining their low LDL despite reduced apoB production (J Clin Invest 1995)
- ApoB/CETP double transgenic mice recreate a human-like lipoprotein cholesterol distribution on chow diet (J Lipid Res 1995)
- CETP expression suppresses hepatic LDL receptor mRNA dose-dependently, explaining apoB-lipoprotein accumulation (J Biol Chem 1993)
- Stable-isotope kinetics show CETP deficiency raises HDL by slowing apoA-I and apoA-II catabolism, not by increasing production (J Clin Invest 1993)
- CETP deficiency dose-dependently raises HDL2 cholesterol up to sixfold in homozygotes and twofold in heterozygotes (Metabolism 1991)
- First human CETP transgenic mice show that active plasma CETP causally reduces HDL cholesterol (J Biol Chem 1991)
- A twin study introduces the CETP locus as a variability gene that shapes the spread, not the average, of cholesterol levels (Clin Genet 1989)
- A Polynesian-specific CETP missense variant lowers CETP activity by 27.9% and improves the lipid profile (HGG Adv 2023)
- Serum amyloid A is required for CETP to promote atherosclerosis in mice, suggesting CETP inhibition may help patients with high inflammation (J Lipid Res 2023)
- A genome-wide significant signal near CETP is linked to doubled HDL cholesterol in youth with type 2 diabetes (J Endocr Soc 2021)
- Mendelian randomisation links genetically raised HDL and LDL cholesterol, including a CETP locus signal, to higher breast cancer risk (PLoS Med 2020)
- Genetic variants at the CETP inhibitor target show split effects on ischaemic small vessel stroke and brain haemorrhage (Brain 2020)
- Genetic CETP inhibition doesn't touch particle-size-defined LDL-C the way statins do, but lowers remnant, VLDL and HDL-triglyceride content instead (PLoS Biol 2019)
- A rare CETP variant lowers HDL cholesterol and predicts worse survival in sepsis, with Mendelian randomization suggesting causation (Am J Respir Crit Care Med 2019)
- Mendelian randomisation upends the textbook story: the causal effects of CETP fall mainly on large HDL and small VLDL, not LDL, hinting anacetrapib works by cutting VLDL (Eur J Hum Genet 2019)
- First genome-wide association study identifies genetic determinants of circulating CETP concentration (Circ Genom Precis Med 2018)
- Mendelian randomisation links the CETP inhibitor target locus to lower abdominal aortic aneurysm risk (JAMA Cardiol 2018)
- Large-scale pleiotropy study identifies CETP as one of six newly discovered genome-wide-significant loci for coronary artery disease (J Am Coll Cardiol 2017)
- The CETP locus is the only genome-wide-significant genetic determinant of HDL-C response to statins, independent of baseline HDL-C, in a 27,720-person meta-analysis (J Med Genet 2016)
- CETP -629C/A genotype predicts HDL-C but the CC genotype benefits most from atorvastatin's LDL-C-lowering effect in Chinese CHD patients (Med Sci Monit 2014)
- CETP genotype predicts who benefits most from a low-carbohydrate diet for raising HDL and lowering triglycerides, replicated across two randomized trials (J Lipid Res 2015)
- Mendelian randomization using the CETP TaqIB polymorphism finds genetically raised HDL cholesterol does not translate into lower coronary disease risk (BMC Med Genet 2014)
- CETP enhancer variant rs3764261 boosts statin-associated HDL-C rise but reduces statin protection against myocardial infarction (Clin Pharmacol Ther 2013)
- CETP I405V reverses direction: protective for longevity in Ashkenazi Jews but a risk allele in Chinese (PLoS One 2013)
- Two linked CETP SNPs more than double the odds of fatty liver in adolescent girls, independent of adiposity (J Gastroenterol Hepatol 2012)
- CETP R451Q raises coronary stenosis risk while Taq1B B2 lowers it in a Tunisian angiography cohort (J Cardiovasc Med (Hagerstown) 2012)
- CETP and ABCA1 genotype together determine whether atorvastatin or simvastatin gives a better lipid response (Angiology 2012)
- Heterozygous CETP-deficient HDL is remodeled toward more cholesteryl ester and less triglyceride but keeps normal antioxidative capacity (PLoS One 2012)
- CETP deficiency, not high CETP activity, impairs postprandial lipemia clearance and correlates with carotid atherosclerosis in women (Lipids Health Dis 2011)
- CETP variant rs1532624 reduces heart attack risk in women regardless of physical activity level, unlike an LPL variant with an activity-dependent effect (Circ Cardiovasc Genet 2011)
- CETP TaqI and -629C/A variants predict a bigger HDL-C rise on atorvastatin, while CETP 405I/V predicts higher MI risk in CAD patients (DNA Cell Biol 2010)
- CETP Taq1B B2 allele linked to lower coronary artery disease risk in Asian Indians (J Community Genet 2010)
- A JAMA study links CETP valine-405 homozygosity to slower memory decline and lower dementia incidence (JAMA 2010)
- CETP gene mutations shape LDL and HDL cholesterol from birth through the first year of life (Clin Chim Acta 2009)
- CETP TaqIB B2 allele linked to higher HDL cholesterol in Greek children (Nutr Metab Cardiovasc Dis 2010)
- A novel CETP R37X mutation causes complete CETP deficiency and extreme HDL elevation without atherosclerosis in a Swedish man (Atherosclerosis 2009)
- CETP variants without known cardioprotective effects still raise large HDL particle concentrations by up to 40 percent, questioning what HDL particle size means (Clin Chem 2009)
- CETP Taq1B B2 variant cuts metabolic syndrome risk by up to 57% in a large Austrian cohort (Obesity (Silver Spring) 2008)
- Combined CETP- and hepatic-lipase-lowering gene variants raise HDL cholesterol but still increase coronary disease risk in the REGRESS trial (Atherosclerosis 2008)
- CETP TaqIB B1B1 genotype predicts sudden death in type 2 diabetes, an effect independent of its HDL cholesterol impact (Diabetes Care 2007)
- A rare long CETP allele raises coronary artery disease risk nearly 7-fold in Corsican patients (Exp Mol Pathol 2006)
- A longevity-associated CETP genotype preserves cognitive function in two independent cohorts (Neurology 2006)
- Dense genotyping of the CETP gene in over 2,000 people pinpoints a promoter SNP at position -4,502 as likely functional for HDL cholesterol (J Lipid Res 2007)
- Higher plasma CETP concentration, but not CETP genotype, predicts fewer cardiovascular events in pravastatin-treated coronary disease patients (J Intern Med 2006)
- CETP TaqIB rare allele is linked to lower internal carotid artery thickness in men, in the Framingham Heart Study (Atherosclerosis 2006)
- CETP D442G mutation raises HDL cholesterol in Vietnamese schoolgirls regardless of nutritional status (Pediatr Res 2005)
- CETP TaqI B1/B2 genotype differs significantly in men with venous thrombosis, tracking their low-HDL/high-LDL profile (Circulation 2005)
- CETP haplotype independently predicts triglyceride response to fluvastatin in familial hypercholesterolemia (Atherosclerosis 2005)
- CETP Taq1B genotype predicts who benefits from cardiac rehabilitation's lipid effects (Atherosclerosis 2005)
- CETP variants linked to HDL cholesterol are not the same ones linked to heart attack history, resolving a literature contradiction (Atherosclerosis 2005)
- CETP Taq1B genotype interacts with obesity in women and predicts small dense LDL in men in a 1029-person Austrian cohort (Biomed Pharmacother 2004)
- A moderate-expresser human-CETP transgenic rat model recapitulates female athero-resistance seen in humans (Atherosclerosis 2004)
- Novel CETP L296Q mutation discovered and linked to coronary heart disease and higher LDL cholesterol (Acta Biochim Biophys Sin (Shanghai) 2004)
- First evidence that CETP Taq1B genotype can guide statin therapy: B2 carriers benefit strongly, B1B1 homozygotes do not (Am Heart J 2003)
- CETP TaqIB genotype cuts cardiovascular risk 30% in non-smokers but not smokers in WOSCOPS (Eur Heart J 2003)
- Patients with atherogenic CETP genotypes get more HDL and triglyceride benefit from high-dose atorvastatin, DALI trial finds (Diabetes Care 2003)
- Haplotype analysis reveals that the famous CETP TaqIB polymorphism is not actually a driver of CETP or HDL cholesterol levels (J Mol Med 2003)
- Meta-analysis of over 10,000 people confirms both CETP TaqIB and I405V variants significantly raise HDL cholesterol (J Lipid Res 2003)
- CETP TaqIB and apoE genotypes interact to shape cholesterol levels in 7-year-old children (Nutr Metab Cardiovasc Dis 2002)
- CETP D442G mutation enlarges LDL particle size in coronary heart disease patients, suggesting an antiatherogenic role (Clin Chim Acta 2002)
- CETP B2B2 genotype raises HDL cholesterol and particle size specifically in women in the Columbia BioMarkers Study (Nutr Metab Cardiovasc Dis 2002)
- CETP TaqIB B2B2 genotype replicates its HDL cholesterol and coronary benefit in men with low HDL, VA-HIT trial finds (Arterioscler Thromb Vasc Biol 2002)
- CETP genotype shapes which HDL subfractions rise with endurance exercise training (Metabolism 2002)
- CETP D442G mutation flips its effect in fetal blood, lowering cholesterol instead of raising HDL as it does in adults (Atherosclerosis 2002)
- Statins should benefit CETP TaqIB B1B1 carriers most, since they have the highest baseline CETP activity (J Atheroscler Thromb 2002)
- CETP found directly inside atherosclerotic plaque foam cells, revealing an anti-atherogenic role in cholesterol removal at the earliest step of reverse transport (Atherosclerosis 2001)
- CETP TaqIB B2 allele produces a less atherogenic lipid profile and fewer clinical signs in familial hypercholesterolemia (Metabolism 2001)
- Extra-large HDL particles unique to genetic CETP deficiency may mark reduced atherosclerosis risk (Clin Chim Acta 2000)
- CETP-HDL relationships differ by sex, and CETP genotype does not explain Israel's low population HDL levels (Atherosclerosis 2000)
- New CETP promoter repeat marker links the gene to LDL particle size, triglycerides, and apoB in twins (Circulation 2000)
- CETP genotype combined with apoB signal peptide variant is the strongest predictor of hepatic apoB-100 secretion in obese men (J Lipid Res 2000)
- CETP TaqIB genotype raises HDL-cholesterol and lowers coronary disease only in men with type 2 diabetes (J Clin Endocrinol Metab 1999)
- ApoE4 allele blunts the correlation between CETP activity and LDL cholesterol during colestipol and lovastatin treatment (Eur J Clin Pharmacol 1999)
- A bimodal CETP concentration pattern hints at hidden CETP mutations linked to I405V, raising heart disease risk in men with high triglycerides (J Lipid Res 1998)
- Blocking apoB mRNA editing doubles plasma apoB-100 and shifts cholesterol from HDL to LDL specifically in CETP transgenic mice (Arterioscler Thromb Vasc Biol 1998)
- First Caucasian North American case of CETP deficiency traced to a novel exon 9 stop mutation (J Lipid Res 1998)
- Nearly 50,000-subject Japanese study finds no excess coronary heart disease in CETP-deficient people with very high HDL cholesterol (Prev Med 1998)
- CETP expression suppresses liver LDL receptor mRNA in ApoB/CETP double transgenic mice, reversible by oncostatin M (Arterioscler Thromb Vasc Biol 1997)
- CETP deficiency raises HDL-C in familial hypercholesterolemia but fails to prevent coronary disease (Atherosclerosis 1997)
- Novel CETP nonsense mutation G181X found in 5 of 294 Japanese hyperalphalipoproteinemic subjects (J Lipid Res 1996)
- Combined CETP and hepatic lipase deficiency drives atherosclerotic disease in some patients with marked high HDL (Arterioscler Thromb Vasc Biol 1995)
- LDL particles from CETP-deficient patients bind LDL receptors two to three times less avidly than normal LDL (Eur J Clin Invest 1995)
- CETP co-expression halves HDL cholesterol and roughly doubles VLDL cholesterol in mice modeling type III hyperlipoproteinemia (J Biol Chem 1994)
- A marker linked to the CETP locus shows significant linkage to plasma HDL-cholesterol levels in coronary disease families (Hum Genet 1994)
- CETP TaqIB B2B2 genotype raises HDL2 by 45 percent independent of CETP exchange activity itself (Arterioscler Thromb 1994)
- ApoE genotype has opposite effects on CETP and HDL-cholesterol responses to dietary cholesterol (J Lipid Res 1993)
- CETP activity is twofold higher in familial hypercholesterolemia, linked to worse IDL and HDL composition (Horm Metab Res 1992)
- The human CETP gene transcript is alternatively spliced to skip exon 9, producing an inactive, poorly secreted protein variant (Biochemistry 1992)
- CETP-deficient patients carry two distinct LDL particle species in every density subfraction, suggesting a second LDL formation pathway (Arterioscler Thromb 1991)
- Cloning cynomolgus monkey CETP reveals hepatic mRNA rises fourfold with diet and correlates inversely with HDL cholesterol (ATVB 1991)
- A new immunoassay confirms plasma CETP protein, not just activity, is absent in patients with CE transfer deficiency (Clin Chim Acta 1990)
- The human CETP gene spans 25 kb with 16 exons and shares a signal-sequence motif with lipoprotein lipase and apoA-I/A-IV (Biochemistry 1990)
- CETP TaqI B polymorphism shows a dosage effect on apoA-I levels, limited to nonsmokers (Clin Genet 1989)
- CETP rs3764261 T allele, a known atherosclerosis-protective variant, is linked to protection against eye inflammation after brolucizumab (Genes 2025)
- Predicted CETP and LPL cardiovascular risk genotypes are most prevalent in populations with Native American ancestry (Mol Biol Rep 2025)
- CETP variants show BMI-dependent associations with atherogenic lipids and glucose traits in gestational diabetes (J Matern Fetal Neonatal Med 2024)
- CETP gene polymorphisms are linked to blunted heart rate response to exercise, first study of its kind reports (Int J Mol Sci 2024)
- Mendelian randomisation: genetically proxied CETP inhibition cuts abdominal aortic aneurysm risk (OR 0.127) but shows no benefit for calcific aortic valve stenosis (Rev Cardiovasc Med 2024)
- Mendelian randomisation flags genetically proxied CETP inhibition as associated with higher male infertility risk, partly via vitamin D (Front Endocrinol 2024)
- CETP variants, an update: a review maps how CETP structure, animal models and SNPs shape lipid profiles and cardiovascular risk (Curr Pharm Des 2024)
- Mendelian randomisation across nine drug targets and half a million lifespans finds genetically proxied CETP inhibition extends life expectancy (Lipids Health Dis 2023)
- Genome-wide interaction analysis pinpoints a CETP variant that modifies how sedentary behavior affects HDL cholesterol (Nutrients 2023)
- CETP gene haplotypes raise cardiovascular risk partly through mechanisms independent of triglycerides and HDL cholesterol (Int J Mol Sci 2023)
- Sex and BMI modify how much genetically lower CETP raises HDL-C and lowers LDL-C, though not cardiovascular outcomes (Genet Epidemiol 2023)
- Meta-analysis of 70 studies confirms CETP rs708272 is linked to lower coronary artery disease risk and higher HDL cholesterol (Front Cardiovasc Med 2023)
- CETP missense variants raise HDL cholesterol mainly by reducing protein secretion, not intrinsic lipid-transfer activity (PLoS One 2023)
- Mendelian randomisation finds genetically proxied CETP inhibitors protect against sepsis, an effect explained largely by ApoA-I (Front Cardiovasc Med 2023)
- Rare CETP missense variants are linked to male-specific metabolic syndrome across five ancestries, transethnic exome study finds (Genes Genomics 2022)
- A novel hypothesis links high East Asian CETP deficiency prevalence to historical resistance against a liver-damaging parasite (Front Cell Dev Biol 2022)
- CETP haplotypes predict whether lipophilic statins help or harm cognition in Alzheimer's disease (J Alzheimers Dis 2022)
- CETP promotes triglyceride storage in liver and intestinal cells, unlike its fat-reducing effect in adipocytes (Lipids 2021)
- CETP gene variants predict residual atherogenic dyslipidaemia in Thai patients on statin therapy (Pharmgenomics Pers Med 2021)
- A loss-of-function CETP variant raises HDL cholesterol without raising ApoA1 or protecting against heart attack in Chinese patients (Nutr Metab Cardiovasc Dis 2021)
- First Samoan genome-wide association study confirms CETP-HDL cholesterol link in a previously unstudied Polynesian population (J Hum Genet 2020)
- CETP variant rs5882 carries a 25-fold higher risk of atrophic age-related macular degeneration in a Lithuanian case-control study (Mol Genet Genomic Med 2020)
- CETP promoter variant rs1800775 reduces the odds of essential hypertension in a Mexican population (Genet Test Mol Biomarkers 2020)
- CETP variant rs708272 shows a striking association with childhood HDL cholesterol and triglycerides in a pan-European cohort (Sci Rep 2020)
- In 1,855 Ghanaian adults, CETP variant rs17231520 is the leading genetic signal for HDL cholesterol, replicating a finding rare in West African cohorts (Front Genet 2020)
- CETP variant rs708272 doubles the risk of myocardial infarction in men from Western Siberia (Biomolecules 2019)
- CETP promoter variants that raise HDL cholesterol also lower the risk of type 2 diabetes and diabetic kidney disease in Taiwanese adults (Genes 2019)
- GWAS of 10,093 Indians finds CETP the primary genetic locus for metabolic syndrome, with a seven-variant haplotype as the strongest signal (Biomolecules 2019)
- Rare CETP variants found in most Korean adults with extremely high HDL cholesterol, but do not alter cholesterol efflux (Sci Rep 2019)
- Genetic CETP deficiency loads HDL with apoE, apoC-III, ANGPTL3 and complement proteins, offering a clue why high HDL-C doesn't protect these patients (J Clin Lipidol 2019)
- CETP variant rs1800777 predicts low HDL cholesterol and acute kidney injury risk during sepsis, replicated across two cohorts (Sci Rep 2018)
- CETP I405V variant shows a strong, first-reported association with ischemic stroke risk in a Caucasian population (J Stroke Cerebrovasc Dis 2018)
- CETP Taq1B combined with an NOS3 variant multiplies the risk of type 2 diabetes and cardiovascular disease eightfold (Cardiovasc Diabetol 2018)
- Weight gain prevention counteracts the HDL-lowering effect of CETP variant rs3764261 in young adults, randomized trial finds (Nutr Metab Cardiovasc Dis 2018)
- CETP variant rs708272 raises acute coronary syndrome risk and shifts HDL subclass cholesterol content (Lipids 2018)
- Lower serum CETP levels found in the oldest members of Greek long-lived families (Open Cardiovasc Med J 2018)
- CETP variant rs1800777 A allele linked to milder liver damage in fatty liver disease (Ann Nutr Metab 2018)
- The CETP I405V polymorphism is an independent risk factor for Alzheimer's and vascular dementia in a Southern Italian cohort (J Alzheimers Dis 2018)
- A well-powered Mendelian randomization study finds CETP-driven HDL cholesterol is not associated with Alzheimer's disease risk (Alzheimers Dement 2018)
- Mendelian randomization finds no overall causal link between genetically determined CETP and carotid intima-media thickness (J Clin Lipidol 2018)
- CETP TaqIB B2B2 genotype blunts cholesterol-lowering response to simvastatin in Thai patients (Cardiovasc Ther 2017)
- Meta-analysis confirms the CETP TaqIB B2 allele protects against ischemic stroke (J Stroke Cerebrovasc Dis 2017)
- Five of six CETP polymorphisms are linked to metabolic syndrome in Uyghur adults, with two protective haplotypes identified (Int J Environ Res Public Health 2017)
- CETP knockout rabbits show less atherosclerosis, better cholesterol efflux, and HDL that suppresses endothelial adhesion molecules (Arterioscler Thromb Vasc Biol 2017)
- A year of Mediterranean diet raises HDL cholesterol and lowers triglycerides specifically in carriers of the CETP rs3764261 T allele, CORDIOPREV trial finds (Clin Nutr 2018)
- Meta-analysis of over 40,000 subjects confirms CETP TaqIB B1 allele raises ischemic cardiovascular disease risk and lowers HDL cholesterol (Int J Environ Res Public Health 2016)
- CETP TaqIB and I405V variants strongly linked to centenarian status in Hainan, China (Asian Pac J Trop Med 2016)
- Two CETP variants have opposite effects on coronary artery disease risk in the first such study in Saudi Arabians (Hum Genomics 2016)
- A protective CETP variant buffers the memory-decline effect of APOE4 in older adults (Neurobiol Aging 2016)
- Resequencing the entire CETP gene uncovers rare variants that independently affect HDL cholesterol in both whites and African blacks (Metabolism 2016)
- Two linked upstream CETP variants have opposite effects on gene expression via disrupted transcription factor binding sites (Pharmacogenet Genomics 2015)
- CETP deficiency protects against fatal liver damage from schistosomiasis by starving parasite eggs of HDL cholesteryl ester (J Biomed Res 2015)
- The CETP B2 allele is linked to lower LDL cholesterol specifically in black, not white, South African women (Atherosclerosis 2015)
- Combined CETP B1 and eNOS 4a alleles raise coronary artery disease risk up to 34-fold in Malay and Indian, but not Chinese, ethnic groups (Clin Appl Thromb Hemost 2016)
- Overexpressing full-length CETP in fat cells cuts triglyceride accumulation in half by boosting turnover and blocking synthesis (J Lipid Res 2015)
- Atorvastatin fails to protect against atrial fibrillation in patients with the CETP TaqIB B2B2 genotype (J Atr Fibrillation 2015)
- Fine-mapping of the CETP region identifies five novel variants, including a common intronic insertion, linked to HDL-C (NPJ Aging Mech Dis 2015)
- Meta-analysis of over 17,000 subjects confirms CETP TaqIB B2B2 genotype protects against myocardial infarction (Medicine 2014)
- CETP TaqIB B2 homozygotes get the strongest heart-protective benefit from moderate alcohol intake, replicating a prior finding in men (Alcohol 2014)
- Cache County Study links CETP I405V valine allele to slower cognitive decline in 4,486 older adults (Neurobiol Aging 2015)
- Ten CETP locus SNPs are among the strongest genetic determinants of HDL cholesterol variability in a Latvian population (Meta Gene 2014)
- Meta-analysis links the CETP rs5882 A allele to increased Alzheimer's disease risk in Caucasians (DNA Cell Biol 2014)
- The CETP rs5882 variant predicts white matter microstructure, with opposite effects in young versus older adults (Neurobiol Aging 2014)
- CETP and APOE variants interact to raise hypertriglyceridemia risk in oldest-old Chinese women (Exp Gerontol 2014)
- CETP variant rs3764261 is linked to reduced risk of advanced age-related macular degeneration in a Chinese population (Ophthalmic Genet 2015)
- A single CETP gene variant, rs5883, is identified as the main driver of the exon-9-skipping splice form (Biochem Biophys Res Commun 2014)
- Meta-analysis of seven CETP variants finds rs708272 and rs1800775 are promising biomarkers for myocardial infarction risk (PLoS One 2014)
- CETP TaqIB B2B2 genotype raises atrial fibrillation risk, especially in postmenopausal women with higher triglycerides (J Atr Fibrillation 2014)
- HDL from genetically CETP-deficient carriers is worse at activating eNOS, despite normal cholesterol-efflux capacity (PLoS One 2014)
- CETP deficiency linked to cardiovascular disease and stroke within a high-HDL syndrome, especially in women (Mol Genet Metab Rep 2014)
- The CETP rs1532624 AA genotype has lower CETP activity, higher HDL-C, but a weaker LDL-C response to statins in Jordanian patients (Curr Mol Pharmacol 2013)
- CETP Taq1B B1/B1 genotype predicts a favorable triglyceride/HDL-C response to kiwifruit in hypercholesterolaemic men (Br J Nutr 2013)
- CETP B1B1 genotype tracks with lower HDL cholesterol from birth through age 5-6 in children at cardiovascular risk (Med Sci Monit 2013)
- CETP I405V polymorphism is an independent risk factor for endometriosis in a case-control study of women (Gynecol Endocrinol 2013)
- CETP is the single most common genetic factor influencing HDL cholesterol in the Latvian population, ten-SNP association study finds (PLoS One 2013)
- Novel CETP promoter variants found in hyperalphalipoproteinemia patients sharply cut gene transcriptional activity (Clin Chim Acta 2013)
- Meta-analysis of over 15,000 subjects finds the CETP TaqIB B1 allele raises coronary artery disease risk specifically in Han Chinese (Mol Biol Rep 2013)
- CETP B1 allele combined with an eNOS variant raises coronary artery disease risk 18-fold in Western Iranians (Hum Genomics 2012)
- CETP -629 AA genotype is enriched in metabolic syndrome patients and linked to lower CETP but higher LDL-C and total cholesterol (Mol Biol Rep 2012)
- Common CETP genetic variants do not alter how well the apoB/apoA-I ratio predicts first major cardiovascular events compared with TC/HDL-C (J Clin Lipidol 2012)
- Resequencing finds rare CETP mutations and a common variant far more often in Thai patients with very high HDL cholesterol (Am J Cardiol 2012)
- CETP I405V valine homozygosity is linked to better cognitive function after age 65 (Neurobiol Aging 2012)
- CETP polymorphisms are linked to brain structure and Alzheimer's risk in an APOE-dependent manner (Brain Imaging Behav 2012)
- Low CETP activity more than doubles coronary artery disease risk in an Asian Indian diabetic cohort (Pharmacogenet Genomics 2012)
- CETP variant rs9923854 enriched in the oldest-old across Danish and German cohorts (Age (Dordr) 2012)
- Contradicting earlier reports, the CETP I405V polymorphism is linked to faster cognitive decline and higher Alzheimer's risk in a large US cohort (Aging Cell 2012)
- A novel CETP promoter deletion causing CETP deficiency does not impair HDL function in reverse cholesterol transport (Atherosclerosis 2011)
- CETP Taq1B B1B1 genotype independently raises type 2 diabetes risk, and a hepatic lipase variant amplifies it further (PLoS One 2011)
- CETP promoter variant -629C>A is strongly linked to cardiovascular disease specifically in Asian Indian patients with type 2 diabetes (J Diabetes Complications 2011)
- CETP variants raise HDL cholesterol by up to 14 percent regardless of diet, alcohol, or diabetes status in a high-risk Mediterranean population (J Lipid Res 2010)
- CETP TaqIB fails to protect against coronary heart disease over 10 years despite raising HDL cholesterol, and even raises risk in drinkers (Atherosclerosis 2010)
- CETP TaqIB B1B1 men are most responsive to a high-carbohydrate low-fat diet's HDL-raising effect in young Chinese adults (J Nutr Biochem 2010)
- CETP TaqIB genotype determines whether atorvastatin raises or lowers HDL cholesterol (Open Cardiovasc Med J 2010)
- CETP TaqIB B2 allele partly protects against the atherogenic HDL profile of type 2 diabetes, but only in women with milder insulin resistance (Atherosclerosis 2010)
- CETP Taq1B B1B1 genotype is linked to higher insulin and HOMA levels, suggesting a role in glucose regulation (Nutr Metab Cardiovasc Dis 2011)
- Rare CETP-deficient case reveals independent control of remnant triglyceride and cholesterol after a fat load (Ann Clin Biochem 2009)
- Two new CETP and LIPC gene mutations identified as causes of extremely high HDL cholesterol in Thai patients (Metabolism 2009)
- CETP variant D442G raises HDL cholesterol nearly three times more in obese than normal-weight Chinese individuals (Obesity 2009)
- The CETP SNP rs1800775 explains more variance in HDL cholesterol than any other single lipid gene variant studied in older adults (Eur Heart J 2009)
- CETP locus generalizes as a blood-lipid determinant across black, Mexican American, and white US populations (Circ Cardiovasc Genet 2009)
- CETP TAQIB and I405V rare alleles are modestly associated with reduced obesity risk in Chinese adults, largely via HDL levels (Acta Diabetol 2009)
- A CETP variant raises vascular dementia risk and lowers white matter lesion load, but only in APOE4 non-carriers (J Neural Transm 2009)
- CETP TaqIB B2B2 genotype more than doubles cardiovascular death risk after acute coronary syndrome, unless the patient takes a statin (Clin Chem Lab Med 2009)
- First CETP gene mutations identified in Italian patients with extremely high HDL cholesterol, including two premature-stop-codon variants (Atherosclerosis 2009)
- CETP haplotype G raises early-onset heart-attack risk up to 6-fold in men, independent of HDL-C (Ann Hum Genet 2008)
- Updated pooled analysis finds the CETP B2 allele may raise, not lower, cardiovascular risk in the general population despite higher HDL cholesterol (Pharmacogenomics 2008)
- Both wild-type CETP and its poorly secreted splice variants trigger the same endoplasmic reticulum stress response (J Lipid Res 2008)
- Two novel CETP protein variants identified through resequencing in individuals of Asian ancestry, both partly functional (Atherosclerosis 2009)
- CETP B1B1 genotype combined with APOE or APOC3 risk variants quadruples coronary artery disease risk when all three are present (Atherosclerosis 2008)
- Glucocorticoid replacement erases the CETP promoter variant's link to HDL cholesterol in hypopituitary patients (Clin Endocrinol (Oxf) 2008)
- CETP promoter variant linked to lower CETP levels also impairs the ability of plasma to remove cholesterol from cells, a possible clue to its cardiovascular risk (Biochim Biophys Acta 2008)
- Alcohol only reduces heart disease risk in CETP TaqIB B2 carriers, especially among women, two large US cohort studies find (Eur Heart J 2008)
- CETP Taq1 B2 allele nearly halves ischemic stroke risk in Sardinian women, but not men (J Intern Med 2007)
- Smoking advances first heart attack by up to 9 years in CETP TaqIB B1 carriers, but not in B2B2 homozygotes (Ann Noninvasive Electrocardiol 2007)
- Three newly discovered rat gene loci determine whether human CETP causes severe hypercholesterolemia when expressed as a transgene (J Hypertens 2007)
- CETP I405V VV genotype cuts myocardial infarction risk in men by 43 percent in the Rotterdam Study (Eur J Cardiovasc Prev Rehabil 2007)
- White women with a CETP -629 A/A genotype gain the most HDL cholesterol from 20 weeks of endurance training (Physiol Genomics 2007)
- The Rotterdam Study links CETP I405V VV genotype to increased Alzheimer's disease risk in APOE4 non-carriers (Neurogenetics 2007)
- CETP expression reverses the obesity caused by apolipoprotein CIII overexpression in transgenic mice (Int J Obes 2007)
- CETP deficiency sharply blunts the post-meal triglyceride spike and remnant lipoprotein formation (Atherosclerosis 2008)
- CETP B2B2 genotype protects against acute coronary syndrome only in normal-weight Greeks, not the overweight or obese (Hum Hered 2007)
- CETP gene variants predict how much fat monozygotic twins gain during 100 days of deliberate overfeeding (Atherosclerosis 2008)
- A novel CETP splice-site mutation causes isolated high HDL cholesterol in Caucasians, distinct from ordinary hyperalphalipoproteinemia (J Lipid Res 2007)
- CETP is one of only four genes with consistent lipid effects across sex and race in the CARDIA cohort (Arterioscler Thromb Vasc Biol 2006)
- CETP Taq1B B1 allele linked to worse lipid profile and higher blood pressure in kidney transplant patients (Transplant Proc 2006)
- CETP TaqIB is the only tested genetic system linked to atrial fibrillation, especially when combined with kidney or inflammation markers (BMC Med Genet 2006)
- Full gene screening finds 12 novel CETP variants, three of which raise coronary heart disease risk in Chinese patients (Int J Cardiol 2005)
- The CETP C-629A promoter variant modifies the Alzheimer's disease risk conferred by APOE epsilon4 (J Neurol 2006)
- REGRESS Study identifies three interacting CETP promoter variants that jointly determine plasma CETP concentration (Hum Mol Genet 2005)
- CETP B2B2 homozygotes gain over ten times more HDL cholesterol from simvastatin than B1 carriers, unlike APOE or LIPC genotypes (Clin Chim Acta 2005)
- CETP TaqI B1B2 genotype triples hypertension risk in North Indian diabetics despite no direct T2DM link (BMC Endocr Disord 2005)
- High triglycerides nearly halve the HDL-raising benefit of a protective CETP promoter variant, large PREVEND study finds (J Clin Endocrinol Metab 2005)
- A newly characterized CETP promoter variant raises HDL cholesterol specifically in African Americans by weakening a transcription-factor binding site (Clin Genet 2004)
- CETP TaqB1B1 genotype linked to higher LDL cholesterol in Chinese coronary heart disease patients (Chin Med J (Engl) 2004)
- Genome scan finds an LDL-particle-size linkage locus near CETP in familial combined hyperlipidemia families (Arterioscler Thromb Vasc Biol 2004)
- CETP -629A is one of only two individual gene variants, out of 58 tested, that protect against myocardial infarction (Eur Heart J 2004)
- Elderly men carrying a CETP mutation trend toward the lowest heart disease rates in a 7-year Honolulu Heart Program follow-up (J Lipid Res 2004)
- Review catalogs ten CETP mutations behind hyperalphalipoproteinemia in Japanese CETP-deficient subjects (J Atheroscler Thromb 2004)
- CETP deficiency produces giant HDL particles carrying nearly every major apolipoprotein except apoA-IV (J Lipid Res 2004)
- Japan CETP Study Group finds CETP activity is the strongest determinant of both HDL-C and LDL-C in 591 subjects (Metabolism 2003)
- Hepatic lipase TT genotype protects against vascular disease only in hemodialysis patients with high CETP levels (Kidney Int 2003)
- CETP I405V genotype determines whether dietary plant sterols lower cholesterol and CETP concentration (J Nutr 2003)
- Full resequencing pinpoints the specific CETP promoter and repeat variants most strongly linked to CETP mass and HDL cholesterol (Atherosclerosis 2003)
- Review surveys CETP as both an unresolved genetic risk marker and a newly validated drug target (Curr Opin Lipidol 2003)
- CETP -629A allele linked to larger LDL particle size in 377 healthy middle-aged men (Atherosclerosis 2003)
- A newly discovered CETP splice variant in rabbit intestine, and its human counterpart, lacks the lipid-transfer-critical carboxy-end (Mol Cell Biochem 2003)
- REGRESS study haplotype analysis shows -629C/A, not TaqIB, drives CETP concentration and HDL-C (Hum Mol Genet 2003)
- CETP mutations explain most, but not all, cases of extremely high HDL cholesterol in 624 Japanese patients (Atherosclerosis 2003)
- CETP variants cannot explain why Asian Indians have both the highest heart disease rates and lowest HDL cholesterol in Singapore (Clin Genet 2003)
- CETP Taq1B B1B1 genotype independently predicts coronary artery disease in Koreans (Clin Genet 2003)
- CETP gene haplotypes, not individual SNPs, are the first shown to predict lipid response to statin therapy (Pharmacogenomics J 2003)
- Two newly discovered CETP mutations block protein secretion, explaining more than 60 percent of severe high-HDL cases in Japan (J Lipid Res 2002)
- CETP TaqIB B2 allele is less common in African Americans than Caucasians, ruling it out as an explanation for higher HDL-C (Atherosclerosis 2002)
- D442G CETP mutation raises HDL cholesterol in Korean postmenopausal women but does not alter the HDL response to hormone therapy (Korean J Intern Med 2002)
- CETP TaqIB B2 carriers have higher HDL cholesterol but no lower heart attack risk in a large Physicians Health Study cohort (Atherosclerosis 2002)
- CETP activity does not predict LDL buoyancy in women, but CETP TaqIB genotype does predict CETP mass and HDL3 cholesterol (Arterioscler Thromb Vasc Biol 2002)
- Novel CETP promoter variant -971G/A found to be a non-functional marker linked to HDL-C via other polymorphisms (Atherosclerosis 2002)
- CETP TaqIB B1B1 genotype independently predicts coronary disease, arteriosclerosis, and stroke in Japanese type 2 diabetics (Diabetes 2002)
- CETP EcoN1 GG genotype linked to coronary heart disease risk in a Taiwanese population survey (Atherosclerosis 2001)
- CETP TaqIB predicts heart attack risk and a 2-year later age of onset, but a linked promoter variant does not, Reykjavik Study finds (Atherosclerosis 2001)
- The CETP D442G mutation raises HDL cholesterol in adults but not children, first pediatric study of this variant finds (Pediatr Res 2001)
- CETP deficiency slows parasite egg development, a possible reason it persists at high frequency across East Asia (Biochem Biophys Res Commun 2001)
- Suppressing CETP synthesis in fat cells causes cholesteryl ester to pile up threefold by blocking its normal mobilization (J Biol Chem 2001)
- CETP Ile405Val predicts carotid intima-media thickness in men but not women in the Stanislas Cohort (Clin Genet 2001)
- Review details CETP's LBP-gene-family membership and the molecular basis of CETP-deficiency hyperalphalipoproteinemia (Biochim Biophys Acta 2000)
- Review highlights a paradox: CETP-inhibited rabbits show different atherogenicity than genetically CETP-deficient humans (Curr Opin Lipidol 2000)
- CETP B1B1 genotype predicts a larger cholesterol drop from switching to a low-saturated-fat diet, crossover trial finds (Atherosclerosis 2000)
- A review argues CETP-TaqI-B polymorphism data support genetic testing, while cautioning that CETP-inhibitor cardioprotection remains unproven (Clin Chem Lab Med 2000)
- Review concludes CETP's atherogenic effect depends on metabolic background, proposing it as a therapeutic target in hyperlipidemia (Curr Opin Lipidol 2000)
- Ten CETP polymorphisms mapped in 568 heart-attack patients reveal alcohol-dependent effects on HDL cholesterol (Genet Epidemiol 2000)
- New CETP/-629 promoter variant lowers CETP mass and raises HDL cholesterol via Sp1/Sp3 repression (ATVB 2000)
- CETP variant R451Q lowers carotid artery thickness in men, while I405V harms only heavy drinkers (Eur J Clin Invest 2000)
- Blocking CETP production in liver cells boosts secretion of the smallest, most protective HDL form (Atherosclerosis 1999)
- Abdominal obesity blunts the HDL-raising benefit of the CETP B2 allele in men with insulin resistance features (Int J Obes 1999)
- CETP genotype, not insulin sensitivity, predicts how PLTP activity falls during hyperinsulinemia in men (J Lipid Res 1999)
- Human CETP transgene worsens atherosclerosis in apoE- and LDL-receptor-knockout mice, but effect flips with apoA-I overexpression (ATVB 1999)
- Two CETP variants jointly explain 12 percent of CETP activity variance in a European multi-country cohort, EARS study finds (Eur J Clin Invest 1999)
- SREBP-1 activates the CETP gene in transgenic mice but is not required for its cholesterol-driven up-regulation (J Biol Chem 1998)
- New CETP mutation R451Q raises CETP activity in men but lowers cholesterol in women, a sex-divergent effect (Atherosclerosis 1998)
- CETP TaqIB genotype predicts opposite lipid responses to a cholesterol-lowering diet in type 1 diabetics (Diabetes 1997)
- A novel CETP nonsense mutation produces a paradoxical combination of very high HDL cholesterol and extreme post-meal triglyceride levels (Arterioscler Thromb Vasc Biol 1997)
- Chemically blocking a single CETP cysteine residue selectively shuts off triglyceride transfer while leaving cholesteryl ester transfer intact (Biochim Biophys Acta 1997)
- Exon-14 skipping explains why the common Japanese CETP splicing mutation produces essentially no detectable protein (Arterioscler Thromb Vasc Biol 1997)
- ApoE-rich HDL is a better CETP substrate than apoA-II-containing HDL, three CETP-deficiency genotypes reveal (J Lipid Res 1997)
- Review surveys the molecular genetics of CETP deficiency and its still-controversial link to atherosclerosis (Curr Opin Lipidol 1997)
- CETP gene locus heterogeneity explains why healthy men with low HDL cholesterol carry higher CETP concentrations (ATVB 1997)
- Non-smoking, alcohol-drinking men with the CETP V405 genotype may have up to 40 percent lower heart attack risk, Icelandic study suggests (Clin Genet 1997)
- Transgenic mice map distinct CETP promoter regions controlling liver, intestine, and adrenal expression (J Biol Chem 1996)
- CETP gene variation explains one-fifth of the variability in plasma CETP levels, but not HDL cholesterol, family study finds (J Lipid Res 1996)
- A panel of 16 new antibodies maps four distinct CETP regions essential for cholesteryl ester transfer activity (J Lipid Res 1996)
- Review weighs whether cholesterol redistribution by CETP is proatherogenic or a step in protective reverse cholesterol transport (Horm Res 1996)
- Review surveys the biochemistry and molecular basis of CETP deficiency disorders (J Atheroscler Thromb 1996)
- CETP mutation 442D:G is found in nearly a third of Japanese with very high HDL cholesterol, including the first documented case with atherosclerosis (Atherosclerosis 1995)
- CETP TaqIB genotype distribution differs significantly between cholesterol gallstone patients and controls (J Lipid Res 1995)
- CETP deficiency yields abnormally large, cholesterol-rich apoA-I lipoprotein particles that bind but internalize poorly (Eur J Biochem 1995)
- Molecular genetics reveals CETP as both anti-atherogenic in human deficiency and pro-atherogenic when overexpressed in mice (J Intern Med 1995)
- CETP mutations I14A and D442G together explain a graded rise in HDL cholesterol across 226 Japanese patients (J Clin Endocrinol Metab 1994)
- ApoA-II shields HDL from CETP-driven shrinkage by inhibiting hepatic lipase in transgenic mice (J Clin Invest 1994)
- CETP TaqI B polymorphism predicts CETP activity and HDL cholesterol in non-smoking men, but alcohol and smoking alter the association (Atherosclerosis 1994)
- CETP EcoNI genotype 2-2 predicts higher rates of coronary disease and neuropathy in type 2 diabetes (Clin Genet 1994)
- CETP TaqI polymorphism predicts HDL cholesterol in Greek but not Italian migrants to Australia (Hum Biol 1994)
- An alternatively spliced CETP variant lacking exon 9 sequences blocks secretion of full-length CETP by forming inactive heteromeric complexes (J Biol Chem 1993)
- A CETP nonsense mutation at codon 309, detected via macrophage mRNA, is identified as a new cause of familial hyperalphalipoproteinemia (Biochem Biophys Res Commun 1993)
- Homozygous and heterozygous CETP deficiency show graded shifts toward cholesteryl-ester-rich HDL and cholesteryl-ester-poor IDL that track with serum CETP level (Atherosclerosis 1991)
- In CETP deficiency, LDL cholesteryl esters trace back to intracellular ACAT rather than CETP-mediated transfer from HDL (J Lipid Res 1991)
- CETP TaqIB genotype tracks with HDL cholesterol at the population extremes, with the B2 allele enriched among high-HDL subjects (Clin Sci 1990)
- ApoE-rich HDL that accumulates in CETP deficiency binds the LDL receptor with far higher affinity than LDL itself (J Clin Invest 1990)
- CETP locus DNA polymorphism acts as both a level gene for apoA-I and HDL cholesterol and a variability gene for LDL cholesterol (Acta Genet Med Gemellol 1990)
- Cloning rabbit CETP reveals 81% homology to the human protein and liver-dominant tissue expression across primates and rabbit (J Lipid Res 1988)
- Liver Hep G2 cells secrete CETP, acquiring asparagine-linked sugar and sialic acid during processing (J Biol Chem 1987)
- CETP shows the most consistent gene-diet interaction evidence of any lipid gene, especially with dietary fat composition (Curr Issues Mol Biol 2026)
- Cross-trait GWAS links hearing loss to HDL and triglyceride genetics, flagging CETP as a candidate druggable target (Mol Genet Genomics 2025)
- Largest paediatric lipid GWAS to date confirms CETP as a robust HDL locus in Indian schoolchildren, with rare CETP variants also implicated (J Hum Genet 2025)
- Blood gene-expression signature of ITGB3, VEGFA and CETP tracks the extent of coronary artery stenosis, odds ratio 7.49 (Biochemistry (Mosc) 2025)
- A hierarchical transformer model identifies an APOA4-CETP epistatic interaction underlying triglyceride to HDL cholesterol ratio (bioRxiv 2025)
- CETP promoter and coding variants predict HDL cholesterol levels in a Bangladeshi population (Biochem Biophys Rep 2025)
- CETP genetic variants shape the lipid response to statins in Alzheimer's disease patients (Sao Paulo Med J 2025)
- Systematic review finds PCSK9, CETP and CDKN2B-AS1 polymorphisms among the strongest genetic contributors to myocardial infarction in Saudi Arabia (J Saudi Heart Assoc 2025)
- Mendelian randomisation finds genetically proxied CETP inhibition associated with lower uterine fibroid risk (Heliyon 2025)
- Genome-wide meta-analysis of myopic macular neovascularisation finds the AMD-linked CETP locus rs12720922 also protects against this retinal disease (Ophthalmol Retina 2025)
- CETP rs708272 GG genotype blunts the benefit of a dietary intervention when trans fatty acid intake is high, secondary analysis finds (Nutrients 2024)
- Mendelian randomisation finds higher genetically predicted CETP, alongside HMGCR and PCSK9, associated with greater aortic aneurysm risk (Eur J Prev Cardiol 2024)
- The CETP rs708272 G/G genotype is significantly linked to dyslipidemia in Chinese patients with diabetes (World J Clin Cases 2024)
- CETP gene variants help explain HDL cholesterol levels in children with sickle cell disease (Braz J Med Biol Res 2024)
- Mendelian randomisation finds genetically higher CETP levels associated with increased non-endometrioid endometrial carcinoma risk (Front Endocrinol 2024)
- Traditional dietary pattern adherence modulates the CETP Taq1B link to triglyceride levels in angiography patients (Nutr J 2023)
- A CETP variant is one of four factors in a nomogram predicting behavioral symptoms in Alzheimer's disease (Chin Med J 2024)
- In a highly admixed population, four CETP gene variants explain part of the HDL-cholesterol variation across adolescents, adults and older adults (Clin Nutr ESPEN 2023)
- Dietary acid load interacts with CETP TaqB1 genotype to worsen lipid profile in B1B1 carriers with type 2 diabetes (BMC Endocr Disord 2023)
- A CETP variant is significantly associated with pentosan polysulfate (Elmiron) maculopathy, a genetic study of a drug-induced retinal disease finds (Retina 2023)
- The CETP rs708272 genotype predicts statin response only in women with hyperlipidaemia (Malays J Med Sci 2023)
- Abdominal obesity combines with the CETP TaqIB variant to raise cholesterol in Mexican women (Lifestyle Genom 2023)
- The CETP rs708272 risk allele is linked to higher cardiac gene expression and interacts with diet and smoking to triple the risk of low HDL (Front Nutr 2023)
- Korean GWAS of 72,298 people finds a CETP variant significant for dyslipidaemia overall and a second one only in men (Lipids Health Dis 2022)
- A trans-ancestry GWAS in pregnant women finds the CETP locus approaches genome-wide significance for HDL cholesterol (J Clin Lipidol 2023)
- The CETP TaqIB B1B2/B2B2 genotype raises the risk of fatty liver disease in Mexican women with gallstones (Metab Syndr Relat Disord 2023)
- In two large Korean cohorts, whether CETP raises cholesterol with alcohol depends on a person's ALDH2 genotype (Sci Rep 2022)
- CETP gene promoter hypomethylation is associated with coronary artery disease risk in a Chinese Han cohort (Mol Biol Rep 2022)
- Two CETP gene variants raise coronary artery disease risk but do not predict restenosis after stenting (Arch Cardiol Mex 2022)
- CETP variant rs3764261 has a bigger population-level impact on low HDL cholesterol than smoking, Japanese cohort study finds (J Epidemiol 2022)
- Review of 49 studies finds the TaqIB CETP variant is the most widely studied gene-diet interaction affecting blood lipids (Curr Atheroscler Rep 2022)
- CETP mutations are identified for the first time in South Indian patients with familial hypercholesterolemia (Clin Chim Acta 2022)
- CETP variant rs3764261 emerges as a lean-mass protective marker in a Pakistani obesity genetics cohort (PLoS One 2022)
- Exome study in an underrepresented Mexican cohort finds a novel CETP variant, rs11076176, linked to higher risk of low HDL cholesterol (Front Genet 2022)
- The CETP TaqIB polymorphism interacts with diet quality to shape metabolic markers in type 2 diabetes (J Hum Nutr Diet 2022)
- The CETP rs5883 T allele is linked to higher HDL cholesterol and lower risk of low HDL in postmenopausal obese women (Eur Rev Med Pharmacol Sci 2021)
- CETP TaqB1 polymorphism interacts with dietary insulin index to shape cardiovascular risk in type 2 diabetes (Sci Rep 2021)
- CETP is used to illustrate why Mendelian randomization of drug targets differs methodologically from randomization of biomarkers (Nat Rev Cardiol 2021)
- GWAS confirms CETP as one of only three genome-wide loci for Lp(a) levels while discovering a novel APOH locus (Arterioscler Thromb Vasc Biol 2020)
- CETP variant rs3764261 is linked to polypoidal choroidal vasculopathy in a Portuguese population, but not in a Singaporean cohort (Br J Ophthalmol 2021)
- Fine-mapping in two Kuwaiti Arab cohorts flags rs1864163 in CETP as a candidate causal variant for HDL cholesterol (Hum Genet 2021)
- Carriers of the CETP Taq1B B2 allele only show worse cholesterol with a high-sucrose diet or physical inactivity, a gene-environment study finds (J Hum Nutr Diet 2020)
- Higher serum CETP levels are linked to acute coronary syndrome, with the association modified by TaqIB genotype (Lab Med 2020)
- Certain CETP gene haplotypes raise the triglyceride to HDL cholesterol ratio more often in Roma than Hungarian populations (Genes 2020)
- Korean GWAS discovers six novel CETP SNPs associated with low HDL cholesterol (PLoS One 2020)
- CETP variant rs5882 interacts with monounsaturated fat intake to affect triglyceride levels in overweight and obese adults (Lifestyle Genom 2020)
- CETP TaqIB genotype shapes how plant oils affect metabolic markers in people with diabetes (J Cardiovasc Thorac Res 2020)
- CETP genetic variants predict how much LDL cholesterol falls with statin therapy (Pharmacogenomics J 2020)
- Comparative genomics finds widespread natural loss of the CETP gene across placental mammals (NAR Genom Bioinform 2019)
- CETP variant rs6499861 lowers HDL cholesterol more strongly in obese Korean men and women with a family history of diabetes (J Lipid Atheroscler 2019)
- CETP variant rs708272 GG genotype cuts the odds of optic neuritis with multiple sclerosis by 62% in a Lithuanian case-control study (Ophthalmic Genet 2019)
- CETP Taq1B genotype shifts HDL and LDL subclass distribution in African-American men (Future Cardiol 2019)
- CETP variant rs708272 is linked to reduced risk of pituitary adenoma and its recurrence (Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020)
- Fish intake and dietary fat modify how two CETP gene variants affect cholesterol and triglyceride changes over time (Eur J Clin Nutr 2019)
- CETP rs708272 raises HDL cholesterol and lowers atherogenic index in men but not women, without affecting coronary disease risk (Medicine 2018)
- CETP TaqIB genotype shapes HDL cholesterol but not diabetes risk in Southern Thai adults (Arch Med Res 2018)
- Two CETP polymorphisms and a three-locus haplotype raise coronary artery disease risk in a Polish population (Mol Biol Rep 2018)
- Dietary fat intake modifies how CETP variant rs5882 affects HDL cholesterol and blood pressure risk (Iran J Basic Med Sci 2018)
- CETP markers show strong associations with HDL cholesterol across obesity phenotypes in an Iranian cohort, unlike most FTO variants (Eat Weight Disord 2020)
- CETP variant rs1800777 is linked to greater fat mass, central obesity, and lower HDL cholesterol in obese adults (Endocrinol Diabetes Nutr 2018)
- Meta-analysis identifies two CETP variants among the leading genetic risk factors for polypoidal choroidal vasculopathy in Asians (J Ophthalmol 2018)
- In 1,264 Lithuanians, two CETP variants raise exudative AMD risk up to 1.7-fold while a third, rs3764261, cuts it by 1.8-fold (Gene 2017)
- Nat Rev Cardiol: most genetic variants that raise HDL-C don't lower cardiovascular risk, but CETP variants are a notable exception (Nat Rev Cardiol 2018)
- CETP variant rs3764261 is one of four risk alleles linked to lower HDL cholesterol in pregnant Chinese women (Oncotarget 2017)
- A protective CETP haplotype, but not individual TaqIB or D442G variants, lowers essential hypertension risk in Chinese Mongolians (Turk J Med Sci 2017)
- Meta-analysis links the CETP C-629A polymorphism to higher coronary heart disease risk and circulating CETP in Caucasians (Oncotarget 2017)
- Systematic review of 23 studies finds the CETP B1 risk allele responds better to dietary interventions than B2B2 (Nutr Metab 2017)
- CETP variant rs1800775 is associated with HDL cholesterol and total cholesterol, but not LDL, in pregnant Chinese women (J Clin Lipidol 2017)
- Total fat intake modifies the CETP Taq1B link to HDL cholesterol only in type 2 diabetes patients without dyslipidemia (Clin Nutr 2018)
- Rare CETP coding variants linked to age-related macular degeneration risk in a Japanese population study (Hum Mol Genet 2016)
- CETP Taq1B is linked to glycated hemoglobin levels in hyperlipidemic patients with diabetes, a link modulated by an LIPG variant (Can J Diabetes 2016)
- Plasma CETP is higher in metabolic syndrome, but the Taq1B genotype itself shows no direct link to the syndrome in Iranian subjects (Biochem Genet 2016)
- CETP I405V shows no link to age or cardiovascular disease despite raising HDL cholesterol (BMC Geriatr 2016)
- CETP TaqIB, but not apo AI 75G/A, significantly shapes HDL cholesterol levels in Polish men and women (Arch Med Sci 2016)
- Higher serum CETP levels and the -629A allele are linked to angiographically confirmed coronary atherosclerosis (Indian J Clin Biochem 2017)
- CETP c.*84G>A variant doubles coronary artery disease risk in South Indian patients (PLoS One 2016)
- Eight CETP gene polymorphisms show distinct HDL, LDL, and triglyceride associations in Kazak and Uyghur adults from Western China (Int J Environ Res Public Health 2015)
- CETP is among the genes most strongly linked to lipid change over time and incident hyperlipidemia in a large Chinese cohort study (Circ Cardiovasc Genet 2016)
- Meta-analysis links CETP rs3764261 variant to higher age-related macular degeneration risk across ethnicities (Sci Rep 2015)
- CETP variant rs708272 nearly doubles metabolic syndrome risk in women from southwestern Mexico (Int J Mol Sci 2015)
- CETP variant rs3764261 raises HDL cholesterol but does not affect diabetes risk or recurrent cardiovascular events in vascular disease patients (Atherosclerosis 2015)
- CETP I405V II genotype linked to gray matter diffusion abnormalities in healthy older adults (J Neural Transm 2015)
- CETP variant rs5882 determines whether plant sterol consumption lowers triglycerides, crossover trial finds (Appl Physiol Nutr Metab 2015)
- Novel CETP microdeletion lowers enzyme activity and raises HDL-associated cholesterol in three carriers (Clin Genet 2016)
- CETP variant rs708272 is one of three protective polymorphisms shielding HIV patients on antiretroviral therapy from atherogenic dyslipidemia (AIDS Res Hum Retroviruses 2015)
- Review proposes historic hepatic schistosomiasis as a screening factor behind East Asia's unusually high rate of genetic CETP deficiency (Nutrients 2015)
- CETP variant rs5882 G allele is linked to lower HDL cholesterol in obese and non-obese individuals alike (Gene 2015)
- The CETP locus is one of only three individually significant lipid-associated SNPs confirmed in a first Algerian population genetics study (Int J Clin Exp Pathol 2015)
- CETP variants A373P and Taq1 have opposite effects on low HDL cholesterol risk in Iranian children and teenagers (Atherosclerosis 2014)
- CETP TaqIB B2 allele carriers have higher HDL cholesterol and antioxidant enzyme activity in both healthy and diabetic Argentinians (J Diabetes Investig 2015)
- CETP is one of five gene loci with pleiotropic effects across metabolic syndrome components in over 15,000 African Americans (Circ Cardiovasc Genet 2014)
- CETP TaqIB B2B2 genotype is linked to more favorable HDL cholesterol levels in West Siberian Caucasians (Bull Exp Biol Med 2014)
- CETP I405V Val/Val genotype significantly determines HDL cholesterol levels in myocardial infarction patients (J Clin Diagn Res 2014)
- Meta-analysis finds CETP TaqIB genotype raises Alzheimer's risk only in APOE4-positive Asians, with no overall population association (Neurobiol Aging 2014)
- CETP TaqIB mutation carriers with low HDL cholesterol have a fivefold higher risk of premature coronary artery disease in Egyptians (J Clin Lipidol 2014)
- CETP variant rs708272 lowers coronary atherosclerosis risk while a linked variant shapes HDL cholesterol in Chinese healthy controls (Lipids Health Dis 2013)
- CETP gene promoter variants show no association with longevity in two Han Chinese samples (Mol Biol Rep 2013)
- A Filipino GWAS finds suggestive CETP and TOM1 associations with HDL cholesterol and allelic heterogeneity at the CETP locus (J Lipid Res 2013)
- CETP variant rs3764261 raises the risk of polypoidal choroidal vasculopathy in a Japanese population (Invest Ophthalmol Vis Sci 2013)
- CETP variant rs708272 associates with HDL-C and LDL-C levels in 365 Turkish children (OMICS 2013)
- Absence of the CETP B2 allele doubles coronary artery disease risk, but only in ethnic Chinese Singaporeans (Lipids Health Dis 2013)
- CETP gene promoter methylation correlates with LDL-C, HDL-C, and HDL particle size in familial hypercholesterolaemia patients (Atherosclerosis 2013)
- CETP rs3764261 T allele is the top single-locus HDL-C predictor among 13 SNPs in a 3,050-person Japanese cohort (PLoS One 2013)
- The CETP locus reaches genome-wide significance for baseline Lp-PLA2 mass in a JUPITER-trial GWAS of 6,851 statin-treated participants (Circ Cardiovasc Genet 2012)
- CETP I405V is linked to lower small dense LDL levels, unrelated to coronary artery disease risk, in Indian subjects (Indian J Clin Biochem 2012)
- Meta-analysis confirms CETP TaqIB polymorphism is linked to coronary artery disease in Chinese patients (J Zhejiang Univ Sci B 2012)
- CETP TaqIB genotype tracks with HDL-C differently in long-lived versus younger Chinese Bama Zhuang adults (Lipids Health Dis 2012)
- GWAS replication confirms CETP rs3764261 association with HDL-C in a 3,781-person Asian Indian cohort (PLoS One 2012)
- Three novel CETP gene mutations identified in Japanese patients with hyperalphalipoproteinemia (Clin Chim Acta 2012)
- CETP is one of only two loci genome-wide-significantly associated with Lp-PLA2 mass in a five-study CHARGE Consortium meta-analysis (Eur Heart J 2011)
- Review explains why CETP inhibition raises HDL2 cholesterol without necessarily improving reverse cholesterol transport (Biochim Biophys Acta 2011)
- CETP TaqIB polymorphism flags high coronary risk but cannot distinguish left main from more peripheral disease (Lipids Health Dis 2011)
- Unlike LCAT or ABCA1 mutations, heterozygous CETP mutations leave plasma sphingosine-1-phosphate and apoM levels unaffected (Atherosclerosis 2011)
- Systematic review confirms the CETP Taq-1B minor allele is protective against metabolic syndrome, among only eight genetic associations that hold up (Obes Rev 2011)
- CETP B1 allele raises coronary artery disease and diabetes risk independent of HDL-C in western Iran (Genet Test Mol Biomarkers 2011)
- Large AMD meta-analysis discovers two new genetic loci and confirms CETP among ten previously known susceptibility genes (Hum Mol Genet 2011)
- The PAGE study fails to replicate CETP rs1864163's HDL-C association across roughly 38,000 diverse-ancestry adults despite adequate power (PLoS Genet 2011)
- Combining CETP B2B2 with an ABCA1 variant produces the largest HDL cholesterol gap seen in a Chinese cohort of nearly 1 mmol/L (Acta Cardiol 2011)
- CETP and hepatic lipase gene variants interact to raise carotid atherosclerosis risk in 1,549-person SAPHIR cohort (Atherosclerosis 2011)
- Dense candidate-gene genotyping confirms CETP among established HDL-C loci in a 7,857-person meta-analysis and reveals multiple independent signals at several loci (Circ Cardiovasc Genet 2011)
- Three CETP variants are among only six SNPs linked to HDL cholesterol in European adolescents, first shown in this age group (Atherosclerosis 2011)
- A well-powered study of CETP sequence variation finds no meaningful association with cognitive decline or dementia risk (Int J Mol Epidemiol Genet 2011)
- CETP Taq1B B1B1 genotype is more common in Egyptian metabolic syndrome patients and tracks with lower HDL cholesterol (Diabetes Metab Syndr 2011)
- CETP and LPL polymorphisms jointly predict cardiovascular risk in women with high HDL cholesterol and CRP (Atherosclerosis 2011)
- CETP variant rs5882 is the second-strongest of nine genetic hits for low HDL cholesterol and heart disease risk in a 60-gene screen (J Lipid Res 2010)
- CETP Taq1B B2B2 genotype is linked to the highest HDL cholesterol and lowest oxidative stress marker levels in Tehran adults (Lipids Health Dis 2010)
- CETP variant rs708272 improves diagnostic accuracy for identifying patients with active atherosclerosis (Swiss Med Wkly 2010)
- CETP TaqIB B2 allele more than doubles recurrent event risk in postinfarction patients with high HDL-C and CRP (Arterioscler Thromb Vasc Biol 2010)
- CETP is one of only four genes confirmed to affect HDL cholesterol, with no evidence its effect depends on alcohol intake (Atherosclerosis 2010)
- CETP TaqIB genotype distinguishes a longevity syndrome of simultaneously high HDL and LDL cholesterol (Open Cardiovasc Med J 2010)
- Olive-oil-enriched skim milk raises HDL cholesterol most in children with the CETP B1B1 genotype (Ann Nutr Metab 2010)
- Combined LIPC and CETP I405V variants double coronary artery disease risk, but the effect fades in women with high HDL cholesterol (Genet Test Mol Biomarkers 2009)
- CETP -629C>A promoter variant predicts HDL-C response to growth hormone only in glucocorticoid-treated patients (Eur J Endocrinol 2010)
- CETP TaqIB significantly shapes baseline HDL subpopulation profile in postmenopausal women, though hormone therapy response is largely unaffected (Clin Endocrinol 2010)
- CETP genotype tracks with HDL cholesterol and triglycerides but not with coronary artery disease risk in Turkish angiography patients (Eurasian J Med 2009)
- CETP -629C/A AA genotype raises HDL cholesterol but may still carry higher coronary artery disease risk in Iranian Azeris (Iran Biomed J 2009)
- CETP-HDL association is one of only four gene-lipid-trait pairs replicated using a new cardiovascular gene chip in a multiethnic cohort (J Lipid Res 2009)
- CETP I405V VV genotype is linked to higher HDL cholesterol in Turks, an effect modified by sex and triglycerides (Cell Biochem Funct 2009)
- CETP variant A373P is independently linked to lower HDL cholesterol and ApoA-I-containing lipoproteins, largely independent of other tested genes (Metabolism 2009)
- CETP activity is markedly elevated in Iranian patients with primary combined hyperlipidaemia, modulated by Taq1B genotype (Indian J Med Res 2009)
- CETP I405V V-allele carriers lose more ApoA-I and HDL cholesterol when switched from a high to low polyunsaturated fat diet (Horm Metab Res 2009)
- CETP B1B1 genotype nearly triples coronary heart disease risk in a South Indian population (Clin Chim Acta 2009)
- A CETP gene variant favors healthy survival past age 90 in long-lived Japanese-American men (J Gerontol A Biol Sci Med Sci 2008)
- CETP B1 allele raises metabolic syndrome risk specifically in Turkish women, large cross-sectional study finds (Anadolu Kardiyol Derg 2008)
- CETP Taq1B B2 allele cuts coronary stenosis risk by 18 percent overall, and 38 percent in male nonsmokers, in Tunisians (Arch Cardiovasc Dis 2008)
- CETP TaqIB predicts HDL cholesterol in one Chinese ethnic minority but not in neighboring Han Chinese (J Investig Med 2008)
- CETP genetic variants are linked to plasma vitamin E levels, extending CETP genetics beyond cholesterol transport (Br J Nutr 2009)
- Two CETP variants are among only seven SNPs confirmed to affect HDL cholesterol in a 384-SNP, 251-gene screen (J Lipid Res 2008)
- CETP variants shape cerebral and peripheral cholesterol metabolism but not Alzheimer's disease risk (Brain Res 2008)
- CETP gene is the only lipid-metabolism gene whose HDL-C association shifts with menopause in the ARIC Study (Atherosclerosis 2008)
- CETP B1B1 genotype is nearly twice as common in Taiwanese people with a parental history of cardiovascular disease (Med Princ Pract 2008)
- CETP activity is significantly elevated in Iranian patients with primary hypertriglyceridemia, and modulated by Taq1B genotype (Pak J Biol Sci 2007)
- CETP I405V fails to replicate as a longevity gene in a large American Caucasian cohort (Biogerontology 2007)
- CETP I405V I-allele carriers respond better to simvastatin, with greater triglyceride and HDL cholesterol improvement (Expert Opin Pharmacother 2007)
- The favorable CETP-VV genotype is found to buffer the deleterious effect of the lipoprotein(a) gene in exceptionally long-lived Ashkenazi Jews (PLoS Comput Biol 2007)
- CETP -629C>A genotype effect on HDL cholesterol is only partly explained by its impact on cholesteryl ester transfer activity (Scand J Clin Lab Invest 2008)
- CETP variants replicate their known HDL cholesterol association in renal transplant patients, but do not predict fluvastatin response (J Lipid Res 2007)
- CETP B1B1 genotype triples coronary artery disease risk in Taiwanese patients with type 2 diabetes (Metabolism 2007)
- CETP genotype shows no association with cognitive function or lifetime cognitive change in the Scottish Mental Survey cohort (Neurosci Lett 2007)
- CETP TaqIB B2 allele blunts the post-meal fat spike in patients with familial hypercholesterolemia (Clin Chem Lab Med 2007)
- CETP promoter -1337 CC genotype doubles coronary atherosclerosis risk in Japanese familial hypercholesterolaemia patients (Clin Sci 2006)
- Two novel CETP nonsense mutations produce complete deficiency without coronary disease in a Greek pedigree (J Mol Med 2006)
- CETP I405V homozygotes for the I allele have significantly less severe coronary artery narrowing (Clin Invest Med 2006)
- CETP I405V VV genotype is twice as common in people over 89 as in young adults, and linked to fewer vascular events (Arch Gerontol Geriatr 2006)
- CETP genotype fails to predict LDL cholesterol response to dietary fat, contradicting earlier studies (Nutr Metab Cardiovasc Dis 2005)
- Case report finds significant coronary stenosis in a woman with CETP deficiency and HDL-C of 209 mg/dL (Circ J 2005)
- CETP activity rises with the number of diseased coronary vessels in Tunisian type 2 diabetics (Clin Biochem 2005)
- Carotid imaging shows CETP loss-of-function carriers, unlike apoA-I or ABCA1 mutation carriers, have unaltered atherosclerosis progression (Curr Opin Lipidol 2005)
- Two independent cohorts find no genetic association between CETP polymorphisms and late-onset Alzheimer's disease (Neurosci Lett 2005)
- CETP B2B2 genotype is more common in diabetics but less common after a heart attack, suggesting a role in identifying diabetic risk (Atherosclerosis 2005)
- CETP I405V and healthy aging link does not replicate in Italian centenarians (Mech Ageing Dev 2005)
- A highly variable repeat in the CETP promoter forms unusual DNA structures and predicts HDL-C levels (Biochim Biophys Acta 2004)
- Daily exercise raises HDL cholesterol most in men with the CETP B1B1 genotype (Clin Genet 2004)
- Combined CETP and ApoA-I genotypes span a 0.54 mmol/L range in HDL-C among Japanese women (Nutr Metab Cardiovasc Dis 2004)
- Review examines conflicting evidence on CETP genetic variation and longevity in centenarians (J Atheroscler Thromb 2004)
- CETP activity rises 50% in one ABCA1-heterozygote kindred but not three others, alongside severe HDL abnormalities (Atherosclerosis 2003)
- CETP TaqI B polymorphism only modestly raises HDL cholesterol in Saudis, too small an effect to explain their low HDL levels (Clin Sci 2003)
- The largest study of its kind finds CETP gene variants are not useful markers for predicting restenosis after angioplasty (J Thromb Haemost 2003)
- Mice and rats lack functional CETP due to a shared ancestral nonsense mutation, not altered regulation (Comp Biochem Physiol B 2003)
- CETP deficiency raises HDL cholesterol in Japanese centenarians but does not affect longevity (J Mol Med (Berl) 2003)
- CETP Taq1B genotype only predicts HDL cholesterol in obese women with low fasting insulin (Atherosclerosis 2002)
- CETP I405V, not Taq1B, predicts smaller LDL particle size in Japanese patients (Atherosclerosis 2002)
- CETP levels are elevated in Chinese heart attack and stroke patients, while CETP-deficient carriers show a favorable lipid profile despite low CETP mass (Chin Med J 2002)
- CETP TaqI B2 allele raises HDL cholesterol more strongly in men than women in a rural Japanese population (J Epidemiol 2002)
- The first CETP TaqI genotyping in Egyptians finds a B1:B2 allele split of 0.65:0.35, matching the pattern shared by other Arab-descended populations (Eur J Clin Pharmacol 2002)
- CETP TaqIB B2B2 genotype protects against atherosclerosis only when it actually lowers CETP mass, angiography-based Japanese study finds (Atherosclerosis 2001)
- CETP TaqIB does not predict angiographically documented coronary artery disease risk, large case-control study finds (Clin Genet 2001)
- A dominant-negative CETP promoter mutation cuts transcriptional activity to 8% of wild type in Japanese hyperalphalipoproteinemia (ATVB 2001)
- CETP TaqIB genotype linked to macroangiopathy risk in Japanese patients with type 2 diabetes (Atherosclerosis 2001)
- CETP TaqIB genotype shows no link to diabetic kidney disease severity in a large type 1 diabetes cohort (Nephrol Dial Transplant 2000)
- A lower CETP B2 allele frequency in Valencia may help explain the unexpectedly high heart disease rate in the region (Atherosclerosis 2000)
- CETP mass and activity rise significantly after a meal, with the Taq 1B polymorphism predicting who has the lowest levels (Br J Nutr 2000)
- CETP TaqIB genotype explains major HDL cholesterol differences in renal transplant patients, but only in those without abdominal obesity (Nephron 2000)
- C/EBP-beta binds the CETP gene promoter in liver cells but does not actually drive CETP expression (Atherosclerosis 1999)
- CETP D442G mutation more than doubles vascular disease prevalence in dialysis patients, but only when HDL cholesterol is already low (Kidney Int Suppl 1999)
- A cholesterol response element in the CETP promoter explains why CETP rises, not falls, with cholesterol loading (J Lipid Res 1999)
- CETP mutation G1533A raises transfer activity and lowers HDL cholesterol, tested with a new simplified assay (Clin Chem Lab Med 1998)
- CETP B2 allele raises HDL cholesterol in diabetic men, but moderate alcohol intake shows no benefit unlike in non-diabetics (Scand J Clin Lab Invest 1998)
- A rare CETP intron 14 mutation, usually found only in Japanese, is identified in a Finnish family with high HDL cholesterol (Arterioscler Thromb Vasc Biol 1998)
- A new simple sandwich immunoassay for CETP mass correctly detects genetic CETP deficiency in human serum (Clin Chim Acta 1998)
- CETP Taq1B genotype predicts HDL cholesterol in diabetic patients independent of measured CETP concentration (J Lipid Res 1998)
- A CETP mutation previously reported only once is surprisingly common in North Americans with high HDL cholesterol (Clin Biochem 1997)
- A novel intron 10 splice mutation causes exon 10 skipping and disrupts downstream splicing in CETP deficiency (J Lipid Res 1996)
- A newly found CETP 3-prime-UTR variant lowers CETP activity by nearly 30 percent, replicated in two independent samples (Atherosclerosis 1996)
- CETP deficiency enlarges apoA-I lipoprotein particles and impairs their cholesterol-handling function (J Lipid Res 1995)
- CETP transgenic mice develop more severe, faster-progressing fatty liver than controls, worse in males (Biochem Biophys Res Commun 1994)
- Enlarged HDL2 from CETP-deficient patients fails to protect macrophages from cholesterol accumulation (J Biochem 1994)
- Intron 14 CETP splicing defect is found in 3.5% of Japanese patients with marked hyperalphalipoproteinemia and an estimated 1/42,000 homozygote frequency (Atherosclerosis 1993)
- A rapid NdeI-based PCR screen finds the intron 14 CETP splicing defect in 21 of 121 Japanese patients with hyperalphalipoproteinemia (Hum Genet 1993)
- CETP and apoA-I gene polymorphisms show no association with coronary heart disease in a Sri Lankan population, though the CETP B1 allele tracks with lower HDL cholesterol (Atherosclerosis 1990)
- Taiwan Biobank GWAS of 40,773 people finds a three-way APOA5-LPL-CETP gene interaction behind metabolic syndrome susceptibility (Genome Biol 2026)
- Splice-site CETP mutations are found in 10% of a South Indian familial hypercholesterolemia cohort (Cureus 2025)
- Machine learning flags CETP as an immune biomarker for diabetes-tuberculosis comorbidity, AUC 0.804 (Microorganisms 2025)
- Mendelian randomisation study finds no genetic link between CETP-mediated LDL-C and pulmonary vascular disease, unlike NPC1L1 and PCSK9 (Pulm Circ 2025)
- Mendelian randomisation study centred on HMGCR also finds CETP-mediated LDL-C consistently associated with lower aortic aneurysm risk (Nutr Metab 2024)
- CETP TaqIB genotype shows no association with the effect of dulaglutide on HbA1c or hepatic steatosis, unlike PNPLA3 (Endocrine 2024)
- CETP variant rs5817082 is individually linked to extramacular drusen independent of overall AMD genetic risk (Invest Ophthalmol Vis Sci 2024)
- The CETP rs708272 AA genotype is linked to higher HDL cholesterol in an Iranian coronary artery disease cohort (J Clin Lab Anal 2024)
- CETP variant rs708272 emerges as a candidate screening marker for type 2 diabetes risk in Filipinos, genomic study finds (PLoS One 2024)
- First Mendelian randomisation of lipid drug targets and diabetic retinopathy finds a PCSK9 signal but no CETP association (J Lipids 2024)
- A CETP variant predicts who loses the most weight with a digital lifestyle-modification program (Sci Rep 2023)
- Dietary antioxidant intake does not interact with the CETP Taq1B polymorphism to affect lipid profile or coronary stenosis severity (Food Sci Nutr 2024)
- Whole-genome sequencing of unexplained severe familial hypercholesterolaemia turns up a novel CETP deletion variant (Vavilovskii Zhurnal Genet Selektsii 2023)
- Targeted sequencing finds low-HDL-linked variants in CETP and three other genes in one in six people with metabolic syndrome (Diabetol Metab Syndr 2022)
- Systematic review names CETP-TaqIB as one of the most consistently studied gene-diet interactions in cardiovascular disease research (BMC Cardiovasc Disord 2022)
- Iranian case-control study finds no direct link between CETP polymorphism rs708272 and coronary artery disease, but flags a CETP-activity/HDL-C interaction (BMC Cardiovasc Disord 2022)
- CETP genetic variants predict baseline LDL cholesterol but not atorvastatin response in Jordanian patients (Drug Metab Pers Ther 2022)
- CETP variant rs1532624 is among the five most prevalent clinically relevant pharmacogenomic markers found in Pakistani ethnic groups (Evol Bioinform Online 2022)
- Atorvastatin exposure is about twice as high in healthy Korean volunteers as in Caucasians, partly explained by eight variants including one in CETP (Front Genet 2022)
- An ABCG1 gene variant is linked to higher CETP activity in a Brazilian population study (Biochem Genet 2022)
- GWAS of 49,915 Koreans finds CETP among the lipid genes shared by metabolically unhealthy normal-weight and obese phenotypes (Sci Rep 2021)
- eMERGE Network study fails to replicate the CETP-triglyceride association found in prior smaller studies (BMC Med Genomics 2021)
- Review names the CETP TaqIB polymorphism as one of three gene variants that heighten cardiovascular risk in heavy drinkers (Curr Neurovasc Res 2021)
- Gut metabolite TMAO shows no link to genetically determined CETP levels in coronary artery disease patients (Sci Rep 2020)
- In a north Indian CAD study, CETP rs708272 alone was not significant, but showed a synergistic interaction with physical inactivity (BMC Cardiovasc Disord 2020)
- CETP variant rs708272 ranks among the top ten SNPs in a 24-gene model predicting childhood and adolescent obesity, alongside diet and gut microbiota (Sci Rep 2020)
- Genetically determined CETP concentration shows only a weak link to clotting factor VII and no link to venous thrombosis risk (J Thromb Haemost 2019)
- CETP rs5883 polymorphism does not distinguish coronary artery disease patients from controls in a Turkish cohort (In Vivo 2019)
- CETP TaqIB variant is linked to diabetic retinopathy incidence over nine years, though HbA1c and triglycerides prove the stronger predictors (Diabetes Res Clin Pract 2017)
- CETP TaqIB genotype shapes how herbal tea affects HDL cholesterol and triglycerides in hypercholesterolemic patients (Asia Pac J Clin Nutr 2017)
- CETP gene variants are associated with neuropsychiatric symptom severity in Alzheimer's disease (Braz J Psychiatry 2017)
- CETP gene variants linked to memory loss risk in a rural and tribal Indian cohort study (J Alzheimers Dis 2017)
- CETP variant rs820299 nominally associates with metabolic syndrome and interacts with lifestyle factors in a Taiwanese replication study (Sci Rep 2016)
- Whole-body model finds high-activity CETP genotypes raise LDL-C more with ageing than low-activity genotypes (Biosystems 2016)
- A genome-wide meta-analysis in Hispanic populations confirms CETP as a genome-wide-significant locus for HDL cholesterol (Sci Rep 2016)
- CETP I405V variant shows no association with premature coronary artery disease presence or severity in Iranian patients (Bosn J Basic Med Sci 2016)
- Review highlights zebrafish, which retain a cetp ortholog, as an emerging model for dyslipidaemia research (Front Endocrinol (Lausanne) 2016)
- CETP variant rs5882 shows no association with LDL cholesterol lowering from plant sterols, unlike CYP7A1 and APOE variants (Am J Clin Nutr 2015)
- CETP G allele carriers show distinct waist circumference and metabolic profiles, independent of glucose and lipid changes (Diabetes Res Clin Pract 2014)
- Two CETP variants are among only eight significant HDL predictors identified across 65 SNPs and 23 candidate genes (Lipids Health Dis 2013)
- A CETP variant is among four SNPs significantly linked to plasma cholesterol, though only APOB and NPC1L1 show novel diet-gene interactions (J Lipid Res 2013)
- CETP genotype frequencies do not differ between centenarians, nonagenarians, and average-lifespan controls (Angiology 2013)
- CETP variant rs17231506 is one of five genes shaping sex-specific cholesterol efflux capacity independent of HDL-C (Arterioscler Thromb Vasc Biol 2013)
- Baseline CETP activity nearly doubles in carriers of the eNOS T-786C polymorphism, atorvastatin crossover study finds (Arq Bras Cardiol 2013)
- CETP TaqIB genotype raises HDL cholesterol but does not predict Alzheimer's disease risk in a Han Chinese cohort (Lipids Health Dis 2012)
- CETP I405V and Taq1B polymorphisms show inconsistent links to subclinical carotid atherosclerosis in Brazilians (Lipids Health Dis 2012)
- CETP variant rs5882 is one of only four significant SNP predictors of plasma homocysteine among 64 tested in healthy adults (J Nutr 2012)
- Annual exercise-genomics review highlights physical activity modifying how CETP and two other genes affect HDL cholesterol (Med Sci Sports Exerc 2012)
- NMR fine-mapping finds CETP among only four loci linked to bulk serum lipids, versus eight linked to lipoprotein subfractions (Hum Mol Genet 2012)
- CETP Taq1B polymorphism shows no effect on HDL cholesterol or coronary artery disease risk in a Turkish angiography cohort (Genet Test Mol Biomarkers 2010)
- Review links apoB signal-peptide and CETP B1B1 combination to lower VLDL apoB secretion in obese men (Curr Opin Lipidol 2010)
- CETP TaqIB polymorphism does not predict coronary restenosis after angioplasty and stenting (Angiology 2010)
- CETP -629C>A polymorphism is not among the genetic determinants of coronary artery disease in Turks despite its HDL cholesterol effect (Cell Biochem Funct 2009)
- CETP TaqIB and I405V polymorphisms show sex-specific effects on postprandial triglycerides in familial hypercholesterolaemia (Lipids Health Dis 2009)
- CETP TaqIB variant, unlike APOE4, shows no link to obesity or blood pressure in North Indian subjects (Mol Cell Biochem 2008)
- The CETP D442G variant shows a preliminary protective association against Alzheimer's disease in Chinese APOE4 carriers (Brain Res 2008)
- Review concludes the link between CETP and atherosclerosis risk depends on gene-environment interaction, unlike the direct effects of APOA1 and ABCA1 (Curr Opin Lipidol 2007)
- Unlike hepatic lipase and LPL variants, the CETP-HDL cholesterol link is not modified by dietary fat intake in a large biracial cohort (Atherosclerosis 2007)
- Mapping the CETP gene reveals seven distinct linkage blocks and yields an optimal set of eleven tagging SNPs for future association studies (Ann Hum Genet 2006)
- Combining three CETP polymorphisms predicts lipid profile better than any single variant in South Indians (Clin Chim Acta 2007)
- CETP TaqIB genotype link to HDL-C is stronger in alcohol drinkers than non-drinkers (Atherosclerosis 2007)
- Review states the once-promising CETP Taq-I to statin-response link has now been disproved (Vascul Pharmacol 2006)
- CETP TaqIB genotype shows no link to plaque composition or neointima after carotid endarterectomy, unlike hepatic lipase variant (Atherosclerosis 2005)
- Large pharmacogenetic screen finds CETP-HDL response to pravastatin too weak to qualify, unlike the dominant HMG-CoA reductase signal (JAMA 2004)
- CETP Taq1B B2B2 genotype linked to low HDL cholesterol in Turkish type 2 diabetic patients (Int J Mol Med 2004)
- CETP TaqI B genotype shows no association with late-onset Alzheimer's disease or interaction with APOE4 or lipoprotein lipase (Neurosci Lett 2004)
- CETP TaqIB genotype shows no link to preeclampsia or pregnancy lipid profile, unlike apoE (Eur J Obstet Gynecol Reprod Biol 2004)
- The effect of CETP genotype on HDL cholesterol is unaffected by physical activity level in a population-based Swiss cohort (Med Sci Sports Exerc 2003)
- New statistical method for analyzing gene haplotypes is validated using CETP variants and HDL cholesterol data from the REGRESS trial (Ann Hum Genet 2003)
- A newly mapped major gene, not CETP or five other known HDL genes, controls large HDL particle levels in baboons (Atherosclerosis 2002)
- Genetic CETP deficiency nearly doubles plasma PLTP concentration by accumulating its inactive form (J Lipid Res 2002)
- CETP genotype, like four other candidate genes, fails to predict cholesterol response to plant stanol esters (Eur J Clin Invest 2002)
- Novel splice-site mutation in the CETP gene found in a patient with hyperalphalipoproteinemia (Metabolism 2002)
- CETP promoter and intron 1 SNPs form haplotypes linked to HDL and LDL cholesterol, with sex-dependent strength (Hum Hered 2002)
- CETP D442G and TaqIB variants track with higher HDL cholesterol in Taiwanese Chinese, but the link weakens with obesity (Hum Genet 2001)
- Heterozygous CETP D442G carrier shows apolipoprotein E trapped in HDL at triple the level of other carriers (Clin Chim Acta 2000)
- CETP I405V genotype, unlike apoB EcoRI variation, does not predict cholesterol response to diet in an Israeli cohort (Atherosclerosis 2000)
- A retinoic acid receptor element is identified in the human CETP gene promoter (Biochem Biophys Res Commun 1999)
- Probucol regresses established aortic plaques in hyperlipidemic rabbits and significantly raises CETP activity, likely via antioxidant action (Atherosclerosis 1998)
- ApoA-IV 360His variant, not CETP or LCAT activity, explains why some people respond more to dietary fat changes (J Lipid Res 1997)
- CETP gene screening finds no significant link to abdominal aortic aneurysm, ruling it out as a candidate gene (Clin Genet 1997)
- CETP D442G mutation is found in two families with Lowe syndrome and elevated HDL cholesterol (Acta Paediatr 1997)
- The ApoA-IHelsinki mutation lowers HDL cholesterol and cuts CETP activity by 25% in a Finnish kindred (ATVB 1995)
- A silver-stained PCR-SSCP assay rapidly detects the intron 14 CETP-deficiency mutation without radioactivity (Clin Chem 1994)
- A family study traces complete CETP deficiency to an intron 14 splicing defect found on a routine health check (Intern Med 1994)
- CETP TaqI RFLP frequencies are remarkably uniform across Italian, Greek, and other Caucasian populations (Hum Hered 1994)
- Rabbit liver's nonparenchymal cells express more CETP mRNA than the parenchymal cells that dominate most other lipid genes (J Lipid Res 1993)
- A PCR-based site-directed mutagenesis method detects one CETP-deficiency homozygote and three heterozygotes among 554 Japanese subjects (Biochim Biophys Acta 1993)
- CETP Taq1B polymorphism shows no association with cardiovascular risk factors or angiographic severity in Iranian angiography patients (Iran J Med Sci 2024)
- A systematic review finds no clear link between CETP genetic variation and intestinal cholesterol absorption (Prog Lipid Res 2022)
- CETP genotype does not modify how DHA supplementation lowers triglycerides, randomized feeding trial finds (Lipids 2018)
- CETP TaqIB polymorphism shows no link to metabolic syndrome in Southern Thai subjects (Biochem Genet 2015)
- Review names CETP as one of only two candidate genes for lipid response to exercise training, despite roughly 100 inconsistent studies (J Appl Physiol 2011)
- CETP TaqIB and LPL Ser447Ter polymorphisms show no association with ischaemic stroke in Greek patients (Neurosci Lett 2005)
- Novel LCAT mutation in a Polish family leaves CETP activity at the low end of normal (Atherosclerosis 2006)
- Lymphocyte gene expression profiling finds CETP expression unaltered in Alzheimer's disease patients (Psychiatr Genet 2005)
- A hidden CETP gene variant caused false positives in fluorescence-based TaqIB genotyping (Clin Chem 2001)
- CETP TaqIB polymorphism proves noninformative for apo B levels linked to parental heart-attack history (Atherosclerosis 2001)
- A young man with familial hypercholesterolaemia is found to also carry heterozygous CETP deficiency (Intern Med 1998)
- An apoA-I promoter variant does not affect HDL cholesterol regardless of CETP deficiency status in Japanese subjects (Hum Genet 1995)
LDL and apoB 70
Why the class is now developed on an LDL-lowering claim.
- CETP activity correlates with LDL-cholesterol but not HDL-cholesterol in 586 healthy Japanese adults (Atherosclerosis 1996)
- Plasma CETP rises up to 85 percent in dysbetalipoproteinemia and severe chylomicronemia, correcting with dietary treatment (Arterioscler Thromb 1991)
- CETP activity, but not mass, is independently linked to coronary disease in patients with high HDL cholesterol (Anatol J Cardiol 2026)
- CETP expression abolishes the atheroprotective effect of large HDL particles in mouse models of type 1 diabetes (Circ Res 2024)
- Baseline CETP level predicts how much pitavastatin lowers LDL-C, via LXR-dependent suppression of CETP transcription (Lipids Health Dis 2016)
- CETP activity is 30 percent higher in South Asians than Europeans and tracks the full pattern of atherogenic dyslipidemia (Eur J Prev Cardiol 2014)
- Inhibiting secretory phospholipase A2 raises CETP activity via VLDL-apoE content, offsetting its antiatherosclerotic benefit in triple-transgenic mice (Arterioscler Thromb Vasc Biol 2013)
- CETP protects against the rise in VLDL caused by reconstituted HDL infusion, resolving a mouse-versus-human discrepancy (J Lipid Res 2011)
- CETP activity is higher in obese adolescent boys and correlates with more TV watching and higher milk intake (Arch Med Res 2011)
- Berry anthocyanins raise HDL and lower LDL cholesterol via natural CETP inhibition in a placebo-controlled trial (Am J Clin Nutr 2009)
- CETP drives atherosclerosis mainly by raising VLDL-cholesterol, not by lowering HDL-cholesterol, in APOE*3-Leiden mice (Atherosclerosis 2009)
- CETP activity rises 46% in nephrotic-range proteinuria, contributing to its atherogenic lipoprotein profile (Atherosclerosis 2001)
58 more in LDL and apoB
- Atorvastatin preferentially reduces CETP-mediated cholesteryl ester transfer from HDL to the largest VLDL subfraction (Arterioscler Thromb Vasc Biol 2000)
- VLDL-bound lipoprotein lipase boosts CETP-mediated cholesteryl ester transfer partly independent of its lipolytic action (J Lipid Res 1999)
- Simvastatin lowers CETP mass and activity by 16 percent in type IIb hyperlipidemia without changing CETP specific activity (Atherosclerosis 1999)
- CETP, unlike PLTP, rises with hyperlipidemia but stays flat in diabetes, a new ELISA study shows (Arterioscler Thromb Vasc Biol 1999)
- Simvastatin, unlike cholestyramine, lowers plasma CETP by 15 percent in primary hypercholesterolemia (Can J Clin Pharmacol 1999)
- Combined LCAT and CETP action in vitro converts VLDL and LDL into the small, dense particles seen in hypertriglyceridemia (Atherosclerosis 1998)
- CETP and PLTP activity, not diabetes itself, drive elevated cholesteryl ester transfer in NIDDM (Atherosclerosis 1998)
- Two hyperalphalipoproteinemia profiles show elevated, not deficient, CETP activity, with differing atherosclerosis risk (Atherosclerosis 1998)
- CETP preferentially enriches VLDL1 with cholesteryl ester during postprandial lipemia, marking it as atherogenic (Arterioscler Thromb Vasc Biol 1998)
- Growth hormone excess raises CETP activity and shifts LDL toward the small dense subfraction in acromegaly (Atherosclerosis 1997)
- Combined hyperlipidaemia blocks net CETP-mediated cholesteryl ester transfer from HDL to LDL despite elevated CETP mass (Eur J Clin Invest 1996)
- Pravastatin cuts CETP-mediated cholesteryl ester transfer to LDL by 24 percent in familial hypercholesterolemia without changing CETP mass (Arterioscler Thromb Vasc Biol 1995)
- A high trans fatty acid diet raises serum CETP activity compared with linoleic or stearic acid diets (Atherosclerosis 1995)
- Simvastatin cuts CETP activity 30 percent in type II hyperlipoproteinemia, but the change is unrelated to lipoprotein subfraction shifts (Atherosclerosis 1995)
- CETP activity is 42 percent higher in hypercholesterolemia and correlates strongly with LDL cholesterol (Arterioscler Thromb Vasc Biol 1995)
- Trans-elaidic acid raises CETP activity more than cis-oleic acid, correlating with falling HDL cholesterol (Atherosclerosis 1994)
- Review examines how CETP and peripheral lipoproteins may contribute to vascular cognitive impairment and dementia (Mol Neurodegener 2023)
- CETP activity is highest in cord and maternal blood of growth-restricted neonates, alongside multiple proatherogenic lipoprotein changes (J Clin Lipidol 2017)
- Urban versus rural residence predicts opposite CETP and PLTP activity patterns in Polish men, independent of smoking and alcohol use (Arch Med Sci 2016)
- A high-dose tetanus toxoid-CETP vaccine lowers CETP activity and raises HDL-C in rabbits but fails to reduce atherosclerotic lesions (Biomed Pharmacother 2016)
- Extended-release niacin/laropiprant abolishes the postprandial rise in CETP activity and boosts HDL's fecal cholesterol removal capacity (Arterioscler Thromb Vasc Biol 2015)
- PPAR-delta agonist GW501516 lowers CETP activity alongside broad apoB and apoC-III kinetic changes in obese dyslipidemic men (J Clin Endocrinol Metab 2011)
- High CETP is an independent negative determinant of LDL size and tracks with CAD prevalence in haemodialysis patients (Nephrology (Carlton) 2011)
- CETP concentration is higher in coronary heart disease patients but is not itself an independent predictor of LDL particle size (Bosn J Basic Med Sci 2011)
- Brucella infection raises CETP activity and leaves an unresolved atherogenic lipid profile four months after treatment (J Lipid Res 2009)
- Reducing proteinuria lowers LDL cholesterol together with plasma CETP mass, but also lowers HDL cholesterol (Expert Opin Ther Targets 2009)
- Only triglyceride-rich apoB lipoprotein subclasses accept cholesteryl esters transferred by CETP (Eur J Clin Invest 2008)
- Elevated CETP levels track with oxidized LDL in dyslipidemic patients (Clin Biochem 2007)
- Prebeta1-HDL concentration tracks LDL-cholesterol independent of CETP mass (Clin Chim Acta 2000)
- Improving glycemic control lowers postprandial CETP activity and chylomicron particle numbers in type 2 diabetes (Atherosclerosis 2000)
- LDL acts as a secondary cholesteryl ester donor to chylomicrons via CETP during postprandial lipemia (Atherosclerosis 1999)
- A 24-hour intravenous fat load leaves CETP activity unchanged acutely but raises it a week later (J Lipid Res 1999)
- CETP accounts for 5% of small dense LDL variability in Chinese diabetic patients despite unchanged CETP activity (Atherosclerosis 1999)
- Estrogen raises LDL cholesterol and atherosclerotic lesions in apoB100xCETP transgenic mice without altering CETP activity (Arterioscler Thromb Vasc Biol 1999)
- Etophylline clofibrate lowers CETP mass while improving lipoprotein profile in mixed hyperlipidemia (Atherosclerosis 1995)
- Fasting CETP levels rise only on the highest dietary cholesterol dose and track LDL cholesterol changes in young men (Arterioscler Thromb 1994)
- Pravastatin lowers LDL and raises apoA-I but leaves CETP levels and abnormal HDL subpopulation composition unchanged (Atherosclerosis 1993)
- CETP-driven lipid transfer from HDL enlarges LDL particles, a candidate mechanism for LDL subfraction polymorphism (J Lipid Res 1990)
- Reduced CETP activity accompanies an atherogenic small dense LDL profile in long-standing type 1 diabetes (Front Endocrinol 2026)
- The EUROASPIRE IV survey finds lower CETP activity in coronary patients with elevated triglycerides and residual apoB-driven risk (Clin Chim Acta 2026)
- Kinetic tracer studies reveal CETP inhibition raises apoA-I and lowers apoB by shifting catabolism rates of HDL and LDL in opposite directions (Curr Opin Lipidol 2016)
- Niacin/laropiprant lowers CETP activity alongside multiple inflammatory markers but modestly improves HDL efflux without changing HDL antioxidant capacity (J Am Heart Assoc 2015)
- Meta-analysis finds LDL-C and non-HDL-C, not HDL-C, predict lesion reduction across CETP-expressing animal and human trials (Eur J Pharmacol 2015)
- Flaxseed oil lowers small dense LDL alongside CETP and apoB concentrations after twelve weeks in Japanese men (Nutr J 2015)
- Six weeks of endurance training lowers CETP activity regardless of egg intake in unfit adults (J Nutr Biochem 2008)
- Normal CETP activity in hypertriglyceridemic patients rules out CETP as the cause of reduced LDL receptor binding affinity (Atherosclerosis 1999)
- High-viscosity pectin lowers plasma CETP activity along with cholesterol in hamsters (J Nutr 1998)
- CETP activity stays normal and unchanged with insulin lispro or regular insulin in type 1 diabetes (Metabolism 1998)
- CETP activity, not LDL receptor pathways, may explain why LDL cholesterol rises with dietary fat in some people (Curr Opin Lipidol 1997)
- Gemfibrozil enlarges LDL particles and trends toward lowering CETP activity without changing LDL receptor binding (Atherosclerosis 1995)
- CETP and LCAT activity rise postprandially in NIDDM, but neither differs from controls at baseline (Atherosclerosis 1995)
- CETP activity shows no relation to LDL subfraction composition, unlike lipoprotein and hepatic lipase (Atherosclerosis 1993)
- Liver-humanized mice show a human-like cholesterol lipoprotein profile without needing CETP (Hepatology 2020)
- Cryo-electron tomography reveals a polyhedral, not spherical, 3D structure for VLDL particles (J Lipid Res 2016)
- Pioglitazone does not change CETP or improve peripheral vessel function in nondiabetic patients over nine months (Cardiology 2015)
- Low CETP activity and enhanced HDL2 paraoxonase found together in a patient with unusually low LDL-to-cholesterol ratio (Int J Mol Med 2010)
- Thyromimetic T-0681 cuts atherosclerosis 80% in rabbits by raising hepatic LDL receptors, not by changing CETP (J Lipid Res 2008)
- Bile acid sequestrant cholebine shrinks large light LDL without touching CETP or LCAT activity (Atherosclerosis 1997)
HDL biology 513
Reverse cholesterol transport, efflux and the hypothesis that started it.
- The original discovery that hamster CETP uniquely drives one-way lipid flow from VLDL to HDL reveals CETP orthologs are not functionally equivalent across species (J Lipid Res 2014)
- CETP expression multiplies atherosclerotic lesion area 7-fold in the new E3L.CETP mouse model (Arterioscler Thromb Vasc Biol 2006)
- HDL from CETP-deficient people shows 2- to 3-fold greater cholesterol efflux from macrophages via an ABCG1-dependent pathway enriched in LCAT and apoE (J Clin Invest 2006)
- The Hugh Sinclair Lecture synthesizes how ABCA1, LCAT, CETP, hepatic lipase, and PLTP together remodel HDL, naming CETP inhibition as a resulting therapeutic strategy (Atheroscler Suppl 2002)
- CETP and Cyp7a share an LXR-controlled sterol response, coordinating hepatic cholesterol ester catabolism with bile acid synthesis (J Clin Invest 2000)
- CETP expression cuts aortic lesion area 41% and restores HDL cholesteryl ester clearance in LCAT-transgenic mice with dysfunctional HDL (J Biol Chem 1999)
- LTIP, not CETP itself, explains why cholesteryl ester transfer favors HDL over LDL, overturning a long-held assumption (Arterioscler Thromb Vasc Biol 1999)
- An antibody blocking CETP-mediated lipid transfer sharply cuts HDL cholesteryl ester uptake by human adipocytes, revealing a direct CETP-dependent route into fat cells (J Biol Chem 1997)
- CETP incubation shrinks reconstituted HDL from 9.4 to 7.8 nm while raising particle count 50%, the first direct evidence of CETP-driven particle fusion (J Biol Chem 1997)
- Purified recombinant CETP acts as a lipid carrier with Km of 700 nM for LDL and 2000 nM for HDL, establishing its core kinetic mechanism (Biochem J 1996)
- Exon-9-deleted CETP mRNA yields an inactive protein, while hypercholesterolemia and development favor full-length transcript accumulation (J Biol Chem 1996)
- In mice, whether CETP protects against or promotes atherosclerosis depends entirely on triglyceride status, protective only when hypertriglyceridemic (J Clin Invest 1995)
501 more in HDL biology
- Two independent inhibitors reveal separate CETP binding sites for cholesteryl ester and triglyceride transfer, uncoupled in vivo (J Biol Chem 1995)
- K233 and R259 are essential CETP residues for lipoprotein binding, conserved across the CETP/PLTP/LPS-binding-protein gene family (Biochemistry 1995)
- CETP binds preferentially to the edge of nascent discoidal HDL particles, with affinity boosted 3- to 10-fold by cholesteryl ester or cholesterol content (J Biol Chem 1995)
- A comprehensive Annual Review of Biochemistry synthesis by Alan Tall concludes CETP is dominantly antiatherogenic in vivo despite lowering HDL cholesterol (Annu Rev Biochem 1995)
- CETP enriches HDL with triglyceride, accelerating lipolysis-driven apoA-I shedding and shortening apoA-I half-life, explaining low HDL in CETP mice (J Biol Chem 1994)
- CETP shrinks HDL from 10.3 to 7.6 nm and increases apoA-I catabolic rate 35% in hypertriglyceridemic transgenic mice, revealing the kinetic basis of low HDL (J Clin Invest 1993)
- CETP crossed with human apoA-I transgenic mice deepens HDL cholesterol loss to 66%, revealing an enhanced human-CETP/human-apoA-I interaction (J Clin Invest 1992)
- A 50% rise in CETP activity after probucol tracks plasma drug levels and inversely predicts the fall in HDL cholesterol (Eur J Clin Invest 1991)
- Linker-insertion mutagenesis maps three CETP regions essential for lipid transfer, at residues 48-53, 165, and 373-379 (Biochemistry 1991)
- An anti-CETP antibody fully blocks CETP-driven HDL3 size conversion, proving CETP drives structural remodeling beyond lipid transfer (J Lipid Res 1990)
- A neutralizing anti-CETP antibody eliminates all neutral lipid mass transfer in human plasma, while HDL serves as the main early LCAT substrate (J Clin Invest 1989)
- CETP boosts HDL cholesteryl ester uptake into HepG2 liver cells 2.8-fold, the original demonstration of CETP-facilitated selective cellular cholesterol delivery (J Biol Chem 1987)
- Human but not rat lipoprotein-deficient serum drives cholesteryl ester efflux from cultured arterial smooth muscle cells, implicating CETP in interstitial cholesterol removal (Biochim Biophys Acta 1985)
- Without CETP, LCAT activity stalls once cholesteryl ester reaches a 0.03 ester-to-lecithin ratio; CETP clears the product to sphingomyelin liposomes to keep LCAT running (Biochemistry 1980)
- The Morton lab introduces substrate-preference modification as a new paradigm for engineering CETP-targeting drugs (J Lipid Res 2015)
- A landmark review proposes the first comprehensive step-by-step molecular model of CETP action: sensing, penetration, docking, ternary complex, transfer, dissociation (J Lipid Res 2012)
- Molecular dynamics simulations reveal helix X of CETP as a lid gating lipid exchange with HDL (PLoS Comput Biol 2012)
- CETP expression preserves endothelial function in female mice via enhanced estrogen receptor-alpha and eNOS signaling, unlike its harmful effect in males (Am J Physiol Heart Circ Physiol 2023)
- HDL-cholesterol predicts carotid atherosclerosis only when CETP concentration is low, in the IMPROVE study (Biomedicines 2021)
- Swapping hamster CETP for human CETP cuts HDL by 60% and boosts hepatic cholesterol 1.8-fold in a human-like hamster model (J Lipid Res 2021)
- Elevated CETP activity during acute STEMI independently predicts endothelial dysfunction and 12.8-fold higher 30-day mortality risk (Atherosclerosis 2014)
- CETP discovered to protect mice against lethal bacterial endotoxin by dampening the inflammatory response (Shock 2008)
- Niacin raises HDL cholesterol by suppressing hepatic CETP expression, not by any CETP-independent route (Arterioscler Thromb Vasc Biol 2008)
- CETP expression boosts macrophage reverse cholesterol transport in mice via the LDL receptor pathway (Circulation 2007)
- Fenofibrate raises HDL cholesterol by up to 91% only in the presence of CETP, via a 72% reduction in hepatic CETP expression, in transgenic mice (J Lipid Res 2007)
- The EPIC-Norfolk study finds elevated CETP predicts higher future coronary artery disease risk, but only in people with high triglycerides (Circulation 2004)
- High baseline CETP predicts worse atherosclerosis progression on statins in familial hypercholesterolemia (Atherosclerosis 2004)
- Plasma CETP concentration, not TaqIB genotype, predicts atherosclerosis progression and pravastatin benefit in REGRESS (Eur J Clin Invest 2004)
- CETP transgene expression reverses the cholesterol-raising effect of LXR agonists and instead lowers hepatic cholesterol while boosting biliary excretion in mice (J Lipid Res 2004)
- ApoC-I identified as the natural CETP inhibitor carried on HDL (J Biol Chem 2000)
- Combining a CETP transgene with PLTP deficiency additively lowers HDL cholesteryl ester and apoA-I in mice, showing no functional redundancy (J Biol Chem 2000)
- CETP remodeling of HDL boosts SR-BI-mediated cholesteryl ester uptake 2- to 4-fold, synergizing with hepatic lipase in reverse cholesterol transport (J Lipid Res 1999)
- Vitamin E blocks the CETP-lowering effect of pravastatin and raises CETP concentration on its own (Coron Artery Dis 1998)
- Oleate suppresses LTIP activity over 80%, unleashing maximal CETP-mediated lipid transfer between all lipoproteins including LDL (Arterioscler Thromb Vasc Biol 1997)
- ARP-1 acts as both repressor and activator of the CETP gene promoter depending on flanking sequence context, via a defined 105-bp regulatory element (J Biol Chem 1995)
- Deleting six carboxyl-terminal residues of CETP abolishes cholesteryl ester and triglyceride binding without affecting HDL association (J Biol Chem 1995)
- CETP is locally synthesized and secreted within the human brain, not just imported from plasma (Int J Clin Lab Res 1992)
- CETP has dedicated binding sites for cholesteryl ester, triglyceride, and phospholipid that let it ferry lipids between particles (J Biol Chem 1988)
- Lipolysis products bind CETP directly to VLDL remnants and HDL, driving faster cholesteryl ester transfer (J Biol Chem 1985)
- Lipoprotein lipase and CETP together boost cholesteryl ester transfer 2 to 8 fold beyond CETP alone (J Biol Chem 1984)
- A mathematical model extends CETP-mediated triglyceride flux estimation to chylomicrons in postprandial lipemia (J Lipid Res 2025)
- CETP expression in macrophages curbs mitochondrial oxidant production and dampens pro-inflammatory, cholesterol-laden phenotypes (Antioxidants 2022)
- Abdominal aortic aneurysm patients show 49% higher CETP activity and altered HDL cholesterol efflux compared with atherosclerosis controls (Front Immunol 2022)
- Hibernating brown bears raise CETP activity by 36% to stabilize HDL lipid composition and avoid atherogenic dyslipidemia (Sci Rep 2021)
- Advanced mass spectrometry reveals that CETP is secreted in medium-large HDL and stays there, unlike LCAT which appears on HDL only after a delay (JCI Insight 2021)
- A human CETP minigene improves insulin sensitivity and reduces fatty liver in female but not male mice on a high-fat diet (Front Physiol 2021)
- Swapping hamster CETP for human CETP in chow-fed hamsters humanizes their lipoprotein profile, cutting HDL up to 50% (J Lipid Res 2020)
- Elevated CETP activity in early pregnancy predicts prediabetes five years later, tracking with monocyte activation (J Clin Endocrinol Metab 2020)
- ApoF knockdown boosts CETP-mediated cholesterol ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters (J Lipid Res 2019)
- CETP-deficient patients show markedly more large HDL particles but fewer small, more anti-atherogenic HDL particles, alongside more atherogenic very small LDL (PLoS One 2018)
- Weight loss plus exercise normalizes the HDL lipidome, lowers CETP activity, and boosts cholesterol efflux capacity in metabolic syndrome (Arterioscler Thromb Vasc Biol 2018)
- Glucocorticoids downregulate CETP gene expression in macrophages, and doubling hydrocortisone dose lowers CETP activity and raises HDL size in patients (Eur J Clin Invest 2017)
- Arsenic trioxide independently raises CETP protein levels in liver cells while suppressing LXR-beta and cholesterol efflux (Chem Biol Interact 2016)
- Topoisomerase II inhibitors etoposide and teniposide activate hepatic CETP expression via LXR and boost reverse cholesterol transport in CETP transgenic mice (J Biol Chem 2015)
- Bone marrow-derived hepatic lipase mitigates the HDL-lowering effect of bone marrow-derived CETP in double-knockout mice (J Lipid Res 2014)
- Fibrates and fish oil, but not corn oil, activate PPAR-alpha to raise hepatic CETP expression and plasma activity in transgenic mice (J Nutr Biochem 2014)
- Bile-acid-activated farnesoid X receptor identified as a novel driver of CETP expression, explaining low HDL-C in cholestasis (J Lipid Res 2013)
- HIV/HAART patients show a blunted triglyceride-HDL cholesterol relationship driven by higher CETP mass but lower CETP-specific activity, not altered total CETP activity (Metabolism 2013)
- In the Framingham Heart Study, low CETP or high PLTP activity predicts more than double the cardiovascular risk in men but not women (Atherosclerosis 2013)
- Plasma cholesteryl ester transfer activity, not CETP mass, predicts incident cardiovascular disease in a nested case-control study (Atherosclerosis 2011)
- CETP restores HDL cholesterol in SR-BI-deficient mice but fails to prevent atherosclerosis (Arterioscler Thromb Vasc Biol 2010)
- LXRalpha, not LXRbeta, drives human CETP transcription, confirmed in monkeys, human-CETP-transgenic mice, and HepG2 cells (Atherosclerosis 2010)
- Falling CETP levels during hospitalization predict mortality in patients with severe sepsis (Eur J Clin Invest 2010)
- Pioglitazone lowers plasma CETP mass and hepatic triglyceride content while raising HDL cholesterol in type 2 diabetes, confirming prior mouse findings (Diabetes Care 2010)
- CETP raises HDL triglyceride but leaves triglyceride production and clearance unchanged in APOE*3-Leiden mice (J Lipid Res 2010)
- High fasting CETP levels predict a larger postprandial HDL cholesterol drop after fat-rich meals, independent of triglyceride rise, in the Hoorn prandial study (Metabolism 2010)
- Ciprofibrate boosts CETP gene expression and speeds cholesterol delivery to the liver in CETP-transgenic mice (Lipids Health Dis 2009)
- Higher CETP quartiles predict more coronary calcium and thicker carotid intima-media in Japanese men, independent of D442G genotype (Am J Cardiol 2009)
- CETP delays clearance of dietary fat by slowing triglyceride clearance and suppressing lipoprotein lipase (Biochem J 2009)
- Tesaglitazar lowers CETP mass and activity and halts progression of existing atherosclerosis in CETP-transgenic mice (Br J Pharmacol 2009)
- Rising VLDL-triglyceride from bexarotene drives CETP activity up and HDL cholesterol down (Endocrinology 2009)
- CETP expression reverses the direction of PXR agonism effect on HDL cholesterol, turning an increase in mice into a dose-dependent decrease (Biochim Biophys Acta 2009)
- The combined action of SAA, secretory phospholipase A2, and CETP remodels HDL during the acute phase response while preserving cholesterol efflux capacity (Arterioscler Thromb Vasc Biol 2009)
- Acute coronary syndrome reduces leucocyte CETP expression up to 6-fold, with recovery tracking reduced inflammation, confirmed in CETP transgenic mice (J Intern Med 2008)
- Apple polyphenols improve cholesterol distribution in hamsters by directly inhibiting CETP activity (Mol Nutr Food Res 2008)
- FXRalpha suppresses CETP gene expression by competing with LXRalpha at a shared promoter element (Mol Cells 2008)
- CETP plasma levels are positively correlated with blood clotting speed, and recombinant CETP enhances prothrombinase activity, revealing a previously unknown procoagulant role (Thromb Haemost 2007)
- Complexing with spherical HDL protects CETP from mast cell chymase degradation, while CETP reciprocally protects discoidal HDL (J Lipid Res 2008)
- Atorvastatin's HDL-raising effect in mice requires CETP expression, proving statins work partly by suppressing CETP (Atherosclerosis 2007)
- Pioglitazone and rosiglitazone move CETP activity in opposite directions despite similar glucose control (Diabetes Metab Res Rev 2007)
- Higher plasma CETP predicts lower cardiovascular event risk specifically in men with low triglycerides, in the PREVEND study (Eur Heart J 2007)
- Bone marrow-derived CETP alone drives a proatherogenic lipid profile and 1.8-fold more atherosclerosis, and Kupffer cells supply half of hepatic CETP, in LDL receptor knockout mice (Circ Res 2007)
- CETP expression protects SR-BI-deficient mice from diet-induced atherosclerosis by remodeling buoyant HDL toward normal density (Arterioscler Thromb Vasc Biol 2007)
- A rapid 6-hour HDL subfractionation method reveals HDL has a dual role in oxidation: CETP-dependent prooxidant during VLDL oxidation, antioxidant during LDL oxidation (J Lipid Res 2007)
- CETP directly delivers HDL cholesteryl ester to the liver independent of SR-BI and LDL receptor pathways (Biochim Biophys Acta 2006)
- A DNA vaccine displaying a CETP epitope on hepatitis B core protein cuts aortic lesion area by 80.6% in a rabbit atherosclerosis model (Vaccine 2006)
- CETP expression cuts atherosclerotic lesion size 44% in testosterone-deficient mice (J Lipid Res 2006)
- A high-fat monounsaturated diet blocks cholesterol from stimulating CETP by suppressing LXR-alpha expression, unlike a low-fat diet (J Lipid Res 2005)
- A CETP-epitope vaccine carried by heat shock protein-65 reduces aortic lesions by up to 30.8% in rabbits (J Cardiovasc Pharmacol 2005)
- ApoCI overexpression backfires as a CETP-blocking strategy by triggering compensatory CETP gene induction (Biochem J 2005)
- Rosuvastatin cuts CETP mass 33-37% and, in hypertriglyceridemic patients, transfer activity by 59% (Atherosclerosis 2003)
- Probucol still lowers HDL cholesterol in humans with complete CETP deficiency, disproving its CETP-dependent mechanism (Atherosclerosis 2003)
- Streptozotocin-induced diabetes raises CETP mass and activity in transgenic mice, partly reversed by insulin (Can J Physiol Pharmacol 2003)
- LTIP steers CETP's lipid-transfer preference toward HDL3 while keeping HDL2 activity low and constant (J Biol Chem 2003)
- Garlic supplementation lowers CETP activity and shrinks atherosclerotic lesions in cholesterol-fed rabbits (Life Sci 2003)
- Sp1 and Sp3 transcription factors regulate the human CETP gene promoter through three binding sites, with the Sp1/Sp3 ratio determining their relative activity (J Lipid Res 2003)
- An Alu repeat represses and a CPF binding site activates the human CETP gene's distal promoter (J Lipid Res 2003)
- CETP expression halves aortic lesion area in ovariectomized mice, an atheroprotective effect blunted by estrogen therapy (J Lipid Res 2003)
- Expressing simian CETP in Fisher rats cuts HDL cholesterol by 48%, selectively depleting large apoE-containing HDL1 particles by 74% (J Lipid Res 2002)
- Meal-induced CETP activity redirects HDL cholesterol esters toward atherogenic VLDL-1 particles, rising 32-fold in type IIB hyperlipidemia versus healthy controls (J Lipid Res 2002)
- High plasma CETP does not speed reverse cholesterol transport in vivo despite raising liver cholesteryl ester uptake (Atherosclerosis 2002)
- Higher-dose atorvastatin cuts CETP-mediated cholesteryl ester transfer 30% while boosting cholesterol efflux in type IIB hyperlipidemia (Atherosclerosis 2002)
- LCAT deficiency posttranscriptionally suppresses plasma CETP levels, likely via loss of HDL (Arterioscler Thromb Vasc Biol 2002)
- Serum CETP is roughly double in obese children and falls with weight-loss therapy (Obes Res 2002)
- PLTP, not CETP, drives generation of pre-beta HDL in transgenic mice, a 3-fold rise versus CETP-only or wild-type animals (Biochem J 2001)
- First prospective study finds insulin therapy raises CETP without atherogenic lipid changes (Ann N Y Acad Sci 2001)
- CETP-LDL associations are strongest with saturated fat, hinting at why it drives atherogenesis (J Lipid Res 2001)
- Higher CETP levels roughly halve vascular disease risk in hemodialysis patients with normal or high HDL cholesterol, odds ratio 0.31 (Am J Kidney Dis 2001)
- Small-for-gestational-age neonates have lower CETP mass but higher cholesteryl ester transfer, possibly explaining later CHD risk (Metabolism 2001)
- Bile-acid feeding represses hepatic CETP expression in male mice but induces it in female mice, revealing a sex-specific regulatory response tied to LRH-1 (J Biol Chem 2001)
- Four CETP-transgenic mouse strains show lipoprotein cholesterol shifting between HDL and LDL in an allelic dose-dependent manner across a 2.9 to 37.4 microg/ml CETP range (Biochem Biophys Res Commun 2001)
- Rising triglycerides redirect CETP-mediated cholesterol transfer from LDL toward VLDL1, fueling small dense LDL in type 2 diabetes (Arterioscler Thromb Vasc Biol 2001)
- LDL oxidation redirects CETP transfer backward, pulling cholesteryl ester out of LDL and into HDL instead (Clin Chim Acta 2001)
- Combining apoA-II and CETP transgenes triggers massive VLDL overproduction in mice (J Lipid Res 2001)
- Infants have naturally high CETP activity that is unaffected by thyroid hormone status, unlike prior reports (Metabolism 2000)
- Chronic growth hormone replacement lowers CETP activity alongside LCAT, improving the lipoprotein profile (J Lipid Res 2000)
- Beta-adrenergic stimulation drives CETP secretion from hamster adipose tissue through a cAMP pathway (Atherosclerosis 1998)
- Probucol raises CETP mRNA up to 221% and boosts cholesterol efflux 354% in a dose-dependent manner in CETP-transfected hamster ovary cells (Biochim Biophys Acta 1998)
- CETP preferentially transfers cholesteryl ester over triglyceride when interacting with HDL, independent of its HDL binding (J Biochem 1998)
- Expressing simian CETP in obese diabetic KKAy mice cuts HDL from 159 to 25 mg/dl by enriching HDL with triglyceride 10-fold (Am J Physiol 1998)
- Plasma CETP activity rises in hyperthyroidism and falls in hypothyroidism, correcting with treatment (J Clin Endocrinol Metab 1998)
- Lipoprotein-bound free fatty acids drive elevated CETP specific activity in nephrotic syndrome (Arterioscler Thromb Vasc Biol 1997)
- Human apoA-I transgenic mouse HDL lacks the heat-labile inhibitor that normally caps CETP activity at high HDL levels (J Biol Chem 1997)
- CETP accounts for 15.2% of HDL cholesterol variation in hypertriglyceridemic men, more than LCAT, lipases, or triglycerides individually (Arterioscler Thromb Vasc Biol 1997)
- CETP predicts low HDL cholesterol independent of lipoprotein lipase in hypertriglyceridemic men but not in normotriglyceridemic men (Arterioscler Thromb Vasc Biol 1996)
- LpA-I:A-II is an efficient CE donor to triglyceride-rich lipoproteins despite low CETP affinity, fenofibrate raising HDL cholesterol 28% without changing CETP mass (Arterioscler Thromb Vasc Biol 1996)
- 13-cis-retinoic acid strongly activates CETP through its negatively charged carboxylic group (Eur J Biochem 1996)
- Lipoprotein lipase deficiency cuts cholesteryl ester transfer despite normal CETP mass, restored by adding lipoprotein lipase (J Lipid Res 1996)
- HDL3 electronegative charge density, peaking near minus 2,200 esu per square centimeter, governs maximal CETP activity (Biochim Biophys Acta 1996)
- Adding CETP to apoA-I transgenic mice doubles prebeta-HDL apoA-I and raises cholesterol efflux and LCAT esterification 1.7-fold (J Lipid Res 1996)
- Endotoxin cuts CETP levels below 20 percent of normal in hamsters, partly via TNF and interleukin-1 (J Clin Invest 1996)
- Analbuminemic patients show elevated CETP activity toward LDL, likely driven by lipoprotein-bound free fatty acids (Arterioscler Thromb Vasc Biol 1996)
- CETP activity, not mass, is elevated in Type 2 diabetes and tracks free cholesterol and apoA-I only in non-diabetic subjects (Atherosclerosis 1996)
- HDL particles from CETP-transgenic mice are more efficient cholesterol acceptors than from apoA-I-only transgenic mice, despite lower HDL levels (J Clin Invest 1995)
- CETP-mediated cholesteryl ester and triglyceride transfer in plasma is not an equimolar exchange (J Lipid Res 1995)
- CETP shuttles oxidized cholesteryl linoleate between LDL and HDL without distinguishing it from the unoxidized form (J Lipid Res 1995)
- The ratio of CETP mass to HDL3 cholesterol predicts carotid wall thickness better than HDL cholesterol itself (J Mol Med 1995)
- CETP activity splits into two distinct subgroups among low-HDL men, with the high-CETP subgroup showing only 30% coronary disease prevalence versus 70% (Arterioscler Thromb Vasc Biol 1995)
- Elevated CETP activity, correlated with low HDL, may explain reduced HDL cholesterol in obesity (Arterioscler Thromb 1994)
- PTP boosts the cholesteryl ester transfer activity of CETP even though the two proteins move phospholipids by distinct mechanisms (J Lipid Res 1994)
- Nine to twelve months of exercise training lowers plasma CETP concentration by about 14 percent (Arterioscler Thromb 1993)
- Elevated LCAT and CETP activities help explain abnormal HDL composition in nephrotic-range proteinuria (Kidney Int 1993)
- ApoE boosts CETP-mediated lipid exchange by raising the affinity of VLDL for CETP (J Lipid Res 1993)
- Probucol significantly raises CETP activity while shrinking large LDL and both HDL subfractions (Artery 1993)
- CETP generates pre-beta HDL-like particles from alpha HDL, completing a cyclical model with LCAT (J Lipid Res 1992)
- Elevated plasma CETP correlates with cholesteryl ester-enriched VLDL and normalizes with corticosteroid treatment in nephrotic syndrome (J Lipid Res 1992)
- CETP drives HDL apolipoproteins A-I and A-II onto LDL particles, an effect greatly amplified by oleic acid (Biochim Biophys Acta 1992)
- Primate CETP transgene dose-dependently depletes large HDL1/HDL2 particles in mice, correlating -0.81 with plasma apoA-I levels (Arterioscler Thromb 1992)
- Alcohol abusers have 27 percent lower plasma CETP concentration and 22 percent lower CETP activity than controls (J Lipid Res 1992)
- CETP and hepatic lipase together shed apoA-I from HDL, which reassembles into new discoidal particles (Biochim Biophys Acta 1992)
- ApoA-II blocks CETP-driven conversion of reconstituted HDL into small particles, while apoA-I-only HDL splits into both large and small particles (J Lipid Res 1992)
- Hepatic sinusoidal cells, not hepatocytes, are the principal source of CETP mRNA in primate liver (J Biol Chem 1991)
- Medium-chain saturated fatty acids boost CETP-driven formation of very small HDL particles, while arachidonic acid blocks it (Biochim Biophys Acta 1991)
- CETP-mediated cholesteryl ester transfer rises with acyl chain length while selective cellular uptake falls, an inverse relationship across four cell types (J Lipid Res 1991)
- Probucol raises plasma CETP by 64 percent while lowering HDL cholesterol, consistent with enhanced remnant-pathway reverse cholesterol transport (Arterioscler Thromb 1991)
- CETP activity falls 15 percent in hypothyroidism, tracking changes in HDL lipid composition (Eur J Clin Invest 1990)
- Alcoholics have 28 percent lower CETP activity than controls, explaining their elevated HDL cholesterol (Eur J Clin Invest 1990)
- CETP is identical to the mysterious HDL conversion factor, and fatty acids greatly amplify its particle-shrinking effect (Biochim Biophys Acta 1990)
- HDL triglyceride and free cholesterol content noncompetitively inhibit CETP, while HDL apoprotein composition uncompetitively modulates it (J Lipid Res 1989)
- Review weighs CETP-expressing hamsters against mice and rats for translational relevance in atherosclerosis modeling (Int J Mol Sci 2025)
- CETP damages perivascular fat function in male mice through oxidative stress and inflammation, but preserves it in females (Function (Oxf) 2024)
- CETP activity rises stepwise from underweight to overweight/obese children, tracking with visceral-adiposity and lipid-accumulation indexes (Nutr Metab Cardiovasc Dis 2023)
- Late-onset preeclampsia blunts the normal second-trimester decline in HDL cholesterol, apoA-I, and CETP activity seen in low-risk pregnancies (Int J Mol Sci 2023)
- In the multi-ethnic MESA cohort, higher HDL cholesterol, HDL particle number, and CETP mass predict lower long-term aortic valve calcification (Arterioscler Thromb Vasc Biol 2022)
- A randomized trial finds lycopene supplements boost HDL PON-1 antioxidant activity and lower CETP activity in HDL2 and HDL3 without changing particle size (Front Nutr 2022)
- Long-term matcha green tea worsens reverse cholesterol transport and fails to prevent diet-induced arteriosclerosis in rabbits (Mol Nutr Food Res 2021)
- The low-density lipoprotein receptor is required for CETP to control triglyceride metabolism in mice of both sexes (Physiol Rep 2021)
- Human ApoC1 transgene reduces atherosclerosis in rabbits partly by inhibiting CETP activity (Atherosclerosis 2021)
- Sepsis rapidly suppresses LCAT and CETP activity while raising PLTP and endothelial lipase, with LCAT activity predicting mortality (Front Cell Dev Biol 2021)
- A randomized trial finds omega-3 supplementation significantly lowers CETP activity and shrinks small HDL in high-cardiovascular-risk patients (Front Nutr 2021)
- Desmodium gyrans extract raises HDL-promoting SR-B1 and apoA-I while lowering CETP expression in liver cells (Indian J Pharmacol 2021)
- Intensive insulin therapy in newly diagnosed type 1 diabetes progressively suppresses serum CETP and PLTP over the first year (Nutr Metab Cardiovasc Dis 2021)
- CETP shifts HDL toward small, immature particles in coronary heart disease patients (Clin Lab 2020)
- CETP impairs triglyceride clearance in male mice through androgen receptor signalling (Lipids 2020)
- The largest cohort study on the topic finds physical activity boosts HDL cholesterol efflux capacity, and shows a U-shaped CETP response in people with diabetes (Eur J Prev Cardiol 2021)
- An undesirable postprandial triglyceride response enhances CETP-mediated cholesteryl ester transfer to chylomicrons and reduces hepatic HDL cholesteryl ester uptake (Biomolecules 2020)
- Homozygous B4GALT1 mutations cause CETP hypoglycosylation and reduced activity, yielding larger HDL particles (J Inherit Metab Dis 2020)
- CETP redirects cholesterol elimination away from the gut and toward bile, steering HDL cholesteryl esters differently than those from LDL (Arterioscler Thromb Vasc Biol 2019)
- CETP activity does not track carotid intima-media thickness once diabetes control is poor, unlike in well-controlled patients (Acta Diabetol 2019)
- A year of higher legume and fish intake lowers CETP activity in a large cardiovascular-risk cohort (Mol Nutr Food Res 2019)
- A randomized trial finds baru almonds reduce waist circumference and CETP expression while raising HDL in overweight women (Nutrition 2018)
- Diet-induced weight loss fails to improve HDL cholesterol efflux or cholesteryl ester transfer in obese men (Atherosclerosis 2018)
- An 8-week randomized trial finds Cuban policosanol lowers blood pressure and CETP activity by 20% while boosting HDL function in healthy women (Oxid Med Cell Longev 2018)
- Aerobic exercise reshapes arterial and macrophage gene expression toward atheroprotection in CETP-transgenic mice, independent of changes in CETP activity (Front Physiol 2018)
- Statin-driven normalisation of HDL lipid composition lags behind LDL and apoB reduction, revealing role of CETP (J Clin Lipidol 2018)
- Active rheumatoid arthritis is linked to higher CETP activity and impaired paraoxonase function, with apoA-I predicting arterial stiffness (Atherosclerosis 2016)
- Pigs bred for high CETP activity show altered hepatic expression of inflammatory genes and microRNAs, with gender and breed effects (Mamm Genome 2016)
- Active hepatitis C infection is associated with higher serum CETP and HDL triglyceride than after viral eradication (World J Hepatol 2016)
- CETP expression does not alter glucose tolerance, insulin secretion, or tissue glucose uptake in transgenic mice across multiple conditions (Lipids Health Dis 2016)
- CETP concentration is elevated and inversely correlates with hemoglobin in women with iron deficiency anaemia (Clin Lab 2015)
- Niacin plus laropiprant, but not fenofibrate, significantly lowers CETP and LCAT activity in type 2 diabetic patients with low HDL (Atherosclerosis 2015)
- Cholesteryl ester diffusion and self-association within the HDL phospholipid bilayer set the pace of CETP-mediated lipid transfer (Arch Biochem Biophys 2014)
- Increased fruit and vegetable intake lowers serum amyloid A and CETP activity in HDL subfractions across two randomized trials (Br J Nutr 2014)
- HDL from patients with CETP- or hepatic-lipase-deficiency hyperalphalipoproteinemia is not dysfunctional and shows enhanced cholesterol efflux from macrophages (Atherosclerosis 2014)
- Very low plasma CETP is linked to impaired HDL cholesterol efflux in the LURIC cohort (Eur J Clin Invest 2014)
- HDL3 reduces macrophage ER stress and partially restores apoE and CETP secretion suppressed by tunicamycin (Biochem Biophys Res Commun 2013)
- Fenofibrate and extended-release niacin raise HDL cholesterol equally but reshape HDL particle size differently, without improving cholesterol efflux (J Clin Lipidol 2013)
- Molecular dynamics simulation reveals CETP forms a more flexible structure in solution than in the crystal, supporting a continuous internal tunnel (Proteins 2012)
- Higher CETP mass independently predicts a lower leukocyte count, and switching atorvastatin to pitavastatin raises CETP mass by 8.8 percent (Am J Cardiovasc Drugs 2012)
- Higher endogenous CETP activity boosts cholesterol efflux capacity via pre-beta1-HDL in women (Arterioscler Thromb Vasc Biol 2012)
- A 12-week lycopene trial lowers serum CETP activity and boosts LCAT and paraoxonase-1 activity in overweight middle-aged adults (J Nutr Biochem 2013)
- ApoC1's natural inhibition of plasma CETP is blunted in dyslipidaemic coronary artery disease patients (J Lipid Res 2012)
- Knocking down hepatic SR-BI raises CETP-mediated cholesteryl ester transfer from HDL to apoB lipoproteins and halves atherosclerotic lesion area in rabbits (Atherosclerosis 2012)
- Non-HDL-C and insulin resistance predict high CETP activity in patients at risk for type 2 diabetes (Clin Biochem 2012)
- Ezetimibe lowers CETP mass by 20 percent in most type 2 diabetes patients, tracking with HDL subclass shifts (Endocr J 2012)
- Women with angina pectoris show enhanced CETP activity in both HDL and LDL alongside impaired HDL antioxidant enzymes (Int J Mol Med 2011)
- ApoA-I stimulates CETP and apoE secretion from lipid-loaded macrophages via NF-kB inhibition and PKA activation (Biochem Biophys Res Commun 2011)
- A 16-week very-low-calorie diet in obese type 2 diabetics cuts plasma CETP by 18% and raises apoA-I by 16%, without improving HDL cholesterol efflux (Diabetes Care 2011)
- Familial hypercholesterolemia patients show elevated CETP-mediated cholesteryl ester transfer and defective reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2011)
- Aerobic exercise boosts macrophage-to-feces reverse cholesterol transport in CETP-transgenic mice without changing CETP activity (Lipids 2011)
- Tree shrew CETP structure-function mapping identifies Asn110 as essential for secretion and residues 344/452 as essential for cholesteryl ester transfer (Lipids 2011)
- CETP mutations raise HDL 27-hydroxycholesterol, and CETP mass correlates more strongly with 27OHC-ester than cholesteryl ester transfer (Atherosclerosis 2010)
- Naturally low CETP and PLTP activity may explain atherosclerosis resistance in tree shrews and Beijing ducks (Lipids Health Dis 2010)
- Up-titrated rosuvastatin and atorvastatin both significantly reduce CETP mass and activity in low-HDL-C cardiovascular patients (Curr Med Res Opin 2010)
- Postprandial lipemia boosts HDL2's cholesterol efflux capacity but raises CETP-mediated transfer and impairs hepatic HDL delivery in type IIB hyperlipidemia (J Lipid Res 2010)
- Gastric bypass weight loss in obese women improves HDL remodeling, with CETP mass changes tracking glucose improvement but not fat-mass loss (J Lipid Res 2010)
- Acute Epstein-Barr virus infection transiently elevates CETP activity alongside other atherogenic lipid changes that resolve within four months (Atherosclerosis 2010)
- Thirty-five days of bed rest raises plasma CETP by 27% independently of fat mass in healthy men (J Clin Endocrinol Metab 2010)
- A review explains why CETP-expressing hamsters, not mice, are the preferred preclinical model for testing reverse-cholesterol-transport drugs (Curr Opin Investig Drugs 2010)
- Metabolic syndrome raises serum CETP activity 38% alongside dysfunctional, antioxidant-depleted HDL (Int J Mol Med 2010)
- The novel SR-BI inhibitor ITX5061 raises HDL cholesterol by 20% in humans and reduces atherosclerosis in mice regardless of CETP expression (Arterioscler Thromb Vasc Biol 2009)
- High-dose atorvastatin reduces pre-beta-HDL formation and CETP activity in type 2 diabetes, mediated by falling PLTP activity and triglycerides, not CETP (Biochim Biophys Acta 2009)
- A PADRE T-cell epitope CETP vaccine paired with CpG adjuvant elicits stronger anti-CETP antibody responses than the CETi-1 vaccine in mice and rabbits (Hum Vaccin 2009)
- CETP-mediated cholesterol transfer cannot substitute for SR-BI in adrenal steroid production (J Lipid Res 2009)
- A fat load raises CETP mass and cholesteryl ester transfer while lowering HDL cholesterol in obese metabolic syndrome men, unaffected by statin or statin-ezetimibe treatment (Clin Endocrinol 2008)
- HIV infection raises CETP mass and activity and redirects cholesterol away from HDL (Atherosclerosis 2007)
- The first molecular characterization of avian CETP finds chicken CETP activity rises with dietary cholesterol and falls with egg-laying maturity, likely regulated by estrogen (Comp Biochem Physiol B 2007)
- Plasma CETP activity tracks hepatic cholesterol synthesis machinery in humanized transgenic mice (Clin Exp Pharmacol Physiol 2006)
- CETP expression amplifies hepatic cholesteryl ester and triglyceride accumulation from apoC-I deficiency by up to 302% in mice (J Lipid Res 2007)
- Fenofibrate lowers CETP activity while raising PLTP activity, reshaping apoB-100 kinetics in metabolic syndrome (Clin Sci (Lond) 2006)
- CETP expression speeds hepatic uptake of HDL cholesteryl ester but leaves VLDL secretion and biliary cholesterol excretion unchanged in mice (Atherosclerosis 2007)
- Atorvastatin lowers CETP activity and raises paraoxonase without changing HDL cholesterol (Clin Biochem 2006)
- CETP mass is elevated in men, but not women, with metabolic syndrome, and tracks inversely with LDL particle size in both sexes (Obesity 2006)
- ApoE-containing HDL activates LCAT less efficiently than apoA-I-HDL and is remodeled by CETP into large fusion products instead of small lipid-poor particles (J Lipid Res 2006)
- Type 1 diabetics show enhanced cellular cholesterol efflux and higher CETP activity, and simvastatin lowers HDL cholesterol-linked CETP transfer without boosting efflux further (Diabetologia 2005)
- High-dose simvastatin lowers CETP activity dose-dependently and normalizes chylomicron remnant clearance in premature CAD (Atherosclerosis 2005)
- A low-fat, low-cholesterol diet lowers CETP activity in type 1 diabetics without harming cholesterol efflux (Scand J Clin Lab Invest 2005)
- SR-BI corrects the atherogenic, cholesteryl-ester-rich HDL seen in CETP deficiency (Atherosclerosis 2004)
- First CETP-specific antibody fragments enable a new quantification assay and link plasma CETP to body fat mass (Clin Chem Lab Med 2004)
- Type 2 diabetes lowers CETP specific activity while total CETP mass and activity remain unchanged, unlike PLTP which rises with triglycerides and obesity (Scand J Clin Lab Invest 2004)
- Review names CETP-driven triglyceride enrichment of HDL as a key mechanism of low HDL in insulin resistance (Clin Biochem 2003)
- CETP expression completely abolishes LXR-agonist-induced HDL enlargement in mice (J Biol Chem 2003)
- Intravenous apoA-I/phosphatidylcholine discs raise plasma CETP concentration by 29.7% and cholesterol esterification rate by 69.5% within 12 hours in healthy men (Arterioscler Thromb Vasc Biol 2003)
- Red pepper supplementation lowers CETP activity and improves the lipid profile in cholesterol-fed rabbits (Clin Chim Acta 2003)
- Bezafibrate lowers CETP activity by 12% and cholesteryl ester transfer by 37% alongside reduced insulin resistance in hypertriglyceridemia (J Lipid Res 2003)
- Short-term hypothyroidism significantly lowers serum CETP concentration but not activity, decoupled from HDL2:HDL3 and LDL-cholesterol correlations seen in controls (Clin Endocrinol 2003)
- CETP activity rises 47% in impaired glucose tolerance and correlates with triglycerides, HDL composition, and apoA-I catabolic rate (Croat Med J 2003)
- Higher CETP activity in Hispanic postmenopausal women tracks with abdominal fat, not ethnicity itself (Metabolism 2003)
- ApoCI deficiency doubles CETP-driven HDL cholesteryl ester depletion in transgenic mice (J Biol Chem 2002)
- Review focuses on CETP inhibitors and ABC1-inducing nuclear receptor agonists as new HDL-raising drug approaches (Mini Rev Med Chem 2002)
- Adding CETP shifts lipoproteins toward VLDL and IDL/LDL, and appears to blunt diabetes-driven hyperlipidemia in LPL-deficient mice (J Lipid Res 2002)
- CETP activity is an independent predictor of LDL particle size in familial combined hyperlipidemia, alongside triglycerides and hepatic lipase (J Lipid Res 2002)
- Review explains why hypothyroidism keeps HDL normal or high via thyroid-hormone-regulated CETP suppression (Thyroid 2002)
- Serum CETP concentration falls in postmenopausal Chinese women and correlates positively with estradiol, negatively with FSH (Clin Chim Acta 2001)
- CETP activity runs 2-3 times higher in hyperlipoproteinemia patients, peaking in Type V dyslipidemia (Atherosclerosis 2001)
- Psyllium fiber lowers CETP activity 18% regardless of sex, while its triglyceride effects diverge by sex and menopausal status (Am J Clin Nutr 2001)
- CETP transgenic mice reproduce the human-like cholesterol response to dietary fat type, with MUFA and PUFA lowering plasma cholesterol (Br J Nutr 2001)
- Growth hormone replacement transiently lowers CETP concentration and LDL cholesterol together, revealing a shared regulatory link (Lipids 2001)
- CETP activity divides six animal species into two groups: low-CETP mouse/rat/dog with high HDL-C, versus high-CETP hamster/rabbit/monkey with low HDL-C (Biol Pharm Bull 2001)
- Polyunsaturated fatty acids arachidonic, eicosapentaenoic, and docosahexaenoic halve CETP mRNA expression in HepG2 liver cells (Lipids 2001)
- CETP activity differences do not explain how margarine and butter diets change HDL cholesterol (J Lipid Res 2001)
- CETP activity falls in both growth hormone deficiency and acromegaly, tracking with IGF-1 and adrenal status (Atherosclerosis 2000)
- Phospholipid depletion shrinks reconstituted HDL from 9.2 to 8.0 nm and slows early cholesteryl ester transfer via CETP (J Lipid Res 2000)
- CETP concentration and transfer activity are normal in well-matched type 1 diabetics, contradicting earlier reports (Eur J Intern Med 2000)
- Review makes CETP deficiency the central explanation for hyperalphalipoproteinemia and its paradoxical coronary risk (Atherosclerosis 2000)
- CETP activity is lower in children and teens with insulin-dependent diabetes, alongside higher HDL cholesterol and apoA-I (Acta Paediatr 1999)
- Pravastatin lowers serum CETP 21% while probucol raises it 23%, with baseline CETP predicting Achilles tendon xanthoma regression (Atherosclerosis 1999)
- A review finds increased plasma CETP is atheroprotective in transgenic mice even with low but functional HDL, against prior assumptions (Atherosclerosis 1999)
- Probucol and bezafibrate change HDL-cholesterol in cholesterol-fed rabbits via CETP activity, not liver CETP mRNA (Jpn Circ J 1999)
- Dietary palmitic acid raises CETP activity and mass versus lauric and oleic acid diets, with opposite effects on PLTP (Atherosclerosis 1999)
- Radiolabeled HDL cholesteryl ester lingers longer in rat plasma and clears more slowly from perfused liver after ex vivo CETP treatment (Proc Soc Exp Biol Med 1999)
- Adipose tissue CETP mRNA strongly correlates with plasma CETP levels and falls with age in coronary patients (Atherosclerosis 1998)
- Smoking lowers CETP activity and worsens postprandial HDL loss in normolipidemic men (J Lipid Res 1998)
- Desialylation of lipoproteins boosts CETP-mediated cholesteryl ester transfer from HDL while impairing reverse cholesterol transport (Atherosclerosis 1998)
- Simvastatin lowers plasma CETP only in Japanese patients with elevated baseline CETP levels (Clin Chem 1998)
- Probucol sustains elevated prebeta1-HDL in hypercholesterolemic patients while a low-cholesterol diet lowers it, tracking CETP mass change (Atherosclerosis 1998)
- Oleic acid roughly doubles full-length CETP transcription in Caco-2 intestinal cells without affecting exon-9-deleted splice variant (Mol Cell Biochem 1997)
- Acute hyperinsulinemia suppresses plasma CETP activity via a fall in free fatty acids, less so in NIDDM patients than healthy subjects (Metabolism 1997)
- LPL activity predicts HDL cholesterol only when CETP is present in mice, revealing a species-specific LPL-CETP interaction (J Lipid Res 1997)
- Cholestyramine lowers plasma CETP alongside LDL cholesterol, likely explaining its HDL-raising effect (Clin Pharmacol Ther 1997)
- Interferon alpha treatment for hepatitis C lowers CETP activity and mass alongside lipoprotein lipase and hepatic lipase (Hepatology 1997)
- Increased CETP activity tracks with the atherogenic lipoprotein profile of obese children (Atherosclerosis 1997)
- Cholesterol feeding raises rabbit CETP production 416% and plasma mass 230%, tracing CETP through fast and slow HDL-bound pools (Arterioscler Thromb Vasc Biol 1997)
- Lipopolysaccharides alter both HDL and LDL size and charge while blocking CETP activity, one of three distinct inhibitory mechanisms identified (Biochim Biophys Acta 1996)
- Plasma triglyceride level, not dietary fat saturation, is the rate-limiting factor for CETP-mediated cholesteryl ester transfer in hypercholesterolemic women (Atherosclerosis 1996)
- CETP and PLTP push HDL particle size in opposite directions, and alcohol withdrawal reveals the effect in patients (J Biol Chem 1996)
- Vitamin E blocks 85% of the HCSF-diet-induced rise in hamster adipose CETP release and 70% of the plasma CETP activity increase (Atherosclerosis 1996)
- SW872 liposarcoma cells offer a high-output model for studying cholesterol-driven CETP secretion (J Lipid Res 1996)
- ApoA-IV activates CETP lipid transfer as effectively as apoA-I, binding lipid emulsions with similar affinity (Biochim Biophys Acta 1996)
- CETP activity rises 20% postprandially in controls but falls in NIDDM patients, despite 35% higher fasting CETP activity in diabetics (Atherosclerosis 1996)
- A palmitic acid diet raises CETP activity 12 percent more than a stearic acid diet in young women (Metabolism 1996)
- Net cholesteryl ester transfer is elevated in hypertriglyceridemic hemodialysis patients, tracking triglyceride levels rather than renal status (Am J Nephrol 1996)
- CETP mediates the transfer of esterified oxysterols between lipoproteins, limiting their uptake into cells (J Lipid Res 1996)
- CETP activity exceeds that of adults and control children in kids on peritoneal dialysis for end-stage renal disease (Nephron 1996)
- Gemfibrozil raises HDL3 cholesterol 34.5% and plasma CETP activity 15.8% in hypertriglyceridaemic patients (J Intern Med 1995)
- Plasma free fatty acids raise CETP mass and HDL-to-VLDL/LDL transfer but not LDL-to-HDL transfer, a directionally selective effect (Arterioscler Thromb Vasc Biol 1995)
- A fluorescence assay tracks CETP-mediated lipid transfer to equilibrium in under 30 minutes, supporting an adsorption-exchange-desorption-diffusion mechanism (Chem Phys Lipids 1995)
- Review questions whether CETP-mediated cholesterol transfer to apoB lipoproteins undermines the antiatherogenic label of reverse cholesterol transport (Atherosclerosis 1995)
- Oleic acid, unlike linoleic acid, blocks the cholesterol-induced rise in CETP activity in hamsters (Atherosclerosis 1995)
- Liver-specific CETP transgenic mice show 30-40% lower HDL cholesterol and loss of the apoE-rich HDL1 subclass (Biochim Biophys Acta 1995)
- A review synthesizes transgenic-mouse evidence that CETP links plasma triglyceride metabolism to low HDL cholesterol levels (Trends Cardiovasc Med 1995)
- Unesterified cholesterol up to 17 mol% speeds CETP-mediated lipid exchange without increasing CETP binding to the donor emulsion (Biochem J 1994)
- CETP activity is lower in diabetic men without coronary disease than in disease-free non-diabetic men (Metabolism 1994)
- A review proposes CETP as the mechanistic switch converting protective HDL2 into atherogenic lipoproteins when triglyceride-rich particles accumulate (Atherosclerosis 1994)
- Dietary cholesterol raises plasma CETP activity in baboons regardless of dietary fat type (Metabolism 1994)
- CETP triggers dissociation of lipid-free apoA-I from HDL only when VLDL or LDL are also present (J Lipid Res 1994)
- Intraperitoneal insulin delivery raises CETP activity 25 percent independent of glucose control in type 1 diabetes (Metabolism 1994)
- ApoA-II binds CETP and shuts down its cholesteryl ester transfer activity while apoA-I and apoA-IV enhance it at low doses (J Lipid Res 1994)
- CETP activity is higher in IDDM patients with macroalbuminuria but does not correlate with HDL, HDL2, or HDL3 cholesterol (Diabetes Care 1994)
- LpA-I-associated CETP concentration is significantly higher in women than men, while hyperlipidemic men shift CETP toward LpA-I:A-II particles (J Lipid Res 1994)
- A bicycle marathon cuts CETP mass 29 percent and activity 14 percent while raising HDL cholesterol (Metabolism 1994)
- ApoAII enrichment of HDL3 acts as an uncompetitive inhibitor of CETP-mediated cholesteryl ester transfer (J Biol Chem 1994)
- LpA-I, not LpA-I:A-II, shows an inverse relationship with plasma CETP mass within the HDL3 density region (J Lipid Res 1994)
- Gemfibrozil raises HDL3 cholesterol 16% and CETP activity in NIDDM patients, alongside 14.7% and 18.8% rises in LPL and hepatic lipase (Atherosclerosis 1993)
- CETP activity and mass rise in primary biliary cirrhosis, more so with hyperalphalipoproteinemia, correlating tightly with each other (r=0.90) (Hepatology 1993)
- Probucol raises plasma CETP 31% while paradoxically lowering adipose CETP mRNA, suggesting effects beyond local synthesis (J Lipid Res 1993)
- CETP activity is 26% lower in alcoholics, detecting 63% of cases at 82% specificity, but insufficient alone as an alcoholism marker (Alcohol Alcohol 1992)
- CETP and lipoprotein lipase together, not separately, shrink HDL particles via free fatty acid synergy (Biochim Biophys Acta 1992)
- Trans-elaidic acid increases CETP-mediated cholesteryl ester transfer while cis-oleic acid inhibits it at high concentration (Biochim Biophys Acta 1992)
- Medium and long chain nonesterified fatty acids boost CETP-mediated cholesteryl ester transfer while short chains do not (Biochim Biophys Acta 1991)
- A monounsaturated-fat diet lowers CETP activity more than a polyunsaturated diet, paralleling LDL cholesterol reductions (Atherosclerosis 1991)
- CETP activity is 70% higher in smoking IDDM men than controls and 30% higher than nonsmoking IDDM men (Diabetes Care 1991)
- Copper-induced plasma oxidation frees CETP from HDL and shifts it onto LDL more sensitively than known oxidation markers (J Lipid Res 1991)
- Plasma CETP rises as an adaptive response to peripheral cholesterol flux and jumps further with probucol treatment (Clin Cardiol 1991)
- Sodium oleate disrupts the CETP-mediated LDL-HDL equilibrium, driving cholesteryl esters into a shrunken, lipid-depleted HDL fraction (Atherosclerosis 1990)
- Hepatic lipase shrinks HDL particles only when VLDL and CETP are both present, and lipoprotein lipase blocks the effect (Atherosclerosis 1990)
- Plasma CETP levels vary nearly fourfold and correlate with apoA-I and apoE, with CETP concentrated in 129-154 kD HDL3/VHDL particles (J Clin Invest 1990)
- A single-incubation isotopic assay simultaneously measures LCAT esterification and CETP-mediated cholesteryl ester transfer (Atherosclerosis 1990)
- A newly purified phospholipid transfer protein, LTP-II, lacks CETP cross-reactivity but boosts CETP-mediated cholesteryl ester transfer (J Lipid Res 1988)
- Hepatic overexpression of the hepatokine Tsukushi impairs HDL-mediated reverse cholesterol transport in hamsters without changing CETP activity (J Lipid Res 2026)
- Higher CETP concentration is linked to coronary plaques in familial hypercholesterolemia, but not independently after adjustment (J Clin Lipidol 2026)
- Children with obesity show reduced CETP activity alongside broader HDL antioxidant breakdown and higher oxidative stress (J Clin Lipidol 2026)
- In Tangier disease, CETP activity drives an LDL-triglyceride buildup on top of near-total HDL loss, a four-patient case series shows (J Clin Endocrinol Metab 2025)
- Tofacitinib raises CETP and atherogenic lipids in rheumatoid arthritis patients naive to prior biologic therapy (J Clin Lipidol 2025)
- Case report finds pemafibrate paradoxically lowers HDL cholesterol in a patient with CETP deficiency (J Clin Lipidol 2025)
- CETP-driven HDL lowering, unlike ApoE knockout, does not worsen muscle wasting in dysferlin-deficient mice (Lipids Health Dis 2024)
- Bioinformatics and molecular docking identify the soy isoflavone genistein as binding CETP among three key HDL-raising natural-product targets (J Transl Med 2023)
- Small-quantity lipid-based nutrient supplements do not alter maternal HDL enzyme activity in pregnancy, but CETP and LCAT activity vary by season in Ghana (Curr Dev Nutr 2023)
- CETP is one of only three lipid-metabolism proteins strongly enriched in pre-beta-HDL, the small, highly active HDL subspecies (Basic Res Cardiol 2023)
- CETP is among seven cholesterol-handling genes up-regulated in peripheral blood of coronary artery disease patients (Curr Issues Mol Biol 2023)
- Review notes that impaired apoC1 inhibition of CETP in diabetes may explain elevated CETP activity in diabetic patients (Cardiovasc Diabetol 2022)
- miR-16 simultaneously suppresses CETP alongside five other atherosclerosis-related genes in liver cells without toxicity (Sci Rep 2022)
- A mathematical model of triglyceride lipolysis explains why cholesterol acquisition by HDL is maximal at intermediate HDL concentrations (Metabolites 2022)
- Human CETP transgene boosts macrophage reverse cholesterol transport in mice, but cannot rescue PLTP deficiency (J Physiol Biochem 2021)
- A high triglyceride to HDL cholesterol ratio predicts elevated CETP activity in children (Indian J Pediatr 2021)
- Obesity alters LCAT and CETP activities and shifts HDL toward smaller, less anti-oxidative particles in young women (Biomedicines 2021)
- Roux-en-Y gastric bypass lowers CETP activity alongside other markers of HDL function in severe obesity (Obes Surg 2020)
- A new ELISA for oxidized HDL finds the highest levels in patients with CETP-deficiency-related hyperalphalipoproteinemia, and lower levels with probucol treatment (J Atheroscler Thromb 2021)
- Swapping dietary palmitic acid for stearic acid raises CETP mass without changing its activity (Clin Nutr 2020)
- LDL receptor enables a CETP-independent route for macrophage cholesterol to reach faeces, mouse study finds (Circ Res 2020)
- CETP mass and activity vary only slightly across apoE- and apoC-III-defined HDL subtypes, while LCAT concentrates in apoE/apoC-III-free HDL (Lipids Health Dis 2020)
- Diet-controlled type 2 diabetes speeds catabolism of several HDL proteins, and CETP activity tracks inversely with plasma adiponectin (Biomolecules 2020)
- Red yeast rice supplement linked to extreme HDL cholesterol via apparent CETP downregulation in a case report (Lab Med 2020)
- High-dose PFOA raises HDL cholesterol by suppressing cholesteryl ester transfer activity in mice (Toxicol Sci 2019)
- Kiwifruit raises adipose CETP gene expression but not serum CETP activity in hamsters (Avicenna J Phytomed 2019)
- Prebeta-1 HDL, the particle CETP feeds on, is elevated across three dyslipidaemia phenotypes in 2,435 people (J Clin Lipidol 2018)
- Exercise raises HDL in CETP-transgenic mice by lowering CETP activity 19%, and an anabolic steroid specifically blunts that effect (Lipids 2017)
- Human CETP transgenic pigs created as a new model for dyslipidaemia and atherosclerosis research (Lipids Health Dis 2017)
- Neovascular age-related macular degeneration is linked to more HDL and IDL particles, an association unaffected by the CETP D442G mutation (J Lipid Res 2017)
- The SGLT2 inhibitor dapagliflozin lowers HbA1c and body weight in type 2 diabetes but leaves HDL cholesterol, subfractions, and CETP activity unchanged (Cardiovasc Diabetol 2017)
- Policosanol supplementation reduced CETP activity by up to 32% and lowered blood pressure in healthy adults (Int J Mol Med 2017)
- CETP-overexpressing transgenic rabbits show more macrophage foam cells despite unchanged lesion area (Mediators Inflamm 2017)
- Six months of aerobic exercise raises oxidized-HDL levels in women without any change in CETP or adiponectin concentration (Free Radic Res 2016)
- A review shows PON1 activation and its flux across HDL particle sizes during maturation are blocked by CETP and LCAT inhibitors (Clin Chim Acta 2015)
- A review names CETP mutations as a specific genetic cause of high HDL cholesterol, distinct from the mutations that cause low HDL (Curr Med Chem 2014)
- HIV infection is associated with elevated plasma CETP and LCAT alongside low HDL, without one-year progression of subclinical atherosclerosis (Atherosclerosis 2013)
- CETP is the least frequently mutated of three genes (LIPG, CETP, GALNT2) found in Caucasian families with extremely high HDL cholesterol (PLoS One 2012)
- CETP expression partly rescues abnormal HDL distribution but not atherosclerosis in SR-BI-deficient mice (J Biol Chem 2011)
- Higher CETP levels in follicular fluid correlate with more mature oocytes and higher IVF/ICSI fertilization rates (Iran J Reprod Med 2011)
- An orally delivered trefoil-factor-CETP chimeric vaccine raises intestinal and serum anti-CETP antibodies and inhibits atherosclerosis in rabbits (Peptides 2010)
- Octodon degus develop human-like atherosclerosis on a cholesterol diet, with baseline CETP activity comparable to humans (Atherosclerosis 2010)
- A review identifies CETP as a key enzyme liberating serum amyloid A during acute-phase HDL remodeling (Curr Opin Endocrinol Diabetes Obes 2010)
- Nevirapine raises HDL cholesterol in HIV patients by boosting apoA-I production, with a modest CETP activity increase (Arterioscler Thromb Vasc Biol 2009)
- LCAT overexpression raises HDL cholesterol but does not boost macrophage reverse cholesterol transport, even alongside SR-BI or CETP coexpression (Circulation 2009)
- Review attributes statins' modest HDL-raising effect to reduced CETP-mediated cholesterol flow (Cardiovasc Drugs Ther 2008)
- LTIP loses its CETP-inhibiting activity when sequestered into a 470 kDa apolipoprotein complex (J Lipid Res 2008)
- Probucol lowers ANGPTL3 and large-HDL phospholipids while raising prebeta1-HDL in hypercholesterolemic patients (Atherosclerosis 2008)
- Fenofibrate shifts HDL from large HDL2 to small HDL3 particles over 5 years in type 2 diabetes without changing CETP, PLTP, or LCAT activity (Diabetologia 2007)
- Review dissects how CETP and PLTP jointly drive low HDL in type 2 diabetes via specific apolipoprotein modulators (Curr Opin Lipidol 2007)
- Psyllium plus plant sterols lowers CETP activity by 11% and raises LDL receptor abundance by 26%, explaining part of its LDL-lowering mechanism (J Nutr 2007)
- Serum CETP correlates positively with total cholesterol, beta-lipoprotein, apoB, and apoE, and is lower overall but higher in women, in type 2 diabetes (Med Princ Pract 2007)
- Plasma CETP mass and PLTP activity, but not adiponectin or resistin, are independently linked to leptin levels in type 2 diabetes (Biochim Biophys Acta 2007)
- Review attributes chronic renal failure's HDL disorders partly to elevated CETP activity (Am J Physiol Renal Physiol 2006)
- ApoCI blocks CETP by disrupting CETP-HDL binding through its electrostatic C-terminal helix (J Biol Chem 2005)
- Familial low HDL patients have markedly reduced prebeta-HDL alongside elevated CETP and hepatic lipase activity, unrelated to prebeta-HDL levels (J Lipid Res 2005)
- Review names CETP inhibition as an emerging strategy for HDL-targeted cardiovascular drug development (Nat Rev Drug Discov 2005)
- CETP transgenic rats show dramatic lipid shifts on a sucrose diet but not on a high-fat/high-cholesterol diet (Atherosclerosis 2005)
- Postprandial triglyceride-rich lipoproteins boost CETP-mediated cholesteryl ester transfer from LDL and HDL regardless of dietary fat type (Am J Clin Nutr 2004)
- The CETP-to-LCAT activity ratio, not either enzyme individually, predicts small HDL3 particle enrichment in healthy Mexican adults (Endocr Res 2004)
- Review reports CETP autoimmunization vaccine has reached human trials alongside apolipoprotein mimetics (Curr Atheroscler Rep 2004)
- Treating periodontitis raises HDL cholesterol by 10.7% and CETP activity by 19.4%, improving cholesterol efflux especially in patients whose CRP fell (J Lipid Res 2004)
- CETP activity rises 32% after a fatty meal, but neither CETP nor PLTP activity correlates with the postprandial rise in plasma cholesterol efflux capacity (Nutr Metab Cardiovasc Dis 2003)
- Tibolone lowers HDL cholesterol by 14% via increased hepatic lipase activity, but preserves cholesterol efflux capacity without affecting CETP activity (Clin Endocrinol 2003)
- Overexpressing phospholipid transfer protein raises VLDL secretion 1.5-fold while lowering HDL cholesterol and CETP activity in CETP-transgenic mice (J Lipid Res 2002)
- Atorvastatin cuts postprandial CETP-mediated cholesteryl ester transfer from HDL to chylomicrons by up to 26% (J Clin Endocrinol Metab 2002)
- Antioxidant vitamins blunt the protective HDL2 rise from simvastatin-niacin therapy, possibly by stimulating CETP activity, a review concludes (Arterioscler Thromb Vasc Biol 2002)
- A review reports that apolipoprotein A-II modulates HDL atherogenicity in opposing directions, inhibiting CETP activity as one of several intermediate effects on reverse cholesterol transport (Atherosclerosis 2002)
- CETP mass varies widely in healthy Japanese people with very high HDL cholesterol (Intern Med 2002)
- Lipid transfer inhibitor protein rises 3-fold in hypercholesterolemia independent of CETP levels themselves (Arterioscler Thromb Vasc Biol 2001)
- HDL cholesteryl esters still reach LDL in ponies despite their total lack of CETP activity (Comp Biochem Physiol B Biochem Mol Biol 2001)
- A review identifies apolipoprotein C-I as the major plasma inhibitor of CETP, one of several ways C-I and C-III modulate lipoprotein metabolism (Curr Opin Lipidol 2001)
- A review finds PLTP, not CETP, is the main driver shaping HDL size and composition via phospholipid transfer and HDL conversion (Atherosclerosis 2001)
- Review traces how CETP deficiency reshapes HDL and LDL and raises coronary risk despite higher HDL-cholesterol (Front Biosci 2001)
- Probucol raises CETP and LCAT activity despite lowering HDL, reframing its HDL reduction as pro-transport rather than atherogenic (Atherosclerosis 2000)
- A review names CETP, apoA-II, and hepatic lipase as prime targets for pharmacologic inhibition among new HDL-directed atherosclerosis therapies (Curr Atheroscler Rep 2000)
- Hypertriglyceridemia with low HDL cholesterol raises CETP activity and impairs cellular cholesterol efflux capacity in men (Atherosclerosis 2000)
- Apolipoprotein L levels rise in primary CETP deficiency and correlate with triglycerides across hyperlipidemic and diabetic subjects (J Lipid Res 2000)
- CETP rises over time regardless of whether progestogen is added to low-dose estradiol in diabetic women (Diabet Med 2000)
- Insulin lowers CETP activity 9.5% in healthy adults but not in type 2 diabetes, while PLTP responds to both insulin and Acipimox in both groups (Diabetes 1999)
- A new sandwich ELISA measures plasma CETP concentration with under 10% assay variability (Clin Biochem 1999)
- Testosterone suppression by cetrorelix raises apoA-I, insulin, and leptin, with only small CETP and hepatic lipase decreases in pooled analysis (Exp Clin Endocrinol Diabetes 1999)
- A review asks whether CETP is beneficial or harmful, weighing evidence for both proatherogenic and antiatherogenic roles (Crit Rev Clin Lab Sci 1998)
- CETP activity rises in hyperthyroidism and falls in hypothyroidism, tracking free T4, though hepatic lipase drives the HDL2 changes (J Clin Endocrinol Metab 1998)
- Smoking cuts lipoprotein lipase and LCAT activity but leaves CETP activity unchanged, though CETP still tracks HDL3 in non-smokers (Eur J Clin Invest 1998)
- CETP-driven cholesterol enrichment of remnant particles worsens atherosclerosis risk in diabetic dyslipidaemia (Eur Heart J 1998)
- An overview of reverse cholesterol transport shows CETP pulling in the opposite direction from apoA-I (Eur Heart J 1998)
- PLTP shares the same optimal HDL surface charge as CETP, showing both lipid transfer proteins are governed by electrostatics (J Lipid Res 1998)
- HDL and VLDL levels, not CETP activity, determine the direction of cholesteryl ester transfer in alcohol abusers (Arterioscler Thromb Vasc Biol 1997)
- A direct LDL isolation technique offers a simpler alternative for measuring CETP activity (Clin Chim Acta 1997)
- CETP shares seven lipid-binding helical arrays with apoA-I, apoA-II, apoC-I/II/III, and apoE despite a smaller active surface (Mol Cell Biochem 1997)
- Review contrasts how CETP and PLTP remodel HDL size distribution through distinct mechanisms (Trends Cardiovasc Med 1997)
- Species already low in CETP and high in lipoprotein lipase respond most to NO-1886, a compound that raises HDL cholesterol without touching CETP activity (Metabolism 1997)
- Free fatty acids fluidize the lipoprotein surface, offering a physical explanation for how they modulate CETP activity (Eur J Biochem 1996)
- CETP activity rises in the second trimester of pregnancy alongside falling hepatic lipase and rising estradiol (J Lipid Res 1996)
- Plasma triglycerides, not LCAT or CETP concentration, drive cholesterol esterification and HDL remodeling (ATVB 1995)
- A Tall-lab review reconciles CETP deficiency and CETP overexpression both showing antiatherogenic signals, via its role in reverse cholesterol transport (Curr Opin Lipidol 1995)
- Smoking lowers and drinking raises HDL2-C and HDL3-C in healthy men, but neither affects CETP or LCAT activity (Jpn Circ J 1995)
- A new immunoassay measuring CETP activity via radiolabeled cholesteryl ester transfer matches the ultracentrifugation method with r=0.94, without separating donor and acceptor lipoproteins (Clin Chem 1995)
- Dietary cholesterol raises both LDL and HDL cholesterol in young women without changing fasting plasma CETP levels (Arterioscler Thromb Vasc Biol 1995)
- CETP shrinks reconstituted HDL from 9.2 to 8.0 nm by swapping cholesteryl ester for triglyceride and losing an apoA-I molecule (J Biol Chem 1995)
- CETP and LCAT localize mainly to LpA-I, not LpA-I:A-II, particles, a review finds, explaining why LpA-I promotes more cholesterol efflux (Atherosclerosis 1994)
- CETP mRNA sequences are detected in ovary, lung, intestine, and heart tissue, not just liver, suggesting a locally active membrane-bound CETP form (Biochem Biophys Res Commun 1994)
- A review identifies probucol as the sole drug shown to stimulate CETP activity and boost reverse cholesterol transport (Pharmacol Ther 1994)
- Heart transplant recipients' paradoxically high HDL traces to partial CETP and hepatic lipase deficiency (Atherosclerosis 1993)
- CETP reshapes HDL3 differently depending on whether particles carry apoA-II alongside apoA-I (Biochim Biophys Acta 1992)
- A review by Alan Tall names CETP and hepatic lipase as key genetic determinants of HDL catabolism, with lipoprotein lipase driving HDL formation (J Intern Med 1992)
- CETP and PLTP occupy different HDL-sized macromolecular complexes across four vertebrate species (Atherosclerosis 1991)
- A review credits probucol as the only drug shown to directly raise CETP activity and mass, potentially aiding cholesterol removal from tissues (Atherosclerosis 1991)
- Impaired cholesteryl ester transfer to the HDL3 pool is linked to vascular disease across several hyperlipidemic disorders (Atherosclerosis 1989)
- A minor pre-beta lipoprotein containing apoD, LCAT, and CETP channels newly esterified cell cholesterol into HDL (J Biol Chem 1989)
- Stripping cholesteryl arachidonate from HDL via CETP-mediated transfer reduces its ability to trigger endothelial prostacyclin release (J Lipid Res 1985)
- Indian patients with high HDL cholesterol are more active, leaner, and at lower cardiovascular risk, with numerically but not significantly lower CETP levels (Ir J Med Sci 2025)
- A methodology review highlights the APOE*3-Leiden.CETP mouse as a model that closely mimics human lipoprotein metabolism (Vasc Biol 2024)
- Cholesterol efflux capacity, but not CETP-mediated cholesterol ester transfer, correlates inversely with peripheral plaque volume (Biomedicines 2023)
- CETP activity correlates with atherogenic VLDL levels in women with anorexia nervosa (Biomedicines 2022)
- Eating up to two eggs daily downregulates CETP mRNA in blood cells without affecting overall cholesterol balance in young Chinese adults (Food Sci Nutr 2022)
- HDL and CETP: a textbook chapter surveys the tunnel structure, reverse cholesterol transport role and the still-unsettled case for inhibitors versus agonists (Adv Exp Med Biol 2022)
- A systematic review of 118 randomized trials finds unsaturated fats, antioxidants, and moderate alcohol improve HDL functional traits including CETP activity (J Clin Med 2021)
- Lower plasma CETP tracks with milder depression severity, including anhedonia and guilt, in a preliminary mood-disorder proteomics study (J Psychiatr Res 2021)
- CETP concentration does not differ between peripheral artery disease patients with or without type 2 diabetes (Vasc Med 2021)
- Fetal HDL carries reduced CETP activity despite similar enzyme levels to the mother, review finds (Biomedicines 2021)
- ApoC-II and apoC-III move from VLDL preferentially into larger HDL3 particles, and a CETP inhibitor does not change this transfer (Biol Chem 2021)
- Prolonged bedrest suppresses HDL cholesterol efflux capacity without affecting CETP or LCAT activity (Sci Rep 2020)
- A review of PLTP and CETP in atherogenesis weighs the mixed record of CETP inhibitors against open questions about PLTP (Adv Clin Exp Med 2018)
- Electron microscopy shows CETP binds HDL through hydrophobic surface interactions, not protein contacts (Sci Rep 2015)
- Atomistic simulations reveal how CETP penetrates HDL via a tryptophan anchor and phenylalanine barrier (J Lipid Res 2015)
- LDL apheresis transiently reduces CETP-mediated cholesteryl ester transfer and cholesterol efflux capacity in familial hypercholesterolemia (J Lipid Res 2012)
- Review notes CETP transgene expression normalizes hepatic HDL cholesteryl ester delivery in humanized SR-BI knockout mice (World J Gastroenterol 2010)
- CETP activity stays unchanged despite severely disrupted lipoproteins in Hantaan virus renal failure (BMB Rep 2010)
- A dietary lysine-to-arginine ratio trial finds no effect on CETP or LCAT activity, though it modestly shifts postprandial VLDL, triglycerides, and inflammation markers (Atherosclerosis 2010)
- A review revisiting a 40-year-old study names the CETP, VLDL-triglyceride, and hepatic lipase cluster as drivers of atherogenic HDL and LDL remodeling (Rom J Intern Med 2008)
- Metabolic syndrome patients show hypoadiponectinemia, elevated adhesion molecules, and higher CETP-mediated cholesteryl ester-triglyceride exchange (Atherosclerosis 2008)
- Vitamin E supplementation modestly lowers HDL cholesterol in statin-treated patients without affecting CETP or CYP3A activity (Am J Health Syst Pharm 2007)
- Rosuvastatin lowered CETP activity and mass while raising HDL-C in metabolic syndrome patients (Atherosclerosis 2008)
- Mini-review places CETP-mediated cholesteryl ester transfer within the broader reverse cholesterol transport pathway (Rom J Intern Med 2007)
- Simvastatin lowers cholesterol in cholesterol-fed rabbits without changing CETP activity (Drug Dev Ind Pharm 2006)
- A review proposes that CETP is one of four enzymes that remodel spherical HDL into the lipid-poor apoA-I needed for reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2006)
- SR-BI processing of HDL2 segregates apoA-I and apoA-II catabolism into distinct particles, independent of CETP, LCAT, or PLTP (J Lipid Res 2005)
- Review names CETP inhibitors among emerging HDL-targeted therapies for insulin resistance syndrome (Semin Vasc Med 2004)
- Postprandial chylomicrons are up to 40 times more potent than VLDL at accepting cholesterol from LDL and HDL via LCAT and CETP (J Lipid Res 2004)
- Omega-3 fatty acid concentrate selectively raises HDL2 cholesterol by 40% and paraoxonase by 10% without affecting CETP or LCAT in familial combined hyperlipidemia (Metabolism 2004)
- A review names CETP among three plasma factors that release lipid-poor apoA-I from HDL during remodeling, the key acceptor for ABCA1-mediated cholesterol efflux (Arterioscler Thromb Vasc Biol 2004)
- A review of HDL structure names CETP among four proteins, alongside LCAT, SR-BI, and ABCA1, that remodel HDL particles in vivo (Front Biosci 2003)
- Men who respond strongly to dietary cholesterol also show higher CETP activity during high-egg feeding, suggesting boosted reverse cholesterol transport (J Nutr 2003)
- ApoA-I-free HDL-LpE particles are more than twofold more abundant in CETP-deficient subjects and efflux cholesterol as effectively as apoA-I (J Lipid Res 2003)
- Estradiol fatty-acid esters transfer from HDL to LDL via a CETP-associated process, a review finds, while their broader physiologic roles remain under study (Cardiovasc Res 2002)
- Review names CETP inhibitors among five emerging drug targets for lipid disorders beyond statins (Curr Atheroscler Rep 2002)
- Review names CETP inhibitors among four novel drug classes targeting low HDL cholesterol (Expert Opin Investig Drugs 2001)
- High-trans-fat margarine trends toward higher CETP levels while lowering cholesterol esterification rate (J Lipid Res 2001)
- Thyroid hormone excess doubles CETP activity and accelerates HDL clearance in transgenic mice (Metabolism 2001)
- A review names PLTP and CETP as joint targets of the nuclear receptors FXR and LXRalpha, central to reverse cholesterol transport (Curr Pharm Des 2001)
- Red wine, not alcohol alone, raises HDL cholesterol and cholesterol efflux capacity 7% in young men, without altering CETP (Nutr Metab Cardiovasc Dis 2000)
- Heat-induced loss of plasma gamma-LpE exceeds 80% but is independent of LCAT or CETP activity (J Lipid Res 1998)
- Triglyceride enrichment, not CETP alone, is what makes PLTP remodel HDL into larger and smaller particles (J Lipid Res 1998)
- A review names LCAT, hepatic lipase, and CETP as the key HDL-remodeling enzymes suppressed during cytokine-driven hyperlipidemia (Z Ernahrungswiss 1998)
- Low-HDL-cholesterol normolipidemic men show a shift from alpha1 to alpha3 HDL subpopulations, possibly via CETP-driven interconversion (Arterioscler Thromb Vasc Biol 1997)
- Continuous and cyclic HRT regimens both reshape HDL subclasses in postmenopausal women without altering CETP activity (Atherosclerosis 1997)
- Swapping dietary palmitic acid for trans elaidic acid raises CETP activity and lowers HDL more in cebus monkeys (J Nutr 1997)
- A review identifies LCAT and CETP as the two key enzymes driving reverse cholesterol transport, though its antiatherogenic role remains unproven (Can J Cardiol 1996)
- A review names CETP among four enzyme mutations that reshape HDL particle size and regulate HDL cholesterol and apoA-I levels (Curr Opin Lipidol 1996)
- Hepatic lipase, insulin, and triglycerides, not CETP or LPL activity, independently predict low HDL2b in men with NIDDM and coronary disease (J Lipid Res 1995)
- Alcohol-induced HDL cholesterol rise is driven by lipoprotein lipase, not CETP, hepatic lipase, or LCAT activity (Atherosclerosis 1994)
- A review names CETP, LCAT, and lipases as the enzymes driving HDL subclass interconversion in mature HDL formation and reverse cholesterol transport (Curr Opin Lipidol 1994)
- Horses show no significant cholesteryl ester transfer protein activity despite having VLDL, LDL, and HDL (Comp Biochem Physiol B 1993)
- HepG2 cells secrete an unidentified factor that reshapes nascent HDL into HDL2b particles, with cholesteryl ester transfer detected but not attributable to CETP (J Lipid Res 1993)
- A review names LCAT and CETP as the joint enzymatic drivers of reverse cholesterol transport from tissues to the liver (J Am Osteopath Assoc 1992)
- A symposium report names LCAT and CETP as joint mediators of the Glomset reverse cholesterol transport hypothesis, still clinically unproven (J Lipid Res 1990)
- Cholesterol feeding boosts CETP mRNA up to 5-fold via LXRalpha in rabbits before FXR activation catches up (J Lipid Res 2003)
- The inability of rat serum to transfer dietary oxidized cholesterol to LDL/HDL points to CETP as the mediator (J Lipid Res 2003)
- A review by Barter and Rye finds continuing conflict in the evidence on whether cholesteryl ester transfer protein is atherogenic or anti-atherogenic (Curr Opin Lipidol 2001)
- A methods chapter frames CETP, also known as lipid transfer protein I, as the enzyme linking triglyceride-rich and cholesterol-rich lipoprotein metabolism (Methods Mol Med 2001)
Mechanisms 222
The transfer protein itself: structure, kinetics, what inhibition does.
- Eliminating liver Kupffer cells abolishes hepatic CETP expression and lowers plasma CETP, identifying their cellular origin for this protein (Hepatology 2015)
- Human CETP overexpression in hypertensive Dahl rats spontaneously causes combined hyperlipidemia, myocardial infarction and reduced survival, proving CETP can be proatherogenic (Nat Med 1999)
- Modeled on BPI's crystal structure, a proposed CETP mechanism has C-terminal residues 461-476 forming a helix that gates lipid entry into a hydrophobic pocket (Curr Opin Struct Biol 1998)
- Deletion mutagenesis pinpoints residues Phe463 to Leu475 as essential for both TP2 antibody binding and CETP's neutral-lipid-transfer activity (J Biol Chem 1992)
- Baculovirus-expressed CETP deletion mutants pinpoint residues Phe-Leu-Leu-Leu (454-457) as essential for lipid transfer, a motif shared with LCAT, LBP, BPI and other lipid-binding enzymes (Proc Natl Acad Sci U S A 1992)
- Neutralizing antibodies against the 74kDa CETP eliminate essentially all plasma cholesteryl ester and triglyceride transfer activity, proving CETP is the responsible protein (J Biol Chem 1988)
- The original isolation of the 74kDa human plasma CETP reveals a leucine-rich, highly hydrophobic protein specific for cholesteryl ester over triglyceride transfer (Proc Natl Acad Sci U S A 1987)
- Landmark purification establishes human CETP as a unique 74-kDa hydrophobic plasma apolipoprotein (J Biol Chem 1987)
- Landmark 1978 paper reports the original isolation of the human cholesteryl ester transfer protein itself (Proc Natl Acad Sci USA 1978)
- CETP C-terminal peptides drive lipid particles from large aggregates into small micelle-like structures via disorder-to-order transitions, a proposed lipid-transfer mechanism (J Struct Biol 2014)
- CETP expression halves atherosclerotic lesion area in non-diabetic LDL-receptor-deficient mice, but this protection disappears with diabetes, another context-dependence finding for the CETP paradox (APMIS 2005)
- A new liposome-based assay shows CETP transfer rate depends jointly on donor AND acceptor surface cholesteryl-ester content, with LDLs varying 1.8-fold in CE-presenting capacity (J Lipid Res 2003)
210 more in Mechanisms
- Chemical labeling localizes an unpaired active-site cysteine, likely residue 333, whose modification sterically blocks CETP's cholesteryl-ester transfer activity (Chem Phys Lipids 2002)
- A new self-quenching BODIPY-cholesteryl-ester microemulsion assay enables simple fluorescence-based measurement of CETP activity in plasma (J Lipid Res 1993)
- CHO-cell expression and site-directed mutagenesis show all four potential N-glycosylation sites of CETP are occupied, explaining its glycoprotein doublet on SDS gels (Biochemistry 1993)
- C/EBP binds the CETP gene promoter and boosts its reporter-gene activity in liver cells, with C/EBP and CETP mRNA loss occurring in parallel in cultured hepatocytes (J Biol Chem 1992)
- Within three days, an atherogenic diet raises rabbit liver CETP mRNA 2.8-fold and plasma CETP mass 3.2-fold, while other liver mRNAs stay unchanged (J Clin Invest 1990)
- CETP retains lipid-transfer activity after protease fragmentation but not as isolated E. coli-expressed fragments, showing no independent catalytic subunit exists (J Biol Chem 1989)
- Chromatography, electrophoresis and immunoprecipitation together show apolipoprotein D and CETP are distinct proteins, resolving early confusion about CETP's identity (Biochim Biophys Acta 1981)
- Liver-targeted CETP expression improves glucose tolerance in female mice but worsens it and drives fatty liver in males (bioRxiv 2026)
- Despite no direct LPS-binding activity, human CETP raises mortality in mouse models of endotoxemia and sepsis by impairing lipoprotein-mediated protection (J Lipid Res 2020)
- In female mice, CETP enables an estrogen-SHP pathway raising VLDL triglyceride production and, independently, an ERalpha pathway boosting liver fat oxidation (J Lipid Res 2016)
- Human CETP transgenic mice show higher survival and lower IL-6 after polymicrobial sepsis, linked to reduced macrophage TLR4 and NF-kB activation (Mediators Inflamm 2016)
- Inflammatory macrophages selectively lose the LXR-driven induction of CETP seen in noninflammatory cells, even as ABCA1 and ABCG1 induction persist (Arterioscler Thromb Vasc Biol 2009)
- Bulky hydrophobic residues Leu475, Phe471, Leu468, Phe461 and Phe454 on one face of a C-terminal helix drive CETP's cholesteryl-ester transfer activity, distinct from the antibody-binding face (J Biol Chem 1993)
- A tunnel-like hydrophobic channel enables CETP bidirectional neutral lipid transfer, structurally distinct from other lipid-binding proteins (J Mol Graph Model 2026)
- CETP expression in bone-marrow-derived immune cells reduces inflammatory features of atherosclerosis, helping explain trial failures (Biomolecules 2023)
- A specific CETP isoform tracks disease severity and may help neutralize bacterial toxin in Gram-negative sepsis (Mol Med 2022)
- Transgenic CETP expression nearly doubles run distance in obese female mice via increased muscle mitochondrial oxidative capacity and PGC-1alpha (PLoS One 2015)
- Dietary cholesterol dose-dependently drives osteoarthritis in CETP-humanised mice, and atorvastatin but not ezetimibe suppresses it despite similar cholesterol lowering (Ann Rheum Dis 2013)
- Niacin lowers plasma CETP mass 30% by reducing liver macrophage content, not by directly suppressing macrophage CETP expression (Biochem Pharmacol 2012)
- Framingham study finds plasma CETP activity has only minimal association with blood pressure change over time (J Hypertens 2011)
- Chronic CETP deficiency disrupts adipocyte lipid storage, revealing a novel intracellular role for CETP (J Biol Chem 2007)
- In the Hoorn Study, high CETP concentration more than triples cardiovascular disease risk in women with Type 2 diabetes, with no such association in men (Diabet Med 2007)
- Adipose-specific CETP expression alone lowers HDL cholesterol and shrinks adipocytes in mice (J Lipid Res 2006)
- CETP moves HDL lipids into adipocytes without receptors or endocytosis, overturning the prevailing uptake model (J Lipid Res 2004)
- Immunohistochemistry and in situ hybridization localize CETP production to smooth muscle cells within the human aortic intima and media (Atherosclerosis 2001)
- In a 24-week RCT, French-press coffee raises CETP activity up to 18% within two weeks, preceding the later rise in LDL cholesterol (J Intern Med 2000)
- A refined CETP epitope map, built from eight monoclonal antibody binding sites, supports a BPI-based structural model of CETP's overall conformation (Protein Sci 1999)
- N-linked glycosylation, not the N-terminal cysteine, proves essential for CETP lipid-transfer activity in a new Pichia pastoris recombinant expression system (J Lipid Res 1996)
- CETP boosts Hep G2 cell uptake of HDL cholesteryl esters indirectly, via LDL receptor-mediated re-uptake of secreted lipoproteins, not directly (J Biol Chem 1989)
- CETP expression raises body metabolism and leanness in female mice during both cold exposure and thermoneutrality (FASEB J 2025)
- CETP expression rises with obstructive sleep apnoea severity in obese young rats (Sleep Breath 2024)
- Correcting hyperglycemia does not restore apoC1 inhibition of CETP activity in type 1 diabetes (Metabolites 2024)
- Combined GIPR/GLP1R agonism additively lowers triglycerides, hepatic steatosis and Kupffer-cell-driven liver inflammation in CETP-humanised NAFLD mice (EBioMedicine 2023)
- Time-restricted eating reduces atherosclerotic lesion size and inflammatory cell content in CETP-humanised mice during simulated shift-work (EBioMedicine 2023)
- CETP activity raises brain cholesterol levels by reducing cholesterol efflux in transgenic mice (J Lipid Res 2022)
- Unlike three other newly identified EGPA biomarkers, CETP is selectively downregulated and negatively correlates with eosinophil count, aiding diagnosis versus severe asthma (Front Immunol 2022)
- Elafibranor reduces steatosis, hepatic inflammation and fibrosis progression in CETP-humanised NASH mice, with 87% pathway overlap to human NASH (Sci Rep 2021)
- CETP inside endothelial cells directly causes oxidative stress and vascular dysfunction, independent of its effect on HDL (Biomolecules 2021)
- Exon-9-deleted CETP isoform blocks full-length CETP secretion and redirects cells toward storing triglyceride (J Lipid Res 2020)
- Alternating light-dark cycles mimicking shift work roughly double atherosclerotic lesion size and severity in CETP-humanised mice (J Pineal Res 2019)
- Four weeks of oral Akkermansia muciniphila lowers cholesterol and reshapes immune cell populations in CETP-humanised mice, but does not reduce cuff-induced neointima formation (Mol Nutr Food Res 2019)
- Neither a liraglutide RCT nor a 1,611-person cohort finds any link between liver fat content and circulating CETP, despite CETP's hepatic Kupffer-cell origin (Sci Rep 2019)
- Lower CETP levels track with more severe heart failure and higher natriuretic peptide (Lipids Health Dis 2018)
- Metabolic liver inflammation in obesity does not clearly lower CETP, unlike bacterial-endotoxin activation of Kupffer cells (Atherosclerosis 2018)
- Bacterial LPS lowers CETP by switching off resting Kupffer cells, an anti-inflammatory response that raises HDL during infection (J Am Heart Assoc 2018)
- Structural study refutes the ternary tunnel complex model of how CETP transfers cholesteryl ester (J Struct Biol 2016)
- Across 6,606 adults and multiple imaging-based fat measures, no association is found between body fat and serum CETP, challenging the adipose-tissue-as-CETP-source hypothesis (Atherosclerosis 2016)
- Contrary to expectation, higher plasma TMAO from L-carnitine correlates with smaller aortic lesions in CETP-expressing ApoE-deficient mice (Atherosclerosis 2015)
- CETP-deficient cells cannot efficiently convert diglyceride into stored triglyceride (J Lipid Res 2015)
- CETP inhibitors reduce hepatic LDL receptor and PCSK9 via an off-target SREBP2 mechanism (Atherosclerosis 2014)
- Glycation destroys apolipoprotein C1's natural ability to inhibit CETP in patients with diabetes (Diabetes Care 2014)
- CETP transgene protects obese female mice from insulin resistance via bile acid signalling (Mol Metab 2013)
- Chemical remodeling of LDL, not release from its inactive complex, drives LTIP activation, requiring either LCAT or CETP activity (J Lipid Res 2011)
- CETP enhances insulin-stimulated glucose uptake in human adipocyte cells (Life Sci 2011)
- A four-week rimonabant intervention in CETP-humanised mice cuts body weight 9.4% and plasma cholesterol 24%, with systems-lipidomics revealing distinct plasma and liver lipid signatures (PLoS One 2011)
- Diet-induced hypercholesterolemia raises plasma LTIP mass 2.5-fold while suppressing its hepatic mRNA, diverging from CETP's response in hamsters and rabbits (J Lipid Res 2008)
- Cyclosporine and Rapamycin, but not Tacrolimus or Mycophenolate, raise in vitro CETP activity while all four immunosuppressants suppress lipoprotein lipase (Int J Pharm 2008)
- Patients with the highest CETP-driven cholesteryl ester transfer rate had their first heart attack 18 years earlier (J Am Coll Cardiol 2007)
- Oleate-induced negative surface charge on LDL blocks LTIP activity at ten micromolar while only fully suppressing CETP above twenty micromolar (J Lipid Res 2003)
- Bariatric-surgery weight loss of 28.7 kg lowers CETP mass 27% and activity 25% in morbidly obese women, alongside an increase in LDL particle size (Arterioscler Thromb Vasc Biol 2002)
- Feeding, not fasting, raises liver CETP mRNA two-fold and plasma CETP activity 20% in human-CETP transgenic mice, independent of insulin or glucose (J Nutr Biochem 2000)
- CETP mRNA is 96% higher in the immature stromal-vascular fraction of human fat tissue than in mature adipocytes, unlike lipoprotein lipase or apoE (Biochim Biophys Acta 1998)
- Endotoxin suppresses CETP via adrenal corticosteroid release, raising HDL in transgenic mice (J Clin Invest 1995)
- A monoclonal antibody that blocks CETP's triglyceride transfer but not cholesteryl-ester transfer suggests the two lipids use distinct binding sites (J Biochem 1992)
- HepG2 hepatocytes secrete CETP activity bound mainly to apoA-I and apoA-II, unlike plasma's strong apoA-I skew, alongside a distinct heat-labile lipid-transfer inhibitor tied to apoE particles (Atherosclerosis 1989)
- CaCo-2 enterocytes secrete CETP (LTP-I) exclusively from their basolateral surface at twice the rate of HepG2 cells, and uniquely regulate secretion by fatty acid levels (J Biol Chem 1988)
- CETP activity and cholesteryl ester transfer rise two- to fourfold in hypercholesterolemic and dysbetalipoproteinemic plasma (J Clin Invest 1987)
- HepG2 human liver cells synthesize and secrete a protein immunochemically identical to plasma LTP-I, identifying hepatocytes as a candidate source (Arteriosclerosis 1987)
- Phospholipid plugs inside two side pores of CETP accelerate triglyceride transfer through a newly described 'gliding' mechanism (Comput Struct Biotechnol J 2026)
- Endothelial dysfunction develops earlier in male than female CETP-humanised hyperlipidaemic mice, preceding atherosclerosis (Geroscience 2025)
- Knocking down CETP shrinks triple-negative breast cancer xenografts by 86% and restores tamoxifen sensitivity in resistant cells (IUBMB Life 2024)
- Ginseng compound Ginsenoside Re protects rat hearts from hypertrophy partly by suppressing CETP, matching the classical inhibitor anacetrapib (Cureus 2024)
- CETP and apoA1 levels rise in blood during recovery from COVID-19, opposite to the acute-phase pattern (Sci Rep 2024)
- CETP-expressing mice heal cutaneous leishmaniasis lesions faster, shifting macrophages toward a healing M2 phenotype (Front Immunol 2024)
- Molecular dynamics explains why the R201S and double I443W/V198W mutations cripple lipid transfer through CETP by warping its tunnel geometry (Biophys Chem 2023)
- Simulating CETP as it really is, not the crystallography mutant, finds a new lead compound that jams its tunnel shut (Int J Mol Sci 2023)
- Bound phospholipids bend cholesteryl esters into a transferable shape inside CETP, with the N-terminal lipid doing most of the work (J Chem Inf Model 2023)
- Review proposes probucol as an alternative stroke-prevention therapy for patients at high haemorrhage risk (Brain Circ 2023)
- Increased fecal fatty acid and bile acid excretion, not cholesterol absorption, explains triglyceride-response heterogeneity in CETP-humanised mice (Nutrients 2022)
- CETP-overexpressing mice develop worse psoriasis-like skin lesions with higher inflammatory cytokines than normal mice (Lipids Health Dis 2022)
- In APOE3-Leiden.CETP mice with diet-induced NASH, the oxysterol Oxy210 reduces adipose tissue IL-6, MCP-1 and macrophage markers (Int J Mol Sci 2022)
- Walnut supplementation as a statin adjuvant lowers CETP activity and raises HDL cholesterol in hypertensive patients (Clin Exp Hypertens 2022)
- CETP levels track liver enzymes and metabolic markers in psoriasis patients on systemic therapy (Metabolites 2022)
- EPA, but not DHA, significantly lowers CETP activity in a crossover trial of omega-3 fatty acid supplementation (J Clin Lipidol 2022)
- Low CETP activity late in pregnancy, in mother and placenta alike, is linked to giving birth to small-for-gestational-age infants (Sci Rep 2021)
- CETP pushes macrophages toward the M2 phenotype and worsens elastase-induced emphysema in mice, an unexpected lung-disease link (Front Immunol 2021)
- A novel anti-adipogenic role for CETP: it boosts brown fat activity and lipolysis to reduce body fat, across three animal models (Metabolism 2021)
- Diet-induced metabolic syndrome triggers 1396 differentially expressed adipose transcripts, revealing immune and remodeling gene signatures in CETP-humanised mice (Genomics 2020)
- Neither ad libitum nor time-restricted voluntary wheel running altered atherosclerotic lesion size in CETP-humanised mice or lipid profile in obese men (Obesity (Silver Spring) 2020)
- Ellagic acid from unripe Rubus coreanus extract lowers hepatic CETP and HMG-CoA activity while raising LCAT activity, reducing cholesterol in rats (Nutrients 2020)
- In hypertensive rats made to express human CETP, blood pressure rose and fatty liver accelerated, yet atherosclerosis did not (Hypertens Res 2020)
- Hydrocarbon-stapled peptides jam the self-binding switch of CETP more than fivefold better, a new route to blocking the protein (J Mol Graph Model 2020)
- Steered molecular dynamics show torcetrapib and anacetrapib block CETP by physically plugging its lipid-transfer tunnel (Biochemistry 2019)
- Cynanchum wilfordii extract lowers CETP alongside cholesterol and apoB in adults with high LDL cholesterol (Nutrients 2019)
- Colorectal cancer patients have higher CETP activity and lower LCAT and PON-1 activity, with CETP mass an independent risk predictor (Clin Biochem 2019)
- High-dose dietary inulin shifts gut bacteria and raises short-chain fatty acids without reducing cholesterol or atherosclerosis in CETP-humanised mice (Sci Rep 2018)
- CETP promotes exchange of the inflammatory apolipoprotein serum amyloid A between lipoproteins (Arterioscler Thromb Vasc Biol 2018)
- Existing CETP inhibitors were designed against an unglycosylated crystal structure, but simulations show four sugar chains reshape the tunnel dynamics of the protein (Proteins 2018)
- The C-terminal bound phospholipid grips CETP more tightly than the N-terminal one, keeping it bent and ready to carry lipids (J Phys Chem B 2018)
- Curcumin does not significantly change serum CETP levels in metabolic syndrome, trial finds (Avicenna J Phytomed 2018)
- Six-month high-fat feeding of CETP-humanised male mice reveals a biphasic lipid response with insulin resistance preceding dyslipidemia, mirroring human ageing (Physiol Rep 2017)
- CETP can carry triglycerides too, not just cholesteryl esters, and simulations show why the slower TG transfer happens (Sci Rep 2017)
- Basal-bolus insulin lowers maternal triglycerides in gestational diabetes without changing CETP activity (J Obstet Gynaecol Res 2017)
- CETP knockout sensitizes estrogen-receptor-positive breast cancer cells to cholesterol-depleting cytotoxic agents (Genes Cancer 2016)
- Circulating PCSK9 levels and CETP plasma activity are independently correlated in patients with metabolic disease (Cardiovasc Diabetol 2016)
- Novel CETP inhibitor K-312 lowers PCSK9 through a CETP-independent SREBP mechanism (Am J Physiol Endocrinol Metab 2015)
- Computational mapping of CETP missense mutations identifies cholesterol-binding regions relevant to drug design (Arch Biochem Biophys 2014)
- Anti-CETP vaccine reduces atherosclerosis and fatty liver disease in cholesterol-fed rabbits (PLoS One 2014)
- CETP activity and mass are lower in rheumatoid arthritis patients taking glucocorticoids (J Rheumatol 2013)
- Low-normal thyroid function raises plasma cholesteryl ester transfer in type 2 diabetes (Atherosclerosis 2013)
- Specific lysophospholipid micelles reverse the beta-sheet, amyloid-fibril-forming conformation of a CETP C-terminus D470N mutant peptide back to alpha-helix (Biochem Biophys Res Commun 2013)
- Leoligin, a lignan from Edelweiss, is identified as a novel CETP activator (Atherosclerosis 2011)
- A disease-associated CETP mutation drives amyloid formation and cytotoxicity in vitro (Int J Mol Sci 2011)
- Statin-induced LDL and non-HDL cholesterol reductions track with falling CETP mass in type 2 diabetes (Expert Opin Ther Targets 2009)
- Tetrahydroquinoline platform yields a 39nM CETP inhibitor for raising HDL-C (Bioorg Med Chem Lett 2009)
- ALPS study finds CETP mass changes track LDL cholesterol, not HDL, with the probucol derivative AGI-1067 (J Clin Lipidol 2007)
- Review proposes CETP has a novel biological function transporting water-insoluble drugs between lipoproteins (Biochem Pharmacol 2002)
- In type 1 diabetic children, arachidonic acid content of LDL cholesteryl ester correlates with CETP activity independent of CETP concentration, suggesting a route to excess LTB4 (Med Hypotheses 2002)
- CETP inhibitory peptide P28 cuts CETP activity 50% and raises HDL/total-cholesterol ratio 150% in CETP-transgenic mice (J Biochem Mol Biol 2002)
- AICAR lowers blood glucose and insulin by suppressing endogenous glucose production, without correcting dyslipidaemia, in diabetic CETP-expressing KKAy mice (Diabetologia 2001)
- Pravastatin lowers CETP activity in both fasting and postprandial states in hypercholesterolaemia (Atherosclerosis 1998)
- Intraperitoneal insulin normalizes elevated cholesteryl ester transfer in NIDDM, but injections alone do not (Diabetes 1997)
- Antibodies raised against CETP residues 131-142 can immunoprecipitate CETP activity from serum without inhibiting the enzyme, marking a non-active-site epitope (Hybridoma 1996)
- Fenofibrate cuts CETP-driven cholesteryl ester transfer from HDL to VLDL by 38% and normalizes dense LDL (ATVB 1996)
- Net cholesteryl ester transfer roughly doubles in NIDDM even though CETP activity itself is unchanged (Atherosclerosis 1996)
- Diabetic cynomolgus monkeys show accelerated cholesteryl ester transfer, mirroring human diabetic dyslipidaemia (J Lipid Res 1995)
- CETP is localized to brain astrocytes, with increased expression in Alzheimer's disease gray matter (Acta Neuropathol 1995)
- Adding bezafibrate to long-term probucol therapy can trigger severe HDL and apolipoprotein A-I deficiency (Eur J Clin Pharmacol 1995)
- Recombination experiments trace accelerated cholesteryl ester transfer in IDDM to a CETP-containing plasma fraction (Eur J Clin Invest 1994)
- Bezafibrate suppresses CETP activity by 17% and LCAT by 21% while shrinking small, heavy LDL (Atherosclerosis 1994)
- Recombination experiments trace accelerated cholesteryl ester transfer in NIDDM to the VLDL plus LDL fraction (Atherosclerosis 1993)
- Simvastatin lowers cholesteryl ester transfer by reducing CETP concentration itself, not by altering HDL (Atherosclerosis 1993)
- Heavy alcohol drinkers with sky-high HDL show sharply reduced CETP activity and mass, mimicking genetic deficiency (Metabolism 1992)
- Doubling plasma CETP activity via diet does not speed cholesteryl ester clearance from hepatic reticuloendothelial cells in hamsters (Biochim Biophys Acta 1991)
- Radiation inactivation puts the functional size of CETP at 70 000 daltons, consistent with a monomer (FEBS Lett 1985)
- A review positions CETP alongside PCSK9 and ANGPTL3 as emerging lipid-regulatory targets in cancer, though CETP-specific oncology research remains scarce (Biomolecules 2026)
- In liver cells, miR-30b-3p cuts CETP reporter activity by 86% at the mRNA level, but CETP protein itself does not budge (Mol Biol Rep 2026)
- A four-protein urinary panel including CETP, combined with tumor diameter and AFP/GGT levels, predicts microvascular invasion in liver cancer with concordance indices up to 0.809 (BMC Med 2023)
- A purple perilla extract lowers plasma CETP and reduces atheroma formation in apoE-deficient mice (Nutr Res Pract 2023)
- A probiotic strain lowers CETP expression alongside cholesterol-lowering effects in cell and animal models (J Med Food 2023)
- A probiotic normalises diet-induced CETP gene upregulation in a rabbit model of fatty liver disease (Sci Rep 2023)
- CETP is identified as a candidate serum biomarker for diagnosing sarcopenia in older adults (BMC Musculoskelet Disord 2022)
- Proteomic profiling flags CETP as one of three ELISA-confirmed markers elevated in stent restenosis (Front Cardiovasc Med 2022)
- A CETP isoform, CETPI, is highlighted as a newly described contributor to LPS inactivation in the gut-liver axis of sepsis (Biomed Pharmacother 2021)
- Feed efficiency correlates with distinct hepatic gene-expression patterns across diet duration in CETP-humanised mice, per a new dynamic model (Physiol Rep 2021)
- A review commits to covering PCSK9, ANGPTL8, sortilin and CETP as candidate molecular links between psoriasis and cardiometabolic syndrome risk (Int J Mol Sci 2020)
- Calcitriol raises CETP levels alongside HDL-C in a rabbit model of atherosclerosis (Int J Vitam Nutr Res 2019)
- QSAR modelling and molecular docking chart a path to new CETP inhibitor compounds for coronary heart disease (J Biomol Struct Dyn 2020)
- A simple diffusion-like mathematical model estimates how much triglyceride CETP shuttles between lipoproteins from routine lipid measurements (BMC Syst Biol 2019)
- Multi-model computational study of 140 benzoxazole compounds maps the structural requirements for potent CETP inhibition (J Biomol Struct Dyn 2019)
- Saffron-derived crocin raises CETP levels within treated patients, but not significantly versus placebo (ARYA Atheroscler 2017)
- Molecular dynamics simulations support a tunnel mechanism for lipid transfer by CETP (J Biol Chem 2016)
- Molecular dynamics studies show small-molecule CETP inhibitors act by physically blocking the lipid transfer tunnel (J Phys Chem B 2016)
- All-atom simulations show a complete cholesteryl ester can pass through the CETP tunnel at a physiologically realistic rate (J Biol Chem 2016)
- Policosanol combined with reconstituted HDL outperforms anacetrapib at inhibiting CETP in a hyperlipidemic zebrafish model (Rejuvenation Res 2016)
- CETP and PLTP exemplify how BPI-like TULIP proteins form tubular channels to exchange lipids between lipoprotein particles (Biochim Biophys Acta 2016)
- Review highlights that CETP inhibitors lower blood glucose alongside raising HDL cholesterol (Front Pharmacol 2015)
- Plant-produced chimeric protein targeting ApoB100 and CETP epitopes elicits antibody responses in mice (Mol Biotechnol 2014)
- Vitamin E tocotrienol supplementation lowered CETP activity and improved lipids in chronic hemodialysis patients (Vasc Health Risk Manag 2013)
- CETP-driven cholesteryl ester enrichment of apoB particles is exaggerated in type 1 diabetes (Eur J Clin Invest 2012)
- Chinese medicine preparation SUB885C cuts CETP activity 74% and raises HDL-C in ApoE*3Leiden.CETP mice (PLoS One 2012)
- Long-term danazol use lowers CETP mass without significantly affecting HDL cholesterol or atherosclerosis markers (Clin Ther 2008)
- ANGPTL3 abnormalities outnumber CETP abnormalities in Japanese hyperalphalipoproteinemic subjects (Clin Chim Acta 2008)
- Review surveys a CETP-inhibiting vaccine among emerging anti-atherosclerotic vaccine strategies (Cardiol Rev 2008)
- New fluorescence quencher triples the signal window of a CETP activity assay for large-scale drug screening (Anal Biochem 2007)
- Omega-3 fatty acid intake correlates with lower CETP activity in Tunisian women with type 2 diabetes (Nutr Metab Cardiovasc Dis 2006)
- Alcohol abuse alters CETP glycosylation, lowering its surface charge and likely its activity (Alcohol Alcohol 2006)
- LXR agonists raise LDL cholesterol in CETP-expressing hamsters and monkeys, an effect invisible in CETP-lacking mice (J Lipid Res 2005)
- Plant stanol ester spread lowers CETP mass alongside LDL cholesterol and oxidized LDL in a Japanese trial (Nutrition 2003)
- Only atorvastatin, not fenofibrate, lowers CETP activity in metabolic syndrome patients despite both lowering triglycerides (Diabetes 2003)
- Review explains how CETP-mediated cholesteryl ester transfer links low HDL-C to high triglycerides in insulin resistance and type 2 diabetes (Clin Lab 2003)
- CETP inhibitory peptide P28 selectively blocks HDL-to-LDL but not HDL-to-HDL cholesteryl ester transfer (Lipids 2002)
- No CETP mass is detected in human cerebrospinal fluid, unlike LCAT and phospholipid transfer protein (J Lipid Res 2000)
- Atorvastatin cuts CETP activity by up to 26.4% while reshaping apolipoprotein distribution in hypertriglyceridemia (Metabolism 2000)
- A review by the LTIP discoverer surveys how CETP expression, atherogenesis and lipid transfer inhibitor protein activity interconnect (Curr Opin Lipidol 1999)
- Bezafibrate, but not gemfibrozil, significantly lowers cholesteryl ester transfer activity in type IIb hyperlipoproteinaemia (Atherosclerosis 1998)
- Ethanol oxidation, not reduced CETP synthesis, explains alcohol's redistribution of CETP among lipoproteins (ATVB 1996)
- New monoclonal-antibody immunoassays quantify CETP mass down to nanogram levels in plasma and cell culture (J Lipid Res 1995)
- The first competitive ELISA for CETP detects 1 nanogram per well with a coefficient of variation under 6% (Clin Chim Acta 1994)
- A fast two-site immunoassay measures CETP mass in 6 hours with under 9% assay variability (Clin Chem 1994)
- CETP activity peaks in the second trimester of pregnancy and tracks HDL-triglyceride accumulation (Clin Biochem 1994)
- Cholesterol esterification is 16% slower in Alzheimer's disease, echoing earlier findings in Down's syndrome (Mech Ageing Dev 1994)
- A polyclonal-antibody immunoradiometric assay detects CETP down to 0.1 nanograms with under 9% variability (J Lipid Res 1993)
- Unlike LBP, its structural relatives BPI, CETP and PLTP show no expression difference in necrotizing enterocolitis, isolating LBP as the disease-associated biomarker (J Pediatr Surg 2026)
- A wild valerian relative and beta-sitosterol inhibit CETP and lower lipids in triton-induced hyperlipidemic rats (Food Sci Nutr 2024)
- Walnut kernel polyphenols are proposed to improve metabolic syndrome partly by inhibiting SREBPs, PCSK9 and CETP (Food Sci Nutr 2024)
- Three months of water-based exercise moved body weight in obese older men but left CETP activity and blood lipids unchanged (Diabetes Metab Syndr 2021)
- Simvastatin lowers HMGR but not CETP expression in bovine adipocytes (Anim Biotechnol 2020)
- Structural study designs a self-binding CETP peptide stabilized by pi-pi stacking and halogen bonding (Bioorg Chem 2016)
- QSAR models guide design of twelve new diphenylpyridylethanamine CETP inhibitors (Bioorg Med Chem Lett 2015)
- New diterpenes isolated from Engleromyces goetzii fungus show CETP inhibitory activity (Nat Prod Bioprospect 2015)
- LCAT and CETP activity track with disturbed HDL and triglyceride-rich lipoprotein composition after kidney transplant (Cell Biochem Biophys 2013)
- Xanthohumol from hops shows the strongest CETP-inhibitory activity among screened plant chalcones (Food Chem 2012)
- SAR study on the central phenyl ring of biphenyl oxazolidinone CETP inhibitors finds analogs matching anacetrapib in potency (Bioorg Med Chem Lett 2012)
- Saccharin-fed zebrafish show elevated CETP activity while aspartame-fed zebrafish suffer acute deaths under high-cholesterol diet (Food Chem Toxicol 2011)
- A decade-spanning review narrows thirty cholesterol-lowering drug targets to six for detailed chemical and mechanistic analysis, including CETP inhibitors (Curr Med Chem 2011)
- Molecular docking maps the hydrophobic P1/P2 binding pockets used by trifluoro-aminopropanol CETP inhibitors (J Mol Model 2011)
- Plasma CETP and PLTP levels are unchanged in end-stage renal disease despite HDL abnormalities (Nephrol Dial Transplant 2009)
- CETP levels track with bile acid concentration in children with Alagille syndrome cholestasis (Atherosclerosis 2008)
- CETP activity correlates with insulin resistance and leptin in obese subjects, but not independently of other factors (Metabolism 2007)
- CETP activity correlates with HDL triglyceride enrichment and reduced antioxidant capacity in postmenopausal women (Atherosclerosis 2004)
- Egg-induced cholesterol hyperresponders show higher CETP and LCAT activity than hyporesponders (Metabolism 2004)
- Single endotoxin dose triggers rapid LDL decline and slower CETP activity loss in healthy volunteers (J Lipid Res 2003)
- Egg-diet hyperresponder premenopausal women show higher CETP alongside apoB and apoC-III (J Am Coll Nutr 2002)
- Mapping a monoclonal antibody's CETP epitope explains why it blocks triglyceride but not cholesteryl ester transfer (J Lipid Res 1999)
- Low-dose testosterone in women lowers HDL cholesterol without changing CETP activity (Clin Endocrinol 1998)
- A new 1H NMR method tracks CETP-driven lipid transfer in lipoprotein mixtures without ultracentrifugation (NMR Biomed 1997)
- CETP mass and cholesteryl ester transfer are unchanged in normotriglyceridemic type II diabetics, fasting or fed (Atherosclerosis 1996)
- Recombinant cynomolgus monkey CETP is expressed and purified 176-fold from CHO cells for structural study (J Protein Chem 1995)
- Triazine-dye affinity chromatography purifies human CETP up to 100,000-fold from lipoprotein-depleted plasma (Protein Expr Purif 1994)
Pharmacology 6
Dose, exposure, interactions and the practical drug properties.
- Multi-stage virtual screening identifies five novel CETP inhibitor lead compounds, confirmed active by biochemical assay (BMC Chem 2024)
- Newly synthesised fluorinated diaryl sulfonamides reach 100% CETP inhibition in vitro, guided by molecular modelling (Curr Comput Aided Drug Des 2024)
- Trifluoromethylated sulfonamides reach 100% CETP inhibition in vitro, guided by induced fit docking and pharmacophore mapping (Med Chem 2023)
- Bacterial iron-chelating pigments called ferroverdins turn out to be potent CETP inhibitors, with 43 new structural variants identified (Biomolecules 2022)
- New benzyl benzamide compound inhibits CETP by 82.2% in vitro, with docking confirming it fits the drug pocket (Arch Pharm 2017)
- Formulation science: a lipid-based delivery system boosts oral absorption of the CETP inhibitor CP-532,623, and supersaturation, not just solubility, predicts how well (Mol Pharm 2017)
Cognition 1
CETP genotype, cognition and the questions obicetrapib inherited.